



The 3rd  
International  
Clinical  
Oncology  
Congress

The 13<sup>th</sup> Iranian Annual Clinical Oncology Congress  
19-21 December 2018  
Iran - Tehran  
[www.cong2018.isro.org.ir](http://www.cong2018.isro.org.ir)

پیشکسوت  
استاد  
بزرگداشت  
دکتر حسین علاءقنده

انگلوژی  
کلینیک  
سومین کنگره  
رادیوتراپی

۱۳۹۷ آذر ۲۸-۳۰

تهران، درب غربی استادیوم آزادی، هتل المپیک  
سیزدهمین کنگره سالیانه کلینیکال انگولوژی ایران  
همزمان با سومین کنگره بین المللی پرستاری، کارشناسان رادیوتراپی و  
همایش رادیوبیولوژی بالینی ایران



انجمن رادیوتراپی  
انگولوژی ایران



# PegaGen<sup>®</sup>

Pegfilgrastim



Feel  
Neutrophil Stability



Orchid Pharmed  
Skys the Limit

CERTIFIED  
EUGMP

شركة سينان  
CinnaGen

# Xybrone<sup>®</sup> 250

Abiraterone acetate

Stand Up  
& Be a Real Man



Orchid Pharmed  
Sky's the Limit




NANALVAND



# varan

## Parto Darman

نماینده انحصاری کمپانی های واریان و ماکرومدیکس در ایران



# varian



# macromedics

آدرس: تهران، خیابان شهید بهشتی، بعد از خیابان میرعماد، پلاک ۳۰۰، طبقه پنجم

شماره تماس: ۸۸۵۳۷۵۱۸-۸۸۵۱۹۷۹۰

[www.varanparto.com](http://www.varanparto.com)



www.Elekta.com

## Treatment Delivery System



**One Solution. Unlimited Possibilities**

## Flexitron

High dose rate after loader machines available with cobalt and Iridium sources.

Brachytherapy Treatment Delivery

## Treatment Planning System

### Care Management


Clinical and practice management tools

### Treatment Management

Treatment Planning, delivery and assessment tools

### Knowledge Management

Clinical and business intelligence applications



www.Fanavari.com

تهران - خیابان سهروردی شمالی - خیابان شهید قندی (پالیزی) - روبروی کوچه بیستم - پلاک ۷۴  
تلفن: ۴-۸۸۵۲۳۹۵۱ فاکس: ۸۸۷۵۰۶۴۹

Email: info@ Fanavari. com



فن آوری آرمايشگاهی



**Faroxy-ER (oxycodone)**  
10,20,40mg

Moderate to severe acute and chronic pain

Indicated for:

- Cancer related,
- Nociceptive,
- Neuropathic pain.

Considered as:

- Most prescribed analgesic medicine worldwide
- High efficacy for severe pain control.
- High safety profile in very complex pathophysiological conditions.



**LIFE WITHOUT PAIN**



**Faran Shimi**  
Pharmaceutical Co.

[www.faranshimi.com](http://www.faranshimi.com)



CyberKnife®  
Precision Matters.

ACCURAY®



Tomorrow's Radiation  
Oncology Practice  
**IS HERE TODAY**



CyberKnife®  
ACCURAY™

Tomotherapy®  
Helical Tomotherapy.

**Radixact™**  
A UNIQUELY  
SMART RADIATION  
THERAPY SYSTEM



شرکت‌های گروه مطلب

نماینده انحصاری تجهیزات پزشکی ACCURAY® آمریکا در ایران  
دفتر بازاریابی و فروش: تهران، خ مطهری، خ میرعماد، کوچه ۱۳ (شهید جنتی)، پ ۸، تلفن: ۰۲۱-۸۸۵۲۷۶۷۰



Matlab Group Companies  
Accuray Healthcare Authorized Distributor

SIEMENS  
Healthineers

Carestream

Ortho Clinical Diagnostics  
a Johnson & Johnson company



**Pemexed<sup>®</sup>**  
Pemetrexed

**Sobelvin<sup>®</sup>**  
Vinorelbine



**Tarsoban<sup>®</sup> 100**  
Erlotinib

**Carboplat<sup>®</sup>**  
Carboplatin

**Gemsiban<sup>®</sup>**  
Gemcitabine

**Cisplat<sup>®</sup>**  
Cisplatin

The Most Complete  
Portfolio in Lung Cancer


 **Sobhan**  
Oncology  
Keeping Hope Alive

[www.sobhanoncology.com](http://www.sobhanoncology.com)

# Sunitent<sup>®</sup>

## Sunitinib

- Gastrointestinal ST
- Pancreatic NET
- Renal CC




شرکت داروسازی اسوه

تلفن تماس مشتری: ۰۲۱-۸۸۵۶۱۲۶۹

www.osvahpharma.com

# MAKE OVERALL SURVIVAL PERSONAL



With Erbitux in combination with  
radiotherapy  
in locally advanced SCCHN\*<sup>1,2</sup>

With Erbitux in combination with  
platinum-based  
chemotherapy followed by Erbitux  
in maintenance  
monotherapy until disease  
progression,  
in recurrent/metastatic SCCHN\*<sup>1,3</sup>

\*SCCHN: Squamous cell carcinoma of the head and neck

**References:**

1. Erbitux Summary of Product characteristics. 06/2014.
2. Bonner JA et al. N Engl J Med 2006;354:567-578.
3. Vermorken JB et al. N Engl J Med 2008;359:1116-1117.

**ERBITUX**<sup>®</sup>  
CETUXIMAB


See the difference

**MERCK**



# Life is all about Choices

**Zoladex**<sup>®</sup>  
goserelin  
**SafeSystem**<sup>™</sup>



Abbreviated prescribing information  
Name of the medicinal product: ZOLADEX 3.6 mg Goserelin acetate (equivalent to 3.6 mg goserelin). Depot, prefilled syringe & ZOLADEX LA 10.8 mg depot Goserelin acetate (equivalent to 10.8 mg goserelin).  
INDICATIONS AND USAGE: ZOLADEX LA 10.8 mg & 3.6 mg are indicated in the management of prostate cancer suitable for hormonal manipulation. DOSAGE AND ADMINISTRATION: Caution should be taken while inserting ZOLADEX into the anterior abdominal wall due to the proximity of underlying inferior epigastric artery and its branches. Use extra care when administering ZOLADEX to patients with a low BMI and/or who are receiving full anticoagulation medication. Adult Males (including the elderly): One 10.8 mg depot of ZOLADEX LA injected subcutaneously into the anterior abdominal wall, every 12 weeks. No dosage adjustment is necessary for patients with renal impairment. For Zoladex 3.6: One 3.6 mg depot of ZOLADEX injected subcutaneously into the anterior abdominal wall, every 28 days. Females: ZOLADEX LA 10.8 mg is not indicated for use in females. Children: ZOLADEX LA 10.8 mg is not indicated for use in children. WARNINGS AND PRECAUTIONS: Injection site injury has been reported with ZOLADEX, including events of pain, haematoma, haemorrhage and vascular injury. Monitor affected patients for signs or symptoms of abdominal haemorrhage. In very rare cases, administration error resulted in vascular injury and haemorrhagic shock requiring blood transfusions and surgical intervention. Extra care should be taken when administering ZOLADEX to patients with a low BMI and/or receiving full anticoagulation medication. Use Dosage and Administration: ZOLADEX LA 10.8 mg is not indicated for use in females, since there is insufficient evidence of reliable suppression of serum oestradiol. For female patients requiring treatment with goserelin, refer to the prescribing information for ZOLADEX 3.6 mg. ZOLADEX LA 10.8 mg is not indicated for use in children, as safety and efficacy have not been established in this group of patients. The use of ZOLADEX LA 10.8 mg in men at particular risk of developing ureteric obstruction or spinal cord compression should be considered carefully and the patients monitored closely during the first month of therapy. If spinal cord compression or renal impairment due to ureteric obstruction are present or develop, specific standard treatment of these complications should be instituted. In men, preliminary data suggest the use of a bisphosphonate in combination with a LHRH agonist may reduce mineral loss. A reduction in glucose tolerance has been observed in males receiving LHRH agonists. This may manifest as diabetes or loss of glycaemic control in those with pre-existing diabetes mellitus. Consideration should therefore be given to monitoring blood glucose. Androgen deprivation therapy may prolong the QT interval, although a causal association has not been established with ZOLADEX. In patients with a history of or who have risk factors for QT prolongation and in patients receiving concomitant medicinal products that may prolong the QT interval (see Interactions), physicians should assess the benefit risk ratio including the potential for Torsade de Pointes prior to initiating ZOLADEX. CONTRAINDICATIONS: ZOLADEX LA 10.8 mg should not be given to patients with a known hypersensitivity to the active substance, to other LHRH analogues, or to any of the excipients of this product. ADVERSE REACTIONS: Libido decreased, Hot flush, Hyperhidrosis, Erectile dysfunction, Vulvovaginal dryness, Injection site reactions, Glucose tolerance, areduction in glucose tolerance has been observed in males receiving LHRH agonists. This may manifest as diabetes or loss of glycaemic control in those with pre-existing diabetes mellitus. Impaired Paraesthesia, Spinal cord compression, Cardiac failure, myocardial infarction, Blood pressure abnormality, Rash, Alopecia, Bone pain, Gynaecomastia, Tumour flare, tumour pain, Bone density decreased, Injection site reaction, Drug hypersensitivity, Breast tenderness, Anaphylactic reaction, Ovarian cyst, Ovarian hyperstimulation syndrome, Pituitary tumour, Pituitary haemorrhage, Degeneration of uterine fibroid. DRUG INTERACTIONS: None known. Since androgen deprivation treatment may prolong the QT interval, the concomitant use of ZOLADEX with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de Pointes should be carefully evaluated (see Warnings and Precautions). USE IN SPECIFIC POPULATIONS: Pregnancy and Lactation: ZOLADEX LA 10.8 mg is not indicated for use in females. OVERDOSE: There is limited experience of overdosage in humans. In cases where ZOLADEX has unintentionally been readministered early, or given at a higher dose, no clinically relevant adverse effects have been seen. Animal tests suggest that no effect other than the intended therapeutic effects on sex hormone concentrations and on the reproductive tract will be evident with higher doses of ZOLADEX LA 10.8 mg. If overdosage occurs, this should be managed symptomatically.

These highlights do not include all not include all the information needed to use zoladex 10.8 mg & 3.6 mg safely and effectively. See full prescribing information for zoladex 10.8 mg & 3.6 mg. Full prescription information is available upon request. See local prescribing information for full details, as prescribing information may vary from country to country.  
Marketing authorization no: Zoladex 3.6 mg 597475820335575, date: 17 March 2015, Zoladex 10.8 mg 6351674860389736, date: 17 March 2015

\*Zoladex product monograph, AstraZeneca Canada Inc., March 2015

For any patient safety concern please send to [patientsafety@astrazeneca.com](mailto:patientsafety@astrazeneca.com)  
For any medical query please send to [medicalinfo@astrazeneca.com](mailto:medicalinfo@astrazeneca.com)

**AstraZeneca**

AstraZeneca Near East (NE) Swifileh, BLDG 19  
Abdalaheem Al-Hajj Mohammad street P.O.Box 17788  
Zip Code 11195 Amman-Jordan Tel: +96265827580

# ACTERO

ONCOLOGY PRODUCTS

Capecitabine **ACTe**  
The chemotherapy at home



Etoposide **ACTe**



Doxorubicin **ACTe**



**RITUXIVER**  
Rituximab Vials 100, 500 mg



COMING  
SOON

Imatinib **ACTe**



COMING  
SOON

Aprepitant **ACTe**



COMING  
SOON

Temozolomide **ACTe**



DEVELOPING FUTURE



NOVARTIS

# PDlasta®




Pegylated filgrastim

Produced From Trusted PDgrastim®

## Lasts Longer

(Prolonged dosage form of PDgrastim®)

 Together  
We will beat  
the Cancer

-  INJECT ONLY ONCE IN EACH CHEMOTHERAPY CYCLE
-  SELF-REGULATORY CLEARANCE
-  SHORTER ANC NADIR WITH OPTIMAL SERUM LEVEL OF ONCE PER CYCLE INJECTION



 **Pooyesh Darou**  
Biopharmaceutical Co.

Factory: Noavari 18, Pardis Technology Park, 15Km Abali Road, Tehran, Iran  
Tel: +98 21 76250466-70 | Fax: +98 21 76250479

[pooyeshdarou.com](http://pooyeshdarou.com)

Central Office: No. 13, 5<sup>th</sup> Ave, Fatemi St, Tehran, Iran  
Tel: +98 21 88997248-88994590 | Fax: +98 21 88969368







## A RELIABLE CHOICE FOR PROSTATE CANCER



تحت پوشش نود درصدی بیمه های تامین اجتماعی، نیروهای مسلح و خدمات درمانی



  
**HOMA PHARMED**  
Pharmaceutical Co.

 NO. 13 . 5th Ave . Fatemi St . Tehran . Iran  
 +98 21 88 970 980  
 [www.homapharmed.com](http://www.homapharmed.com)  
 [info@homapharmed.com](mailto:info@homapharmed.com)

**TinaPeg**<sup>™</sup>  
Pegfilgrastim  
6 mg / 0.6 mL



# Smart Neutrophilia

A reliable long-acting form of filgrastim

ATG

World class quality in the treatment of neutropenia.



**Tinapeg®**

Solution for injection in preservative-free pre-filled syringe. The single use pre-filled syringe of Tinapeg® contains 6 mg pegfilgrastim at a fill volume of 0.6 ml (10 mg/ml based on protein only).

**Manufacturer and production license holder:**

AryaTinaGene Biopharmaceutical Co., Gorgan, Iran

Communicate with the audience (comments, criticisms, getting help for drug use): 300081911

**ATXG**<sup>®</sup>  
AryaTinaGene  
Biopharmaceutical Co.





# The Third International Clinical Oncology Congress

The 13<sup>th</sup> Iranian Annual Clinical Oncology Congress

Clinical Radiobiology Seminar

The Third International Clinical Oncology Nursing Congress

Annual Radiotherapy Technologists' Congress

Tehran - Iran

---

19-21 December 2018

Iranian Society of Radiation (Clinical) Oncology

**President of Society:** Dr Mohammad Reza Ghavam-Nassiri

**Scientific Committee Chairperson:** Dr Payam Azadeh

**Executive Committee Chairperson:** Dr Pedram Fadavi

**Scientific Chairperson of Clinical Radiobiology:** Prof. Hossein Mozdarani

**Scientific Chairperson of Nursing Congress:** Dr Mahnaz Ilkhani

**Scientific Chairperson of Radiotherapists' Congress:** Hassan Nosrati



Unit # 4, 1st Floor, No # 63, Tousi St;  
Tohid Ave; Tohid Sq; Tehran- IRAN  
Tel: 0098-21-66567619  
Fax: 0098-21-66567620



**The 13th Iranian Annual Clinical Oncology Congress  
Clinical Radiobiology Seminar  
The Third International Clinical Oncology Nursing Congress  
Annual Radiotherapy Technologists' Congress**

19 -21 December 2018  
Tehran-Iran



---

President of Society: Dr Mohammad Reza Ghavam-Nassiri  
Scientific Committee Chairperson: Dr Payam Azadeh  
Executive Committee Chairperson: Dr Pedram Fadavi  
Scientific Chairperson of Clinical Radiobiology: Prof. Hossein Mozdarani  
Scientific Chairperson of Nursing Congress: Dr Mahnaz Ilkhani  
Scientific Chairperson of Radiotherapists' Congress: Hassan Nosrati  
Publisher: MirMah Publishing Co.  
Run: 1000 Copies

---

**Unit # 4, 1st Floor, No # 63, Tousi St; Tohid Ave; Tohid Sq; Tehran- IRAN**  
**Tel: 00982166567619 Fax: 00982166567620**  
**[www.cong2018.isro.org.ir](http://www.cong2018.isro.org.ir)**

---



Faran Shimi  
Pharmaceutical Co.




The Third  
International  
Clinical  
Oncology  
Congress

Sponsors





**ISRO**  
Iranian Society of  
Radiation Oncology





**Dr. M.R. Ghavam-Nassiri**

President of ISRO

In The Name of God

□ Dear colleagues, on behalf of the Iranian Society of Radiation Oncology (**ISRO**), I am delighted to invite you to participate in the 3rd International Clinical Oncology Congress in Tehran, Iran.

For the congress, distinguished national and international speakers have been invited from different countries, who will describe their recent exciting developments covering various topics in the field of oncology.

The congress will feature an interactive and multidisciplinary programs including workshops, plenary session as well as oral abstract and poster sessions.

Needless to say, organizing an event of this caliber, which is hoped to be of high scientific standards, would have been impossible without the efforts and cooperation of many academic individuals and others (from Medical or non- Medical fields) who have spent a lot of time and energy to plan and guarantee the smooth running of the event. It is thus my duty to express my gratitude and that of the members of ISRO's Board of Directors to all these individuals.

For the sake of brevity, I excluded any reference to such subjects as early diagnosis and screening, new treatments, new findings in Cancer pathology (especially the use of Genetics in the diagnosis and classification of Cancer, and even boosting the patients' lifespan), palliative Medicine, supportive care (especially psycho-oncology), and new Nursing systems.

I must finally thank the Board of Directors and all the members of ISRO, especially Dr. Fadavi, the Executive Secretary of the Congress, Dr. Azadeh, the Scientific Secretary of the Congress, and Dr. Foodazi, the Secretary of ISRO, and thanks to MS. Zayeri for handling all administrative Work.

On behalf of the ISRO, I sincerely hope that This congress will contribute to making great progress in the managements of oncology patients. I look forward to personally welcoming you to Tehran for the 3rd International Clinical Oncology Congress, from all parts of the world.





**Payam Azadeh MD**

Scientific Chairperson

The Third  
International  
Clinical  
Oncology  
Congress



Welcome

□ Dear Colleagues,

Following on from the success of the second ISRO international congress in December 2017 in Tehran, we are extremely proud to announce, on behalf of the Iranian Society of Radiation Oncology (ISRO), that the 3rd international clinical oncology congress (and 13th annual clinical oncology congress) will be held from 19-21 December 2018 in Tehran, Iran. Cancer is consistently considered as one of the most important health problems facing every nation in the world, and it is the second leading cause of death in many developing countries, including Iran. It is also one the most costly illnesses in many parts of the world and people with cancer often have high out-of-pocket health care costs. Rapid advances in cancer science have increased the number of new oncology treatment modalities being developed, including sophisticated radiotherapy techniques, complex surgical procedures, and novel systemic therapy options including target therapy and immunotherapy. Through a series of lectures and educational sessions conducted by distinguished national and international speakers, this congress provides an evidence-based review of advances in the field of solid tumors, including prevention, diagnosis and various methods of treatment. Similar to the previous congress, in addition to traditional presentations and lectures by invited speakers, we will be offering delineation workshops for radiation oncologists to refresh and validate their knowledge and skills in this field.

Furthermore, in the first day and through a series of plenary sessions, the congress will provide a review of recent national health care developments, including implementation of national oncology guidelines.

Along with the 3rd international clinical oncology congress, we will have the third international nursing oncology congress, which will provide a distinctive forum to meet experienced professionals in the field of oncology nursing. In addition, the annual congress of radiotherapy technologists and the 1st clinical radiobiology seminar will also be held at the same time, that will have full academic sessions especially on advances in radiation biology, modern radiotherapy techniques, imaging, dosimetry and patient care and counselling.

We look forward to welcoming you all for what promises to be an outstanding educational event.

Sincerely,





**Dr Pedram Fadavi**

Executive Secretary

- In the name of God, the beneficial, the merciful

Greetings

Thanks to the almighty God, for the third year in a row, we host the grand family of the Iranian Clinical Oncology society.

The third international clinical oncology congress and the 13th annual Iranian clinical oncology Conference will be hosted by Iranian society of clinical oncology (ISCO) with collaboration of the European Society for Radiotherapy and Oncology (ESTRO) and will be held at the Olympic Hotel. The congress will be attended by international scholars from all over the world.

Today Cancer is a health dilemma in most countries and although there has been a rapid increase in its incidence, but tremendous developments in diagnostic and therapeutic care has paved our way to find a cure. Evidence suggests that due to the deliberate efforts of scientists and researchers, life expectancy has increased dramatically in cancer patients, and this congress is a scene to showcase these developments.

Like before, at this year's congress, we will present the latest oncology achievements in the form of lectures, posters and specialized panels. Also challenging debates and exchange of scientific opinions between Iranian and foreign scholars would definitely make it a fully dynamic meeting.

At the end, we are grateful to the Board of Directors of the Iranian Society of Radiotherapy and Oncology, the Honorable President of ISCO, Dr. Ghavam Nasiri, and the Secretary-General of the society, Dr. Fudazi.

We also acknowledge our gratitude to:

Mrs. Dr. Malekzadeh, Head of International Relations

Mrs. Dr. Ilkhani, Secretary of the Nursing Congress

Dr. Mrs. Khoshbakht, Head of the executive team

Mr. Nosrati, Secretary of the Congress of Radiation Therapists

And

All members of the Scientific and Executive Committee





## دکتر پیام آزاده

دبیر علمی کنگره

The Third  
International  
Clinical  
Oncology  
Congress

Welcome

□ درود و سپاس پروردگار رحمتگر مهربان که به ما این توفیق را داد تا امسال، برای سومین سال متوالی کنگره بین‌المللی کلینیکال انکولوژی را با حضور و همراهی دست‌اندرکاران خیره حوزه تشخیص و درمان سرطان از تمامی جوامع علمی داخلی و بین‌المللی برگزار نماییم.

این افتخار، نتیجه تلاش جمع کثیری از عزیزان و همکاران در انجمن رادیوتراپی انکولوژی ایران، دانشگاه‌ها، مراکز تحقیقاتی و انجمن‌های علمی است.

امروزه بیماری سرطان به عنوان شایع‌ترین علل مرگ و میر در کشورهای در حال توسعه شناخته می‌شود و بدون شک سرعت پیشرفت‌های علمی با شناخت دقیق بیولوژی مولکولی سرطان، شتاب بیشتری پیدا کرده است، در نتیجه اهمیت و ضرورت تشکیل چنین میتینگ‌های علمی داخلی برای همگان مشخص و مبرهن است. در این کنگره نیز اساتید و همکاران برجسته ملی و بین‌المللی و دست‌اندرکاران و صاحب‌نظران حوزه سرطان تجربیات و نظرات خود را در قالب سخنرانی، پانل‌های تخصصی، کارگاه‌های آموزشی با سایر همکاران به اشتراک خواهند گذاشت.

علاوه بر مباحث علمی در پنل افتتاحیه کنگره سعی خواهد شد تا مبانی توسعه سلامت در حوزه سرطان و ضرورت تدوین گایدلاین‌های بومی مورد بحث و تبادل نظر قرار گیرد.

در کنگره امسال علاوه بر ارائه آخرین دستاوردهای انکولوژی در غالب سخنرانی، بحث‌های چالش‌برانگیز و پانل‌های تخصصی، کارگاه‌های آموزشی طراحی درمان رادیوتراپی به منظور همکاری بین‌رشته‌ای کارگاه‌های تخصصی پستان با حضور اساتید برگزار می‌گردد. در کنگره امسال به مباحث توسعه سلامت، درمان سرطان در کشور ایران، ضرورت تدوین گایدلاین ملی، داروهای بیوسیمیلار، سرطان‌های پروستات، پستان، ریه و دستگاه گوارش پرداخته می‌شود.

در این کنگره علاوه بر مباحث تخصصی انکولوژی سومین کنفرانس پرستاری سرطان و کنفرانس سراسری تکنولوژیست‌های رادیوتراپی و اولین همایش رادیوبیولوژی بالینی با حضور همکاران پرستار، تکنولوژیست و فیزیست‌های رادیوتراپی برای ارائه دست‌آوردهای مراقبت از بیماران سرطانی و تبادل تجربیات در بهبود کیفیت اجرای درمان سرطان و پیشگیری از عوارض احتمالی برگزار خواهد شد.

در خاتمه از کلیه عزیزان و دست‌اندرکاران برگزاری این کنگره به خصوص هیأت مدیره انجمن رادیوتراپی انکولوژی و دبیران محترم برنامه‌های جانبی و اعضای کمیته علمی و اجرایی و شرکت‌های دارویی و تجهیزاتی که ما را در برگزاری این گردهمایی بین‌المللی همراهی و یاری کردند کمال تشکر را دارم، امید است این کنگره مورد رضایت شما سروران را فراهم نموده باشد.







دکتر پدram فدوی  
دبیر اجرایی کنگره



به نام خداوند جان آفرین  
حکیم سخن در زبان آفرین

□ با درود

خدای را سپاس که برای سومین سال پیاپی میزبانی گردهمایی خانواده بزرگ کلینیکال انکولوژی ایران را عهده داریم.

سومین کنگره بین المللی کلینیکال انکولوژی و سیزدهمین همایش سالیانه کلینیکال انکولوژی ایران با حضور اساتید مطرح بین المللی از سراسر جهان و نیز با همکاری انجمن رادیوتراپی انکولوژی اروپا در هتل المپیک برگزار خواهد شد.

امروزه سرطان معمای لاینحل پزشکی نیست هرچند به علل مختلف رشد آن نسبت به ادوار گذشته فزونی یافته اما دست آوردهای نوین تشخیصی و درمانی گوی سبقت را از این بیماری ربوده اند.

شواهد حاکی از آن است که امید به زندگی در بیماران مبتلا به سرطان افزایش یافته است که این مهم مرهون تلاش های مدبرانه دانشمندان و محققان است و این کنگره صحنه ای برای نمایش این پیشرفت هاست.

به سیاق گذشته در کنگره امسال نیز ارائه آخرین دست آوردهای انکولوژی را در قالب سخنرانی، پوستر و پانل های تخصصی خواهیم داشت که همراهی بحث های چالشی روز دنیا در حوزه سرطان و تبادل نظرهای علمی میان اساتید ایرانی و خارجی به پویاتر شدن این محفل خواهد افزود.

در انتها کمال قدردانی و امتنان از هیأت مدیره محترم انجمن رادیوتراپی انکولوژی ایران، ریاست محترم جناب آقای دکتر قوام نصیری و دبیر محترم انجمن جناب آقای دکتر فودازی و همچنین سپاس از تلاش های بی دریغ همکاران مان:

سرکار خانم دکتر ملک زاده، مسوول روابط بین الملل

سرکار خانم دکتر ایلخانی، دبیر کنگره پرستاری

سرکار خانم دکتر خوشبخت، سرپرست تیم اجرایی

جناب آقای نصرتی، دبیر کنگره تکنولوژیست های رادیوتراپی

و

تمام اعضای محترم کمیته علمی و اجرایی





### Hossein Mozdarani, Ph.D

Professor of Tarbiat Modares University  
Scientific Chairperson of Clinical Radiobiology

The Third  
International  
Clinical  
Oncology  
Congress

Welcome


□ Dear Colleagues,

It is my honor to invite you to the 2nd Conference on Clinical radiobiology, to be held on 19 December 2018 in conjunction with the 3rd international and 13th annual congress of Clinical oncology arranged by our dear colleagues in the Iranian society of Clinical oncology, in Tehran, Iran.

It is also my great pleasure to be able to hold the second conference on Clinical radiobiology in Iran. The aim of This conference as similar to other previously held is to update our knowledge, exchange and share our experiences as well as getting familiar with advancements in the field of radiobiology and its application in Clinical oncology.

Over the last decades, we have witnessed, the advancement and application of molecular biology/Genetics techniques in radiobiology that significantly improved our understanding of cellular responses of both normal tissue and tumor cells to ionizing radiation as well as chemotherapy. The last three decades have seen a major shift from a DNA-centric view of radiation induced damages, to a biological view that appreciates the importance of cellular macro- and microenvironment as well as underlying Genetics mechanisms. Radiobiological phenomena such as radio-adaptation, bystander effect and inherent radio-sensitivity have changed classical belief of linear non threshold (LNT) model. While the mechanisms underlying these effects and responses are not well defined, it is apparent that their implications are more panoramic than the field of radiobiology. These biological paradigms might have major implications in radiation carcinogenesis and Cancer radio- and chemo-therapy. Consequently regarding to modern radiation oncology, mechanistic insights resulting from molecular radiation biology Research will provide tools to develop new strategies of individualized therapy and molecular targeting in modern radiation oncology to further improve tumor responses and reduce normal tissue reactions.





This is the second meeting series on Clinical radiobiology that tries to bring together leading academic basic and Clinical scientists as well as Researchers from various disciplines related to radiobiology, to discuss the latest developments in the fields of basic and Clinical radiobiology and share their experiences and Research results on all aspects of radiobiology. To promote translation of basic Research results into Clinical application, an intensified dialogue between basic and Clinical scientists is important. Therefore, prospective Authors, young scientists and Students are kindly encouraged to contribute to the conference through submissions of their Research abstracts. Also, high quality Research contributions describing original and unpublished results of experimental Work in all areas of Radiation Biology are cordially invited for presentation at the conference.

We look forward to your participation in the conference.

Kind Regards,





### Dr Mahnaz Ilkhani

Director of The Third International Clinical Oncology Nursing Congress

Assistant Professor School of Nursing and Midwifery, University of Shahid Behashati

The Third  
International  
Clinical  
Oncology  
Congress



Welcome

□ Professional growth for Iranian oncology nurses' is necessary, due to an increased rate of Cancer morbidity and mortality. Although, Iranian oncology nurses' are facing with many challenges in terms of reducing Cancer morbidity and mortality, improving survival and quality life of patients. Professional development for oncology nurses is possible in the light of Research, education and advance Practice.

**The Third International Clinical Oncology Congress** is the one of prominent and inspiring event in This field. This congress is a unique opportunity to meet inspiring speakers and Experts across the Iran.

**The Oncology Nursing Congress** attempts to provide the latest research and advancement in this field with focus on evidence base practice. This event is a good place to communicate with colleagues and peers as well as to provide a forum for an exchange of ideas related to Cancer care and team collaboration.

Hope to see you at the congress that is interesting to provide high standard of care for patients with Cancer.



## دکتر مهناز ایلخانی

دبیر پرستاری سومین کنگره پرستاری کلینیکال انکولوژی  
استادیار دانشکده پرستاری و مامایی شهید بهشتی



□ فراهم کردن زمینه و توسعه فعالیت‌های حرفه‌ای در زمینه پرستاری انکولوژی در ایران یکی از ضروری‌ترین نیازها، به دلیل افزایش شیوع و موربیدیتی بیماری سرطان محسوب می‌شود. اگرچه پرستاری انکولوژی ایران رودررو با چالش‌های متعدد در زمینه‌های حرفه‌ای من جمله: بهبود کیفیت زندگی، افزایش طول عمر و موربیدیتی بیماران مبتلا به سرطان است. بهر حال، پیشرفت حرفه‌ای در قالب آموزش، فعالیت‌های بالینی و تحقیقات زمینه‌ای امکان پذیر است.

در این راستا، سومین کنگره پرستاری کلینیکال انکولوژی یکی از برجسته‌ترین و فاخرترین کنگره‌های علمی در زمینه پرستاری انکولوژی است. کنگره حاضر برای حرفه پرستاری یک فرصت بی نظیر برای ملاقات با پرستاران متخصص سرطان از سراسر ایران است.

هدف اصلی کنگره پرستاری کلینیکال انکولوژی فراهم کردن و در اختیار قرار دادن آخرین تحقیقات و پیشرفت‌های به روز در رابطه با مراقبت‌های مبتنی بر شواهد در پرستاری از بیماران مبتلا به سرطان می‌باشد. به علاوه این کنگره ایجادکننده یک جایگاه مناسب برای تبادل ایده‌ها و افکار در زمینه مراقبت از بیماران مبتلا به سرطان و فراهم‌کننده زمینه مناسب بهتر در همکاری‌های بین حرفه‌ای در زمینه تحقیقات، آموزش و ارائه مراقبت‌ها می‌باشد.

با آرزوی دیدار همه همکاران علاقمند به مراقبت و حمایت از بیماران مبتلا به سرطان در سومین کنگره پرستاری کلینیکال انکولوژی





### Hassan Nosrati

Scientific Manager of Radiation Therapy Technologists Program

The Third  
International  
Clinical  
Oncology  
Congress



Welcome

□ This is the third year, with the help of God and the help of the responsables of the Iranian Society of Radiation Oncology, third annually Iranian radiotherapy technologist conference that would be held at the third International Clinical Oncology Congress. This year, based on the todays needs of radiotherapy from Radiation Therapy Technologists point of view, three main needs were identified: the First, the definition of standard, practical and local protocols, such as patient educations and patient assessments, quality control, management of unscheduled treatment interruption and other necessities. Second requirement: based on the difficult conditions and shortcomings in the field of radiotherapy, it is necessary to increase the information and knowledge of Experts to optimize maintenance of accelerators in radiotherapy Centers. Finally, need to know the limitations and sources of uncertainty in radiotherapy and ways to minimize them. At the conference we tried to respond to these needs in the form of lectures and Workshops in order to benefit from and share valuable experiences of our colleagues from different radiotherapy Centers. We hope that This collective and multi-month effort will take some small, but useful steps to improve the quality of radiotherapy in our country.



## حسن نصرتی

مسئول کمیته کارشناسان رادیوتراپی انجمن رادیوتراپی آنکولوژی



□ امسال سومین سال متوالی است که با یاری خدا و کمک مسئولین محترم انجمن رادیوتراپی آنکولوژی توفیق برگزاری سومین همایش سالیانه کارشناسان رادیوتراپی ایران را در کنار سومین کنگره بین المللی کلینیکال آنکولوژی را داریم.

امسال براساس نیازسنجی انجام شده در زمینه رادیوتراپی، سه نیاز اصلی شناسایی گردید: نیاز اول، تعریف الگوهای استاندارد، عملی و بومی در موارد اصلی مانند نحوه آموزش به بیماران و ارزیابی بیماران، فرهنگ گزارش خطا، کنترل کیفی، چگونگی مدیریت وقفه‌های درمانی و دیگر موارد ضروری است. نیاز دوم: با توجه به شرایط دشوار و کمبودهای به وجود آمده در زمینه رادیوتراپی، نیاز به افزایش اطلاعات و آگاهی کارشناسان در زمینه نگهداری بهینه دستگاه‌های شتاب‌دهنده موجود در مراکز رادیوتراپی کشورمان. و دست آخر نیاز به دانش و آگاهی تیم درمانی نسبت به محدودیت‌ها و منابع عدم قطعیت در رادیوتراپی و راه‌های به حداقل رساندن آن‌ها بود.

در همایش پیش‌رو تلاش گردید که تا حد امکان با بهره‌مندی و به اشتراک‌گذاری تجربیات ارزشمند همکارانمان از مراکز مختلف رادیوتراپی کشورمان و دیگر کشورها در قالب سخنرانی و برگزاری کارگاه به این نیازها پاسخ داده شود.

امیدواریم این تلاش جمعی و چند ماهه بتواند قدم‌هایی هر چند کوچک اما مفید، در جهت بهبود کیفیت رادیوتراپی کشورمان بردارد.





### بزرگداشت استاد دکتر حسین علاقه‌بند

□ استاد دکتر حسین علاقه‌بند متولد ۱۳۱۸ از یزد، تحصیلات ابتدایی و متوسطه خود را در شهرهای یزد و تهران گذرانده و در کنکور دانشکده پزشکی مشهد پذیرفته شدند و پس از ۲ سال خود را به دانشکده پزشکی اصفهان منتقل و در سال ۱۳۴۸ از این دانشکده فارغ‌التحصیل و سپس برای اخذ درجه تخصصی عازم کشور انگلستان شد. در فوریه ۱۹۷۱ قسمت اول امتحانات دوره D.M.R.T رادیولوژی و فیزیک رادیولوژی را در بیمارستان میدل سکس گذرانیده، در اکتبر ۱۹۷۲ دوره کاروری را در مرکز رادیوتراپی بیمارستان عمومی نیوکاسل انگلستان آغاز کرده و در سال ۱۹۷۴ پس از اخذ گواهینامه مربوطه به‌عنوان متخصص رادیوتراپی شناخته شدند.

استاد در اوایل سال ۱۳۵۳ به ایران مراجعه و در تیر ماه همان سال در دانشگاه علوم پزشکی تهران در گروه آموزشی رادیولوژی به خدمت مشغول شدند، بعد از ۳ سال گروه رادیوتراپی به همت استاد زنده‌یاد مرحوم دکتر دهشیری از گروه رادیولوژی جدا گردید لذا دکتر علاقه‌بند پس از ۶ سال خدمت با درجه دانشیاری در این گروه، در سال ۱۳۸۳ با تقاضای خود باز نشستگی شدند.

ایشان همواره از استاد بزرگوار مرحوم دکتر دهشیری که زحمات زیادی در این گروه انجام داده‌اند یاد کرده و خود را همیشه مدیون اخلاق و بزرگواری ایشان می‌دانند.

دکتر علاقه‌بند از سال ۱۳۸۹ تاکنون در مرکز آموزش علمی-کاربردی نیکوکاری رعد که با مجوز دانشگاه جامع علمی کاربردی به منظور آموزش افراد معلول جسمی-حرکتی در رشته‌های مختلف مقاطع کاردانی و کارشناسی به صورت تلفیقی در کنار افراد سالم برگزار می‌گردد، داوطلبانه و افتخاری خدمت می‌نمایند.

انجمن رادیوتراپی انکولوژی آرزوی پایداری و تندرستی ایشان را خواهان است.





### بزرگداشت استاد دکتر مسعود ناصری پور

□ استاد دکتر مسعود ناصری پور متولد اسلام آباد غرب، متخصص چشم و فلوشیپ شبکیه و آنکولوژی چشم از امریکا هستند.

استاد در سال ۱۳۶۸ مدرک پزشکی عمومی را از دانشگاه علوم پزشکی تبریز اخذ نموده و بلافاصله در رشته تخصصی جراحی چشم در همان دانشگاه پذیرفته شدند. سپس به عنوان فلوشیپ شبکیه در دانشگاه ایران دوره دو ساله خود را سپری کرده و در سال ۱۳۷۹ در بیمارستان فوق تخصصی ویلز امریکا در زمینه سرطان های چشم به تحصیل پرداختند.

علاقه و اهتمام استاد به آموزش و پژوهش مثال زدنی است. چاپ بیش از هفتاد مقاله در ژورنال های معتبر داخلی و خارجی، تألیف کتب تخصصی، انجام بیش از بیست مورد پروژه های تحقیقاتی در زمینه بیماری های چشم و ارائه سخنرانی در بیش از ۱۵۰ کنفرانس علمی از افتخارات ستودنی ایشان است. استاد ناصری پور علاوه بر امر درمان، تدریس و پژوهش، مسئولیت های مهمی را نیز عهده دار بودند که اهم آنها به شرح زیر است:

- ریاست دپارتمان چشم پزشکی دانشگاه علوم پزشکی کرمانشاه
  - ریاست مرکز تحقیقات چشم پزشکی دانشگاه علوم پزشکی ایران
  - ریاست دانشکده پزشکی دانشگاه علوم پزشکی ایران
  - سرپرست هیأت بورد انجمن چشم پزشکی ایران
  - ریاست دانشگاه علوم پزشکی ایران
- انجمن رادیوتراپی آنکولوژی ایران سلامتی و موفقیت بیش از پیش این استاد فرهیخته و بزرگوار را از خداوند متعال خواستار است.

The Third  
International  
Clinical  
Oncology  
Congress



Tribute



Clinical  
Oncology  
**Scientific**  
Committee  
Alphabetical

**Chair :** Dr Payam Azadeh

Dr Hamdy Abdel Azim  
Dr Zeynab Abyar  
Dr Mehdi Aghili  
Prof. Mohamad Esmaeil Akbari  
Dr Majid Akrami  
Dr Alireza Amouheidari  
Dr Farnaz Amozegar Hashemi  
Dr Hossein Alaghband  
Dr Azin Alizadeh Asl  
Dr Mansour Ansari  
Dr Kazem Anvari  
Dr Amir Anvari  
Dr Farshid Arbabi  
Dr Amir Mohammad Arefpour  
Dr Drik Arnold  
Dr Morteza Atri  
Dr Samira Azghandi  
Dr Parisa Aziminejadan  
Dr Mohammad Babaei  
Dr Mohhamadreza Bagherinejad  
Dr Abbas Basiri  
Dr Maedeh Berahman  
Dr Adina Binit Alip  
Dr Mehrdad Bohloli  
Dr Manochehr Davaei  
Dr Hamidreza Dehghan Manshadi  
Dr Saeed Derakhshani  
Dr Iman Divan Beigi  
Elzbieta Senkus-konefka MD  
Dr Ebrahim Esmati  
Dr Farshad Farzad Far  
Dr Abdolah Fazlalizadeh  
Dr Hossein Foudazi  
Dr Mohammad Foutohi

Dr Mohammadreza Ghavam-Nassiri  
Dr Pegah Gorji Bayani  
Dr Peyman Haddad  
Dr Hamidreza Hashemifard  
Dr Simin Hemati  
Dr Mohammad Hoshyari  
Dr Jalil Hosseini  
Dr Masoud Irvani  
Dr Ali Jafarian  
Dr Hamidreza Jamati  
Prof. Hamidreza Jamshidi  
Dr Alireza Javadinia  
Dr Shaghayegh Kamian  
Dr Alireza Keramati  
Dr Helale Khoshbakht Ahmadi  
Dr Marzie Lashgari  
Dr Afsaneh Maddah  
Dr Habibolah Mahmodzadeh  
Dr Hamaideh Mahmoudi Alemi  
Dr Yasha Makhdomi  
Prof. Reza Malekzadeh  
Dr Mona Malekzadeh  
Dr Mohamadreza Masjedi  
Dr Mohammadreza Mir  
Dr Hamidreza Mirzaie  
Dr Khosro Mojir Sheibani  
Dr Bahare Moeini  
Dr Bahram Mofid  
Dr Shiva Moghaddam  
Dr Majid Mokhtari  
Dr Ahmad Mosalaei  
Dr Ali Motlagh  
Dr Masoud Naseri Pour  
Dr Nahid Nafisi  
Dr Saman Nikeghbalian  
Dr Alireza Nikoofar  
Dr Hamed Nikopour  
Dr Mohammadreza Nik Shoar  
Dr Gholam Hossein Noferesti  
Dr Asieh Olfatbakhsh  
Dr Alireza Oliaeimanesh  
Dr Ramesh Omrani pour

The Third  
International  
Clinical  
Oncology  
Congress

Clinical  
Oncology  
Scientific  
Committee



Clinical  
Oncology  
Executive  
Committee  
Alphabetical

Dr Alireza Rasekhi  
Dr Sara Rastin  
Dr Stefan Rauh  
Dr Ali Razi  
Dr Ahmad Mafi  
Dr Alireza Rezvani  
Dr Farhad Samiee  
Dr Mastane Sanei  
Dr Samaneh Sarbaz  
Dr Manochehr Sardari Kermani  
Dr Masoumeh Shafiei  
Dr Hojatollah Shahbazian  
Dr Shahriar Shahriarian  
Dr Jafar Shakeri  
Dr Masoud Sotodeh  
Dr Nasibe Tabatabayi  
Dr Mehdi Tahamtan  
Dr Tayebah Taheri Panah  
Dr Farnaz Taslimi  
Dr Bichay Tewfik Jermyn  
Dr Navid Tofighi Rad  
Dr Anna Wrona  
Dr Ali Yaghobi Joybari  
Dr Hossein Yahyazadeh  
Dr Shadi Zohori nia

**Chair:** Dr Pedram Fadavi

Dr Farshid Arbabi  
Dr Hossein Foudazi  
Dr Helale Khoshbakht Ahmadi  
Dr Ahmad Mafi  
Dr Mona Malek Zadeh  
Dr Kambiz Novin  
Dr Ali Yaghobi Joybari  
Golnaz Zaeri  
Mahnaz Zaeri

The Third  
International  
Clinical  
Oncology  
Congress

Clinical  
Oncology  
Executive  
Committee

Nursing  
**Scientific**  
Committee  
Alphabetical

Froozan Atashzadeh  
Samaneh Bagherian  
Masoud Bahrami  
Tahereh Baloochi Bidokhti  
Maryam Bayati  
Hesam Gholamzadeh  
Fateme Hadadian  
Fateme Hashemi  
Heshmatollah Heidari  
Mahnaz Ilkhani  
Maryam Janatmakan  
Naeimeh Keshavarz  
Sahar Mirzaei  
Jafar Moghadasi  
Solmaz Mousavi  
Parastoo Ojjan  
Pouneh Pirjani  
Kamelia Rohani  
Shahin Salarvand  
Nayereh Salmani  
Mohsen Shahriari  
Amir Tabatabaei  
Fariba Taleghani  
Shokuh Varaei

Nursing  
Coordinator  
Committee  
Alphabetical

Aram Halimi  
Maryam Karami

**Scientific**  
committee of  
Clinical  
Radiobiology  
Seminar  
Alphabetical

**Scientific Secretary:**

Professor Hossein Mozdarani

Dr Payam Azadeh  
Dr Mohsen Bakhshandeh  
Dr Fathollah Bozarjomehry  
Dr Mostafa Farzin  
Dr Hossein Foudazi  
Dr Mohsen Foroghizadeh-Moghadam  
Dr Akbar Gharbali  
Dr Somayeh Gholami  
Dr Abolghasem Haeri  
Dr Ramin Jaberi  
Dr Samideh Khoei  
Dr Maziar Mahdavi  
Dr S Rabie Mahdavi  
Dr Lotfali Mehdipour  
Dr Parinaz Mehnati  
Dr Bahram Mofid  
Dr S.M Javad Mortazavi  
Dr Amin Mosleh-Shirazi  
Dr Hossein Mozdarani  
Dr Hassan-Ali Nedaie  
Dr Ali Neshastehriz  
Dr Alireza Nikoofar  
Dr Alihossein Saberi  
Dr Mahdiah Salimi  
Dr Farhad Samiei  
Dr Ali Shabestani Monfared  
Dr Maryam Shahidi  
Dr Alireza Shirazi

**Executive Secretary:**

Mr Hassan Nosrati, M.Sc.

Members of  
Review of  
Articles  
Committee  
Alphabetical

Dr Azin Ahmari  
Dr Amir Anvari  
Dr Mohammad Barzegar Tahamtan  
Dr Maede Brahman  
Dr Hamidreza Hashemifard  
Dr Afsaneh Maddah  
Dr Morteza Tabatabaeefer  
Dr Taiebe Taheripanah  
Dr Shadi Zohurinia

Members of  
**RTTs Scientific**  
Committee  
Alphabetical

Simin Abbasi  
Sara Adollahi  
Hamed Alizadeh  
Hamzeh Almasroo  
Hanieh Aslani  
Dr Payam Azadeh  
Dr Mohammad Babaei  
Dr Mohsen Bakhshandeh  
Zahra Baratpour  
Tayeb Erfanian  
Mohammad Kazem Faramani  
Dr Mohammad Reza Ghavam-Nassiri  
Dr Mohammad Hadi Gholami  
Mohsen Habibi

Members of  
RTTs  
Executive  
Committee  
Alphabetical

Simin Abbasi  
Roojin Abolhassani  
Hamed Alizadeh  
Noushin Amini  
Ardavan Amiri  
Elnaz Dabiri  
Leila Hosseini  
Zahra Kalaii  
Hireh Lotfi  
Nader Naderian  
Masoumeh Nezami  
Faezeh Rahmati  
Rana Ramezani  
Vida Rezaie

The Third  
International  
Clinical  
Oncology  
Congress

Members of  
Review  
Article  
&  
Scientific  
&  
Executive  
Committee  
of  
Congress

Davoud Hafezi  
Mohammad Esmaeil Hajian  
Dr Ramin Jaberi  
Dr Nima Mousavi Nasiri  
Omar Murik  
Marzieh Nabi Khani  
Mansour Naderi  
Ali Rastjou  
Amirhoushang Sedigh  
Nader Sepanlou  
Keivan Shalchi  
Akbar Shahriari Mehr  
Fariba Soltani  
Mehdi Yazdani



Invited  
International  
Speakers



**Prof. Dr. Hamdy Abdel Azim**

**Founder, Cairocare  
Current Positions and Titles**

The Third  
International  
Clinical  
Oncology  
Congress

Invited  
International  
Speakers

□ Chairman of Kasr Al-Ainy School Of Oncology (KASO), official Cancer education organization, Department of Oncology, Faculty of Medicine, Cairo University.

Professor of Clinical Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt  
President of Africa Middle East Cancer Research Inter group.

Referee for the Annals of Oncology Journal, The Breast Journal (TBJ), BMC Cancer, Chemotherapy journal , Advances in Cancer Research & Treatment , Journal of the Egyptian National Cancer Institute, and the Chinese Clinical Oncology Journal.

Pioneering Activity

Past chairman of the Oncology Department, Faculty of Medicine, Cairo University.

First to represent the Middle East countries on the ASCO international committee, for a period of 5 years (May 1997-May 2002)

Chief editor of 2 educational books ASCO PANARAB Lymphoma Conference (1999) and the MD Anderson Cancer Centre / Cairo University joint meeting (2006)

More than 80 scientific and Research publications.

Scientist of the Year from the International Biographical Centre, Cambridge, UK (2002)

The Order of Merit, Cambridge University (2002)

The Best Arab Oncologist from the Lebanese Society of Medical Oncology (LSMO, 2004)

The recognition award for significant contribution to the Oncology field in the middle east from UAE (Dubai -2013)

Dr Azim signed the Charter of Paris against Cancer on behalf of the Arab World in February 2000.



### **Prof. Dirk Arnold**

**Associate Professor, Department of Radiation  
Oncology  
ESMO Board Member**

□ Dirk Arnold is Director of the Dept. Medical Oncology at Klinik für Tumorbologie, Freiburg, Germany. Before taking This position, he was 2010 appointed as Director of the University Cancer Centre in Hamburg (UCCH) and held positions at the University Departments for Oncology and Haematology in Halle-Wittenberg and Berlin.

His major field of scientific interest are gastrointestinal Cancers, and here specifically modern therapeutic approaches in biomarker-driven decision processes, and multimodal treatment strategies, also including other specialities. Here, he serves as chairman of Colorectal Cancer Study Group of the German AIO, a major collaborative group in Clinical oncology. Within the AIO frameWork, he served as founding member of the Central Clinical Trials Office, underlining his Expertise also in methodology of Clinical Research. Furthermore, his interest is the organisation of larger collaborative Research structures and of integrated Cancer centre neTWorks.

Prof. Arnold is also member of the American Society of Clinical Oncology and Task Force Member of the National Cancer Institute, as well as Board member of the EORTC GI study group.

Furthermore, he is board member of the German Society of Haematology and Medical Oncology (DGHO), and member of the German Cancer Society.

Within ESMO, since 2012 he is section editor for GI Cancers in the Guidelines Committee.

The Third  
International  
Clinical  
Oncology  
Congress

Invited  
International  
Speakers





**Tewfik J. Bichay, Ph.D.**

**Ph.D. in Medical Biophysics**



□ Dr. Bichay obtained his B.Sc. degree in Physiology from McGill University, Montreal, his M.Sc. in Biology from Concordia University, Montreal, and his Ph.D. in Medical BioPhysics from the University of Western Ontario, London, Canada. He is currently Director of Medical Physics, Radiation Oncology, the Lacks Cancer Center at Mercy Health, St. Mary's, Grand Rapids, MI. He started his career as a radiation biologist before transitioning into Medical physicist with a residency at the Ottawa Regional Cancer Center. He is an accreditation surveyor for the ACR, served for a number of years as an ABR MOC examination committee member, and is the previous President of the Great Lakes Chapter of the AAPM, and holds a patent on a compact doorless radiation vault design. He is certified in Radiation Oncology Physics by the ABMP and his present Research interests include SRS and SBRT.







## **Dr Stefan Rauh**

**Consultant of Clinical Radiotherapy and  
Assistant Professor  
Centre Hospitalier Emile Mayrisch (CHEM)  
Luxembourg**

□ Dr Stefan Rauh Works as a Medical Oncologist/Haematologist at the Centre Hospitalier Emile Mayrisch (CHEM), Differdange and Esch in Luxembourg.

Born 1964 in Munich, Germany, he studied medicine in Munich and Lausanne, Switzerland, followed by post-graduate training in Munich, Nancy, France and Luxembourg.

In 1999, he was given the opportunity to develop an oncology unit (including out-patient hospital and palliative unit) at Differdange Regional Hospital. In 2010 the hospital merged with Esch, making a total of 500 beds. He is now part of the CHEM oncology unit with palliative care and President of CHEM's Plateform Cancer.

His Work is mainly Clinical, however his Work also includes teaching and Clinical Research activity and he is interested in co-operations with developing countries.

At present, he serves as a tutor and lecturer at the General Medicine Faculty of the University of Luxembourg.

He is currently involved in eight international clinical phase 3 and 4 studies, and has developed prospective randomised studies in out patient symptom monitoring in Luxembourg (pro-elects). Studies involve the CRP Santé, CIEC and IBBL, some are in collaboration with the CHL.

Dr Rauh is Vice President of the Société Luxembourgeoise d'Oncology and a member of the National Tumor Registry's board, the National Plan Cancer, the Luxembourg National Cancer Center Project and of the Scientific Council of the National Social Security.

Dr Rauh is a qualified member of ESMO and served as the National Representative for Luxembourg for eight years. From 2015, he is the Chair of the ESMO Practising Oncologists Working Group and has a seat on the ESMO Executive Board. In addition, he is an extended member of the ESMO Public Policy Working Group.

He is also a member of ASCO, ASH and a volunteer of Health Volunteers Overseas.





**Anna Wrona, MD PhD**

**Department of Oncology and Radiotherapy,  
Medical University of Gdansk**



▣ Consultant of radiation oncology and academic in one of the most exhilarating Polish Cancer Centers – in the Department of Oncology and Radiotherapy of Medical University of Gdańsk.

**Collaborations:**

- European Thoracic Oncology Platform(ETOP)
- European Organization for Research and Treatment of Cancer(EORTC).

**Memberships:**

- Polish Society of Oncology (PTO),
- European Society for Radiotherapy and Oncology(ESTRO)
- International Association for the Study of Lung Cancer (IASLC).
- Associate editor of Journal Club column in NowoTwory Journal.

**Area of interest:**

- Thoracic oncology.
- Cancer molecular biology and resistance mechanisms.

**Lectures:**

- ESMO 2017.
- Polish Congress of Medical Oncology
- Conference of Polish Lung Cancer Group
- World Conference on Lung Cancer





## Elżbieta Senkus MD

Senior lecturer at the Department of Oncology and Radiotherapy

Elżbieta Senkus is a senior lecturer at the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland. She graduated from the Medical University of Gdańsk in 1991 (diploma cum laude) and finished training in radiation oncology in 1998 and in Medical oncology in 2004. In 1995 she obtained a PhD on brachytherapy of cervical Cancer.

Her main scientific interest in breast Cancer is molecular basis of disease in high-risk patients. She is the Faculty Member for the Breast Cancer of the European Society for Medical Oncology (ESMO) and European School of Oncology (ESO). She is also involved in developing international guidelines for early and metastatic breast Cancer as the Section Editor of the ESMO Guidelines Committee. Elżbieta Senkus is actively involved in Clinical Research, including national and international academic and industry-sponsored programs. She has coordinated 2 national phase III studies and currently is responsible for coordinating some international programs on a national basis.

Elżbieta Senkus serves as a Specialty Editor for the „The Breast” journal and has been actively involved in undergraduate and postgraduate teaching, including courses organized by the European Society for Therapeutic Radiology and Oncology (ESTRO), ESMO and ESO.

Elżbieta Senkus-Konefka is a member of ESMO, the European Society of Breast Cancer Specialists (EUSOMA) and of the Mensa International. Since 2013 she has been a member of the Steering Committee of the EORTC Breast Cancer Group (BCG), of which she is now the Secretary-Elect. She has contributed to over 100 peer-reviewed publications, fifteen book chapters and was an editor of a textbook. Cumulated impact factor of publications: 427; 2479 citations, h-score 21 (Scopus database, viewed Sep. 17, 2017).

She has Two sons of 22 and 20. Her hobbies include traveling, horse-back riding, skiing and designing jewellery.





### **Dr Adlinda Binti Alip**

**Clinical Oncologist  
University Malaya Medical Centre**

**The Third  
International  
Clinical  
Oncology  
Congress**



**Invited  
International  
Speakers**

□ Dr Adlinda graduated from Southampton University, UK and completed general Medical training before being awarded the MRCP by the Royal College of Physician, UK. She obtained FRCR by the Royal College of Radiologist (Clinical Oncology) UK and awarded a certificate of completion (CCT) in Clinical Oncology by General Medical Council UK in 2011. She joined the University of Malaya as a Senior Lecturer and Clinical Oncologist in 2012. She is a principal and sub-investigator for several ongoing and completed Clinical trials. She gives talks and presentation locally and in international meetings. Her main areas of interest include Lung, Breast, Genitourinary and Stereotactic Radiosurgery/Radiotherapy.



# Zol-Var<sup>®</sup> 4mg

## Zoledronic Acid

FDA Approved

EU GMP API

Safe & effective

European Made API



## Zol-Var<sup>®</sup> 4mg

### Zoledronic Acid

Zoledronic acid belongs to the family of medications known as bisphosphonates. It is used to treat multiple myeloma, hypercalcemia and for patients with bone metastases from solid tumors. Zoledronic acid is also used to prevent or delay complications (e.g., bone fractures or bone pain requiring surgery or radiotherapy) due to cancer that has spread to bones (bone metastases) from different types of tumors and multiple myeloma.


Uses: Zol-Var<sup>®</sup> typically is used to reduce bone complications and bone pain caused by advanced-stage breast cancer that has spread to the bone. It's usually given with other chemotherapy medicines.



How it's given: Zol-Var<sup>®</sup> 4 mg concentrate for solution for infusion, further diluted in 100 ml (NS) should be given as a single intravenous infusion in no less than 15 minutes.

Zoledronic acid has been approved for the treatment of multiple myeloma and for patients with bone metastases from solid tumors. For prostate cancer, which is included in this approval, patients should have progressed after treatment with at least one hormonal therapy. The drug is indicated for use in conjunction with standard antineoplastic therapy.





**SUTENT**  
*sunitinib malate*

**AROMASIN**  
Exemestane Tablet

**Cytosar**  
Cytarabine

**Pharmorubicin**  
Epirubicin

**ZAVEDOS**  
Idarubicin

**Adriamycin**  
Doxorubicin

**Daunoblastina**  
Daunorubicin

**Pfizer** Oncology

 BEHESTAN DAROU(P.J.S.)

No.10 Behestan Bldg. Pardis St., Mollasadra Ave.  
P.Code 1991915613 Tehran, Iran P.O. Box 14155-4318  
Tel: +98 (21) 88 77 4200 Fax: +98 (21) 88 78 00 30  
www.behestandarou.com



Reaching testosterone  
level of < 20 ng/dl in the vast majority of patients<sup>1-2</sup>

**Reference:**

1. Perez-Marrero R, et al. Clin Ther 2002;24:1902-14.
2. Chu FM, et al. J Urol 2002;168:1199-203.



For full prescribing information please refer to Astellas Office.  
Adverse event should be reported. Report adverse events to local regulatory authority:  
Behestan Darou, Fax Number; +98 21 8820 8018., Astellas Office : pv@apint-ne.com



BEHESTAN DAROU (P.J.S.)

No.10 Behestan Bldg. Pardis St., Mollasadra Ave.  
P.Code 1991915613 Tehran, Iran P.O. Box 14155-4318  
Tel: +98 (21) 88 77 4200 Fax: +98 (21) 88 78 00 30  
www.behestandarou.com



# Vectibix<sup>®</sup>

(panitumumab)



# Personalised medicine can improve survival

**AMGEN<sup>®</sup>**

Behestan Bldg., #10, Pardis St., Mollasadra Ave., Tehran 1991915613, Iran P.O.Box: 14155-4218 Tel: (+98 21) 88774200 Fax: (+98 21) 88780030



BEHESTAN DAROU (P.J.S.)  
[www.behestandarou.com](http://www.behestandarou.com)





**ZYTIGA is indicated with prednisone or prednisolone for:**

- the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
- the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen
- the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)

For full prescribing information refer to the full package insert (nov.2017).



ZYTIGA<sup>®</sup> 250 mg tablets. Each tablet contains 250 mg of abiraterone acetate.

For Adverse Events or safety related issues on Janssen products, please approach the mail box: P/NEMA@ITS.JNJ.COM

For Product Quality Complaints on Janssen products, please approach the mail box: QANEMA@ITS.JNJ.COM

# Help Stop CINV\* Before It Starts

with EMEND® as part of combination therapy



EMEND is indicated for prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults as part of a combination therapy.

For additional safety information, and before prescribing, please consult the Summary of Product Characteristics.

© MSD International GmbH 2012. All rights reserved.  
07-2014-ONCO-1045119-0001. Date of Preparation: July 2012



**EMEND®**  
(aprepitant, MSD)

Prevention From the Start

\* CINV = Chemotherapy Induced Nausea and Vomiting

TEMODAL® is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.

# The Standard of Care



BEHESTAN DAROUP (P.J.S)

Soraya Bldg, #10 Pardis St, Mollasadra Ave, Tehran, Iran. P.Code: 1991915613  
Tel: +98 021 88774200 Exp: 1627 Fax: +98 021 88760030  
WWW.behestaniran.com

**Temodal®**  
temozolomide



NEORAPA<sup>®</sup>

Everolimus

*Come to life with better choice!*



IR-0819-NRP-4242-AD

Chemotherapy - free approach in:  
Second line metastatic breast  
cancerous patients

\*Everolimus highlights of prescribing information. FDA label 2016. Reference ID: 3944679

*Lilly* | ONCOLOGY

آزمایشگاه پاتوبیولوژی و ژنتیک

**Partolab**  
PATHOBIOLOGY & MOLECULAR DIAGNOSTICS



**Partolab**  
PATHOBIOLOGY & MOLECULAR DIAGNOSTICS

**Partolab**

1p19qdel  
Plavix  
Lung  
Mutation  
Synovial  
Oncotype DX  
HER2  
BRAF  
Celiac  
CALR  
ROS1

TPMT  
BRCA2  
MGMT  
EGFR  
JAK2  
IDH1  
N-MYC  
FIP1L1-PDGFR  
Warfarin  
PML - RARA

T315I  
MPL  
Colon  
c-KIT  
Ewing  
Sarcoma  
Leukemia  
Stroke  
CEBPA  
FLT3

PDGFRA  
Cancer  
EML4-ALK  
IDH2  
BRCA1  
PIK3CA  
5-FU  
Alpha-1 antitrypsin  
Irinotecan  
BCR-ABL  
TERT  
KRAS  
NRAS  
Warfarin

*Let us improve life through science and art*  
**باور ما بر این است که برای هر نمونه یک زندگیست**

تهران، میدان ونک، ابتدای خیابان ملاصدرا، خیابان پردیس، پلاک ۱۴، طبقه سوم  
تلفن: ۰۲۶/۴۲۶۴۵ - ۸۸۶۵۷۴۵۷ (۰۲۱) تلفن همراه: ۰۹۱۲۰۳۶۶۳۱۸  
www.partolab.ir info@partolab.ir

**پرتولاب**  
آزمایشگاه پاتوبیولوژی و ژنتیک



 **Palbocap<sup>®</sup> 125**  
Palbociclib

**Pacl<sup>i</sup>nab<sup>®</sup>**  
Paclitaxel  
albumin-bound particles


**We Deliver Hope**




[www.palbocap.com](http://www.palbocap.com)

[www.paclinab.com](http://www.paclinab.com)



 [www.nanodaru.com](http://www.nanodaru.com)

 +98 21 88780028



# Program of The Third International Clinical Oncology Congress

The 13<sup>th</sup> Iranian Annual Clinical Oncology Congress

Clinical Radiobiology Seminar

The Third International Clinical Oncology Nursing Congress

Annual Radiotherapy Technologists' Program



Clinical  
Oncology  
Program

The Third  
International  
Clinical  
Oncology  
Congress

Main  
Hall

Day 1

Wednesday  
Dec 19  
2018

Day 1: Wednesday, December 19, 2018 - Main Hall

Time	Lecture Title
<b>First Session:</b>	
08:30-10:15	<b>Health Policy</b> <b>Moderator:</b> <ul style="list-style-type: none"> <li>Prof. Mohamad Esmail Akbari</li> </ul>
08:30-08:50	<b>Life Style &amp; Cancer</b> <ul style="list-style-type: none"> <li>Prof. Reza Malekzadeh</li> </ul>
08:50-09:10	<b>Basic in Health Policy</b> <ul style="list-style-type: none"> <li>Prof. Hamidreza Jamshidi</li> </ul>
09:10-09:30	<b>Trend and Level of Cancer Incidence and Mortality: Irans Sdgs Achievement</b> <ul style="list-style-type: none"> <li>Dr Farshad Farzad Far</li> </ul>
09:30-09:50	<b>Insurance Policy in Cancer Treatment</b> <ul style="list-style-type: none"> <li>Dr Alireza Oliaeimansh</li> </ul>
09:50-10:10	<b>Iran National Cancer Control Program: Opportunity and Threat</b> <ul style="list-style-type: none"> <li>Dr Ali Motlagh</li> </ul>
<b>Chairpersons:</b> <ul style="list-style-type: none"> <li>Dr Mohammadreza Ghavam-Nassiri</li> <li>Dr Hossein Alaghehband</li> <li>Dr Jalil Hosseini</li> <li>Dr Morteza Atri</li> </ul>	
10:15-10:30	<b>Challenging on Biosimilar Medicine</b> <ul style="list-style-type: none"> <li>Dr Mohammadreza Bagherinejad</li> </ul>
10:30-10:45	<b>National Guide Line Requirement</b> <ul style="list-style-type: none"> <li>Dr Ahmad Mafi</li> </ul>
10:45-11:00	<b>How to Integrate Survivorship Care into Daily Practice</b> <ul style="list-style-type: none"> <li>Dr Stephan Rauh</li> </ul>





Time	Lecture Title
11:00-11:30	<b>Opening Ceremony</b>
11:30-12:00	Coffee Break
<b>Second Session:</b>	
	<b>Chairpersons:</b>
	<ul style="list-style-type: none"> <li>• Prof. Peiman Haddad</li> <li>• Dr Habibolah Mahmodzadeh</li> <li>• Dr Ali Razi</li> <li>• Dr Abbas Basiri</li> </ul>
12:00-12:30	<b>Prostate Cancer Latest Updates in 2018</b>
	<ul style="list-style-type: none"> <li>• Dr Alireza Amouheidari</li> </ul>
12:30-12:50	<b>Adjuvant or Salvage Radiotherapy in Prostate Cancer</b>
	<ul style="list-style-type: none"> <li>• Dr Ali Yaghobi Joybari</li> </ul>
12:50-13:10	<b>Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer - A Review</b>
	<ul style="list-style-type: none"> <li>• Dr Hossein Yahyazadeh</li> </ul>
13:10-14:10	<b>Lunch</b>
	<b>Satellite Symposium</b>
	<ul style="list-style-type: none"> <li>• Dr Amir Mohammad Arefpour</li> </ul>

**Day 1: Wednesday, December 19, 2018 - Hafez Hall**

Time	Lecture Title
14:10	<b>Work Shop</b>
	<b>Lymphoma Cancer</b>
	<ul style="list-style-type: none"> <li>• Dr Amir Anvari</li> </ul>

## Day 2: Thursday, December 20, 2018 - Main Hall

Time	Lecture Title
	<b>First Session: Breast Cancer</b>
	<b>Chairpersons:</b>
	<ul style="list-style-type: none"> <li>• Dr Azin Alizadeh Asal</li> <li>• Dr Mohammad Reza Mir</li> <li>• Dr Abdollah Fazlalizadeh</li> <li>• Dr Manochehr Sardari Kermani</li> </ul>
<b>08:30-08:50</b>	<b>Management of Precancerous Breast Cancer</b>
	<ul style="list-style-type: none"> <li>• Dr Asieh Olfat Bakhsh</li> </ul>
<b>08:50-09:10</b>	<b>Sequence of Endocrine Treatment in Metastatic Breast Cancer</b>
	<ul style="list-style-type: none"> <li>• Prof. Hamdy Abdel Azim</li> </ul>
<b>09:10-09:30</b>	<b>CDK4/6 Inhibitor</b>
	<ul style="list-style-type: none"> <li>• Prof. Hamdy Abdel Azim</li> </ul>
<b>09:30-09:50</b>	<b>Advances in Breast Cancer Management</b>
	<ul style="list-style-type: none"> <li>• Elzbieta Senkus-Konefka MD</li> </ul>
<b>09:50-10:10</b>	<b>Approach to Triple Negative Breast Cancer</b>
	<ul style="list-style-type: none"> <li>• Dr Mona Malekzadeh</li> </ul>
<b>10:10-10:40</b>	<b>Debate: Local Treatment in Metastatic Breast Cancer</b>
	<b>Moderator:</b>
	<ul style="list-style-type: none"> <li>• Prof. Hamidreza Mirzaei</li> </ul>
	<b>Members:</b>
	<ul style="list-style-type: none"> <li>• Dr Adlinda Binti Alip</li> <li>• Dr Ramesh Omrani Poor</li> </ul>
<b>10:40-11:00</b>	<b>Coffee Break</b>

Time	Lecture Title
11:00-11:40	<p><b>Local Regional Treatment after Neoadjuvant Chemotherapy in Breast Cancer</b></p> <p><b>Moderator:</b></p> <ul style="list-style-type: none"> <li>• Dr Parisa Azimi Nejadan</li> </ul> <p><b>Members:</b></p> <ul style="list-style-type: none"> <li>• Elzbieta Senkus-Konefka MD</li> <li>• Dr Iman Divan Beigi</li> <li>• Dr Nahid Nafisi</li> <li>• Dr Navid Tofighi Rad</li> </ul>
<b>Second Session: Lung Cancer</b>	
	<p><b>Chairpersons:</b></p> <ul style="list-style-type: none"> <li>• Dr Hamidreza Jamati</li> <li>• Dr Gholamhossein Noferesti</li> <li>• Dr Mohamadreza Masjedi</li> </ul>
11:40-12:00	<p><b>Pulmonary Complications of Modern Cancer Management An Overview</b></p> <ul style="list-style-type: none"> <li>• Dr Majid Mokhtari</li> </ul>
12:00-12:20	<p><b>Lung Cancer Immunotherapy</b></p> <ul style="list-style-type: none"> <li>• Dr Anna wrona</li> </ul>
12:20-12:40	<p><b>Toxicity Management in Immunotherapy</b></p> <ul style="list-style-type: none"> <li>• Dr Stephan Raulh</li> </ul>
12:40-13:00	<p><b>Radiotherapy in Lung Cancer</b></p> <ul style="list-style-type: none"> <li>• Dr Adlinda Binti Alip</li> </ul>
13:00-14:00	<p><b>Lunch</b></p> <p><b>Satellite Symposium</b></p> <p><b>Update ESMO 2018</b></p> <ul style="list-style-type: none"> <li>• Prof. Drik Arnold</li> </ul>
14:00-16:00	<p><b>General Assembly</b></p> <ul style="list-style-type: none"> <li>• ISRO</li> </ul>

The Third  
International  
Clinical  
Oncology  
Congress

Main  
Hall

Day 2

Thursday  
Dec 20  
2018



### Day 3: Friday, December 21, 2018 - Main Hall

Time	Lecture Title
	<b>Chairpersons:</b> <ul style="list-style-type: none"> <li>• Dr Kazem Anvari</li> <li>• Dr Mansor Ansari</li> <li>• Dr Mastaneh Sanei</li> </ul>
08:30-08:50	<b>Modern Radiation Technique</b> <ul style="list-style-type: none"> <li>• Dr Tewfik J.Bichay, PhD</li> </ul>
08:50-09:10	<b>Systemic Therapy in Upper GI Cancer</b> <ul style="list-style-type: none"> <li>• Prof. Drik Arnold</li> </ul>
09:10-10:30	<b>Indications and Outcome of CRS+HIPEC for Carcinomatosis</b> <p><b>Moderator:</b></p> <ul style="list-style-type: none"> <li>• Dr Saman Nikeghbalian</li> </ul> <p><b>Members:</b></p> <ul style="list-style-type: none"> <li>• Dr Majid Akrami</li> <li>• Dr Alireza Rezvani</li> <li>• Dr Alireza Rasekhi</li> <li>• Dr Mehrdad Bohloli</li> <li>• Dr Mehdi Tahmatan</li> <li>• Dr Jafar Shakeri</li> <li>• Dr Hamed Nikopour</li> </ul>
10:30-11:00	Coffee Break

Time	Lecture Title
	<b>Chairpersons:</b> <ul style="list-style-type: none"> <li>• Dr Mohamad Reza NikShoar</li> <li>• Dr Manouchehr Davaei</li> <li>• Dr Khosro Mojir Sheibani</li> </ul>
11:00-11:15	<b>Liver Metastectomy in Non Colorectal Cancer</b> <ul style="list-style-type: none"> <li>• Dr Ali Jafarian</li> </ul>
11:15-11:30	<b>Unresectable Cholangiocarcinoma</b> <ul style="list-style-type: none"> <li>• Dr Mehdi Aghili</li> </ul>
11:30-13:00	<b>Panel: Metastatic Colon Cancer</b> <p><b>Moderator:</b></p> <ul style="list-style-type: none"> <li>• Prof. Ahmad Mosalaei</li> </ul> <p><b>Members:</b></p> <ul style="list-style-type: none"> <li>• Prof. Drik Arnold</li> <li>• Dr Shahriyar Shahriyarian</li> <li>• Prof. Masoud Sotodeh</li> <li>• Dr Farhad Samiee</li> <li>• Dr Saeid Derakhshani</li> <li>• Dr Hojat Shahbazian</li> <li>• Dr Masoud Irvani</li> </ul>
13:00-13:15	<b>Finishing Ceremony</b>
13:15-14:00	Lunch

**Day 3: Friday, December 21, 2018 - Hafez Hall**

Time	Lecture Title
14:00	<b>Work Shop</b> <b>Radiotherpay in Lung Cancer</b> <ul style="list-style-type: none"> <li>• Dr Adlinda Binti Alip</li> </ul>

## Day 1: Wednesday, December 19, 2018 - Tooska Hall

Time	Lecture Title
08:00-09:00	<b>Conference Registration Open</b>
09:00-09:15	<b>Welcome and Greetings by Dean of Nursing- Midwifery Faculty of Shahid Behashati University</b> <ul style="list-style-type: none"> <li>• Dr Forozan Atashzadeh</li> </ul>
<b>First Session: Childhood Cancer</b>	
<b>Chairpersons:</b> <ul style="list-style-type: none"> <li>• Dr Forozan Atashzadeh</li> <li>• Dr Jaefar Moghaddasi</li> <li>• Dr Fatemeh Heshmati</li> </ul>	
09:15-09:30	<b>Evaluation of Quality of Life and Its Effective Factors in the Families of Children with Cancer</b> <ul style="list-style-type: none"> <li>• Maryam Janatolmakan (Kermanshah)</li> </ul>
09:30-09:45	<b>Impact of Family-Centered Empowerment Program on the Quality of Life and Self-esteem of Families with Children with Leukemia</b> <ul style="list-style-type: none"> <li>• Jaefar Moghaddasi PhD (Candidate -Isfahan)</li> </ul>
09:45-10:00	<b>Explaining Nurses' Experiences in Caring for Children with Cancer</b> <ul style="list-style-type: none"> <li>• Maryam Janatolmakan (Kermanshah)</li> </ul>
10:00-10:15	<b>The Relationship between Resilience and Spiritual Intelligence among Mothers of Children with Cancer</b> <ul style="list-style-type: none"> <li>• Nayere Salmani</li> </ul>
10:15-10:30	<b>The Effect of a Selected Care Plan on Quality of Life of Adolescents with Cancer</b> <ul style="list-style-type: none"> <li>• Dr Parastoo Oujian (Tehran)</li> </ul>

Time	Lecture Title
<b>Second Session: Ostomy Care</b>	
10:30-10:45	<b>Key Speaker: Patient Preparation for Stoma Surgery What We Did and What We Need to Do More?</b> <ul style="list-style-type: none"> <li>• Dr Fatemeh Heshmati Nabavi (Mashhad)</li> </ul>
10:45-11	<b>Correlation between Adjustment and Self-Efficacy in Patients with Intestinal Ostomy</b> <ul style="list-style-type: none"> <li>• Dr Fatemeh Heshmati Nabavi (Mashhad)</li> </ul>
11 -11.30	<b>Opening Ceremony in Main Hall</b>
11.30-12	Coffee/Tea Break
<b>Third Session: Challenges of Oncology nurses'</b>	
<b>Chairpersons:</b> <ul style="list-style-type: none"> <li>• Dr Fatemeh Heshmati</li> <li>• Dr Mahnaz Ilkhani</li> </ul>	
12:00-12:15	<b>Key Speaker: The Rewards and Challenges of Iranian Oncology Nurses'</b> <ul style="list-style-type: none"> <li>• Dr Mahnaz Ilkhani (Tehran)</li> </ul>
12:15-13:30	<b>Panel: Challenges for Iranian Oncology Nurses</b>
13:30-14:30	Lunch and Pray
14:30-16:30	<b>Workshop: Malignant Wound Care</b> <ul style="list-style-type: none"> <li>• Dr Mahnaz Ilkhani (Tehran)</li> </ul>

## Day 2: Thursday, December 20, 2018 - Tooska Hall

Time	Lecture Title
	<b>Fourth Session: Breast Cancer Care</b>
	<b>Chairpersons:</b>
	<ul style="list-style-type: none"> <li>• Dr Fariba Taleghani</li> <li>• Dr Masoud Bahrami</li> </ul>
<b>09:00-09:15</b>	<b>Key Speaker: Facing with Breast Cancer in Woman: A Journey from Diagnosis to Rehabilitation</b>
	<ul style="list-style-type: none"> <li>• Dr Fariba Taleghani (Isfahan)</li> </ul>
<b>09:15-09:30</b>	<b>How Is Health-related Quality of Life in Breast Cancer Survivors after Treatments?</b>
	<ul style="list-style-type: none"> <li>• Sahar Mirzaei PhD (Candidate -Tehran)</li> </ul>
<b>09:30-09:45</b>	<b>The Effect of a Health Literacy Promotion Program on the Level of Health Literacy and Death Anxiety in Women with Breast Cancer</b>
	<ul style="list-style-type: none"> <li>• Dr Masoud Bahrami (Isfahan)</li> </ul>
<b>09:45-10:00</b>	<b>Develop a Curriculum Short-term Nursing Education Program for Breast Cancer Nurse Specialist</b>
	<ul style="list-style-type: none"> <li>• Fateme Hadadian PhD. (Candidate -Isfahan)</li> </ul>
	<b>Fifth Session: Education and Cancer</b>
<b>10:00-10:15</b>	<b>Review of Measuring Cancer Patients Information Needs: Disease or Action-oriented Questionnaire</b>
	<ul style="list-style-type: none"> <li>• Tahereh Baloochi Beydokhti (Mashhad)</li> </ul>
<b>10:15-10:30</b>	<b>Is the Presence of a Psychiatric Nurse in the Specialized Department of Cancer of Children in Seyyedol Shohada Hospital Necessary?</b>
	<ul style="list-style-type: none"> <li>• Jafar Moghaddasi PhD. (Candidate - Isfahan)</li> </ul>
<b>10:30-11:00</b>	<b>Coffee/Tea Break</b>



Time	Lecture Title
<b>Fifth Session: Education and Cancer</b>	
<b>Chairpersons:</b>	
<ul style="list-style-type: none"> <li>• Dr Varaei</li> <li>• Dr Fariba Taleghani</li> <li>• Dr Mohsen Shahriari</li> </ul>	
11:00-11:15	<b>The Effect of Education on GI Complication in Patient under Chemotherapy</b> <ul style="list-style-type: none"> <li>• Dr Varaei (Tehran)</li> </ul>
11:15-11:30	<b>Effect of Blend Education Programs on Some Performance Indicators in Cancer Patients of Ahwaz in 2014</b> <ul style="list-style-type: none"> <li>• Maryam Bayati (Ahwaz)</li> </ul>
<b>Fifth Session: Palliative &amp; End of Life Care</b>	
11:30-11:45	<b>The Effect of a Family-Centered Empowerment Program on Anxiety, Stress and Depression in the Family of Children with Leukemia.</b> <ul style="list-style-type: none"> <li>• Jaefar Moghaddasi PhD (Candidate - Isfahan)</li> </ul>
11:45-12:00	<b>Empowering Nurses in Providing Palliative Care to Cancer Patients: Action Research Study</b> <ul style="list-style-type: none"> <li>• Dr Mohsen Shahriari (Isfahan)</li> </ul>
12:00-13:30	<b>Workshop: Caring for People at the End of Life</b> <ul style="list-style-type: none"> <li>• Dr Pooneh Pirjani</li> <li>• Dr Naeimeh Keshavarz</li> <li>• Dr Heshmatollah Heidari</li> </ul>
13:30-14:00	Lunch and pray

### Day 3: Friday, December 21, 2018 - Tooska Hall

Time	Lecture Title
	<b>Sixth Session: Symptom Management</b>
	<b>Chairpersons:</b>
	<ul style="list-style-type: none"> <li>• Dr Varaei</li> <li>• Dr Camelia Rohani</li> <li>• Dr Masoud Bahrami</li> </ul>
09:00-09:15	<b>Comparison the Effects of Ear Acupressure on Nausea and Vomiting in Acute and Delay Phase of Patients under Chemotherapy in Breast Cancer Patients</b> <ul style="list-style-type: none"> <li>• Dr Varaei (Tehran)</li> </ul>
09:15-09:30	<b>Fatigue and Its Related Factors in Patients Admitted to Oncology</b> <ul style="list-style-type: none"> <li>• Maryam Janatolmakan</li> </ul>
09:30-09:45	<b>Level of Stigma in Individual with Cancer in Iranian Society</b> <ul style="list-style-type: none"> <li>• Fatemeh Hasan Shiri PhD (Candidate Tehran)</li> </ul>
09:45-10:00	<b>Randomized Trial to Evaluate Foot Reflexology Effects on Quality of Life of Patients Suffering Chemotherapy-induced Neuropathy in Colorectal Cancer Patients</b> <ul style="list-style-type: none"> <li>• Hesam Gholamzadeh (Tehran)</li> </ul>
	<b>Seventh Session: Supportive Care and Cancer</b>
10:00-10:15	<b>Priorities of Care Infrastructures in Interprofessional Supportive Care of Cancer Patients Undergoing Chemotherapy in Iran; the Oncologists' Perceptions</b> <ul style="list-style-type: none"> <li>• Dr Shahin Salarvand (Isfahan)</li> </ul>
10:15-10:30	<b>Key Speaker: Sense of Coherence as a Resilience–recovery Factor in Cancer Patients' Health-related Quality of Life: Investigating the Mediating or Moderating Mechanisms and Its Application in Clinic</b> <ul style="list-style-type: none"> <li>• Dr Camelia Rohani (Tehran)</li> </ul>

Time	Lecture Title
10:30-11:00	Coffee/Tea Break
<b>Eighth Session: Chemotherapy</b>	
<b>Chairpersons:</b>	
<ul style="list-style-type: none"> <li>• Dr Mahnaz Ilkhani</li> <li>• Dr Masoud Bahrami</li> </ul>	
11:00-11:15	<b>The Significant Components of Cancer Patients' Comprehensive Supportive Care Needs Undergoing Chemotherapy; Iranian Oncologists' Perceptions</b>
<ul style="list-style-type: none"> <li>• Dr Shahin Salarvand (Isfahan)</li> </ul>	
11:15-11:30	<b>Therapeutic Touch in Patients with Cancer: A Content Analysis Study</b>
<ul style="list-style-type: none"> <li>• Dr Amir Tabatabaee (Gonabad)</li> </ul>	
11:30-11:45	<b>Studying the Spiritual Needs of Patients with Cancer</b>
<ul style="list-style-type: none"> <li>• Soolmaz Moosavi</li> </ul>	
11:45-12:00	<b>Iranian Cancer Patient's Perception of Dignity: a Qualitative Content Analysis</b>
<ul style="list-style-type: none"> <li>• Samaneh Bagherian PhD (Candidate - Isfahan)</li> </ul>	
12:00-12:10	<b>Closing speech</b>
<ul style="list-style-type: none"> <li>• Dr Mahnaz Ilkhani</li> </ul>	

**Day 1: Wednesday, December 19, 2018 - Hegmataneh Hall**

Time	Lecture Title
<b>08:30-08:50</b>	<b>Opening and Welcome</b>
	<b>Scientific Chair:</b>
	<ul style="list-style-type: none"> <li>• Prof. Hossein Mozdarani</li> </ul>
	<b>Chairpersons: Opening Lectures:</b>
	<ul style="list-style-type: none"> <li>• Dr Bahram Mofid</li> <li>• Dr Amin Mosleh Shirazi</li> <li>• Dr S.Rabie Mahdavi</li> <li>• Dr Ali Neshastehriz</li> <li>• Dr Mohsen Foroghizadeh Moghadam</li> </ul>
<b>08:50-09:20</b>	<b>Co-Radioadaptation of Human Body and Its Microorganisms and the Importance of this Phenomenon in Activities Ranging from Occupational Exposures to Deep Space Journeys</b>
	<ul style="list-style-type: none"> <li>• Dr S.Mohammad Javad Mortazavi</li> </ul>
<b>09:20-09:50</b>	<b>Radiobiological Rationale of Hyperthermia during GBM Chemoradiation</b>
	<ul style="list-style-type: none"> <li>• Dr S.Rabie Mahdavi</li> </ul>
<b>09:50-10:20</b>	<b>Diagnosis and Treatment of Radiation Injuries</b>
	<ul style="list-style-type: none"> <li>• Dr Mohsen Foroghizadeh Moghadam</li> </ul>
<b>10:20-11:00</b>	Coffee break
	<b>Second Session:</b>
	<b>Chairpersons:</b>
	<ul style="list-style-type: none"> <li>• Dr S.Mohammad Javad Mortazavi</li> <li>• Dr Hossein Foudazi</li> <li>• Dr Alireza Nikoofar</li> <li>• Dr Hassan Ali Nedaie</li> <li>• Dr Samideh Khoei</li> </ul>
<b>11:00-11:20</b>	<b>Radiobiologic Modeling of the Probability of Normal Tissue Damage in Radiotherapy</b>
	<ul style="list-style-type: none"> <li>• Dr Amin Mosleh Shirazi</li> </ul>
<b>11:20-11:40</b>	<b>Radiation Toxicity Assessment: From Classical Radiobiology to Radiogenomics</b>
	<ul style="list-style-type: none"> <li>• Dr Hossein Mozdarani</li> </ul>

The Third  
International  
Clinical  
Oncology  
Congress

Hegmataneh  
Hall

Day 1

Wednesday  
Dec 19  
2018

Time	Lecture Title
11:40-12:00	<b>What Is The Value of EQD2 in Short Course Brachytherapy Treatments?</b> <ul style="list-style-type: none"> <li>• Dr Ramin Jaberi</li> </ul>
12:00-12:10	<b>Radiobiological Approach of Hypo-Fraction Technique of Grid Radiation Therapy in Bystander Cells</b> <ul style="list-style-type: none"> <li>• Mrs. Fatemeh Pakniyat</li> </ul>
12:10-12:20	<b>Non-Ionizing and Ionizing Electromagnetic Radiations Could Alter Liver Function in a Rat Model</b> <ul style="list-style-type: none"> <li>• Mr. Sajad Borzoueisileh</li> </ul>
12:20-12:30	<b>Dosimetric and Radiobiological Comparison of Three Different Beam Arrangements in IMRT Treatment Planning of Nasopharyngeal Cancer. Effect on Critical Structures Radiation Doses</b> <ul style="list-style-type: none"> <li>• Mrs. Pegah Saadatmand</li> </ul>
12:30-12:40	<b>Dose Enhancement Factor Due to Gold Nanoparticles in Radiotherapy Using by Gel Dosimetry and Monte Carlo Methods</b> <ul style="list-style-type: none"> <li>• Mr. Hossein Khosravi</li> </ul>
12:40-12:50	<b>Modulating Survivin as a Radioresistant Factor by Omega-3 Docosahexaenoic Acid Sensitizes Radioresistant Colorectal Cancer Cells to <math>\gamma</math>-Irradiation</b> <ul style="list-style-type: none"> <li>• Mrs. Farideh Hosseini</li> </ul>
12:50-13:00	<b>Evaluating the Effects of Radiation and Cisplatin-Based Chemotherapy on Sensorineural Hearing Loss in Patients with Head and Neck Cancer</b> <ul style="list-style-type: none"> <li>• Mr. Abolhasan Rezaeyan</li> </ul>
13:00-14:00	Lunch break
<b>Third Session:</b>	
<b>Chairpersons:</b>	
<ul style="list-style-type: none"> <li>• Dr Mahdi Aghili</li> <li>• Dr Ramin Jaberi</li> <li>• Dr Ali Shabestani Monfared</li> <li>• Dr Abolghasem Haeri</li> <li>• Dr Alireza Shirazi</li> </ul>	



Day 1

Wednesday  
Dec 19  
2018



Time	Lecture Title
14:00-14:20	<b>Role of Nanotechnology in Radiobiology</b> <ul style="list-style-type: none"> <li>• Dr Samideh Khoei</li> </ul>
14:20-14:40	<b>Current and Future Clinical Use of Fractionation and Tolerance of Normal Tissues in Radiotherapy</b> <ul style="list-style-type: none"> <li>• Dr Ali Shabestani Monfared</li> </ul>
14:40-14:50	<b>Preferential Radioenhancement and Genotoxic Effects of ZnO and Gadolinium-doped ZnO NPs in Combination with Megavoltage Radiation in Lung Cancer Cells Measured by Micronucleus Assay and qRT-PCR in Vitro</b> <ul style="list-style-type: none"> <li>• Mrs. Masoumeh Zanganeh</li> </ul>
14:50-15:00	<b>The Synergistic Effect of Magneto-plasmonic Nanoparticles-mediated Radiofrequency Hyperthermia and Radiotherapy on MCF-7 Breast Cancer Cells</b> <ul style="list-style-type: none"> <li>• Mrs Fahimeh Hadi</li> </ul>
15:00-16:00	<b>Panel Discussion: Role of Radiobiology in Modern Radiotherapy</b> <b>Panel Coordinator:</b> <ul style="list-style-type: none"> <li>• Dr Alireza Nikoofar</li> </ul> <b>Panel Members:</b> <ul style="list-style-type: none"> <li>• Dr Mahdi Aghili</li> <li>• Dr Ramin Jaberli</li> <li>• Dr S. Rabie Mahdavi</li> <li>• Dr Ali Neshastehriz</li> <li>• Dr Hossein Mozdarani</li> <li>• Dr Mostafa Farzin</li> <li>• Dr Mohsen Bakhshandeh</li> <li>• Mr. Abolfazl Razzaghdoust</li> </ul>
16:00-16:30	Coffee Break
16:30-17:45	<b>Panel Discussion: Future Prospects of Radiobiology in Iran</b> <b>Panel Coordinator:</b> Dr Hossein Mozdarani <b>Panel Members:</b> Dr Mohammad Javad Mortazavi Dr Alireza Shirazi Dr Amin Mosleh Shirazi Dr Ali Shabestani Monfared Dr Maziar Mahdavi Mr. Hassan Nosrati Mrs. Fatemeh Pakniat

## Day 2: Thursday, December 20, 2018 - Hegmataneh Hall

Time	Lecture Title
08:00-09:30	<ul style="list-style-type: none"> <li>• <b>Opening and Welcome</b></li> <li>• <b>Speech of the Chairman of Iranian Society of Radiation Oncology</b></li> <li>• <b>Speech of Scientific Chairperson of Congress</b></li> </ul> <p style="text-align: center;"><b>Appreciation of Top Students in Radiotherapy</b></p>
<b>First Session: Understanding the Basic Principles and Concepts Needed for Radiotherapy Experts</b>	
<p><b>Chairpersons:</b></p> <ul style="list-style-type: none"> <li>• Dr. Mohammad Reza Ghavam-Nassiri (Clinical Oncologist)</li> <li>• Dr. Mohammad Mohammadi (Medical Physicist)</li> <li>• Mohammad Esmaeil Hajian (RTT)</li> <li>• Davoud Hafezi (RTT)</li> </ul>	
09:30-09:50	<b>Problems of Radiotherapy Technologists and Radiotherapy Students</b> <ul style="list-style-type: none"> <li>• Hassan Nosrati (RTT)</li> </ul>
09:50-10:10	<b>Royal Adelaide Hospital Visiting from Radiation Therapy Technologist Point of View</b> <ul style="list-style-type: none"> <li>• Simin Abbasi (RTT)</li> <li>• Mohammad Mohammadi (Medical Physicist)</li> </ul>
10:10-10:30	<b>RTT Roles in Target Registration and Margination in Advanced Treatment Techniques</b> <ul style="list-style-type: none"> <li>• Hamzeh Almasroo (RTT)</li> <li>• Fariba Soltani (RTT)</li> </ul>
10:30-11:00	<p style="color: #4f81bd;">Break</p>
<b>Second Session: Patients Education and Patients and Devices Assessment in Radiotherapy</b>	
<p><b>Chairpersons:</b></p> <ul style="list-style-type: none"> <li>• Dr. Ramin Jaberi (Medical Physicist)</li> <li>• Amirhoushang Sedigh (RTT)</li> <li>• Yousef Eskandari (RTT)</li> <li>• Amin Ahmadzadeh (RTT)</li> </ul>	
11:00-11:15	<b>Role of Patients Education in Optimizing Treatment Experience of Kurdistan Center</b> <ul style="list-style-type: none"> <li>• Omar Murik (RTT)</li> </ul>
11:15-11:30	<b>The Importance of Patients Assessments in Radiotherapy</b> <ul style="list-style-type: none"> <li>• Mohammad Kazem Farmani (RTT)</li> </ul>
11:30-11:45	<b>Motion Management in Radiotherapy (Intra and Inter Motion)</b> <ul style="list-style-type: none"> <li>• Mohsen Habibi (RTT)</li> </ul>
11:45-12:00	<b>Quality Assurance Tasks for Patient Set-up and Target Localization Devices and Systems</b> <ul style="list-style-type: none"> <li>• Mohammad Mohammadi (Medical Physicist)</li> </ul>



**Day 2**

Thursday  
Dec 20  
2018



Time	Lecture Title
<b>Third Session: Selected Articles</b>	
<b>Chairpersons:</b>	
<ul style="list-style-type: none"> <li>• Dr S. Rabie Mahdavi (Medical Physicist)</li> <li>• Dr Mohsen Bakhshandeh (Medical Physicist)</li> <li>• Mohammad Esmaeil Hajian (RTT)</li> <li>• Nader Sepanlou (RTT)</li> <li>• Omar Murik (RTT)</li> <li>• Mansour Naderi (RTT)</li> </ul>	
12:00-12:20	<b>Evaluation of Patient Set up Accuracy and Determination of Optimal Set-up Margin for External Beam Radiotherapy Using EPID</b> <ul style="list-style-type: none"> <li>• Farshid Arbabi (Clinical Oncologist)</li> <li>• Aram Rostami (Medical Physicist)</li> </ul>
12:20-12:40	<b>Unscheduled Treatment Interruption; Management and Compensation</b> <ul style="list-style-type: none"> <li>• Sara Abdollahi (Medical Physicist)</li> </ul>
12:40-13:00	<b>Errors Analysis in Radiotherapy</b> <b>One-year Report from a Radiotherapy Center</b> <ul style="list-style-type: none"> <li>• Hanieh Aslani (RTT)</li> </ul>
13:00-13:20	<b>On Board Imaging and Comparison with DRR</b> <ul style="list-style-type: none"> <li>• Marzieh Nabikhani (RTT)</li> <li>• Teyeb Erfanian (RTT)</li> </ul>
13:20-13:40	<b>Evaluation of Daily Set up Variations in External Beam Radiation Therapy by Using EPID</b> <ul style="list-style-type: none"> <li>• Zahra Baratpour (RTT)</li> </ul>
14:00-15:00	<b>Lunch</b>
<b>Fourth Session: Optimal Use and Maintenance of Radiotherapy Devices With The Participation of Varian, Electra and Siemens Companies</b>	
<b>Chairpersons:</b>	
<ul style="list-style-type: none"> <li>• Keivan Shalchi (RTT)</li> <li>• Mehdi Yazdani (RTT)</li> <li>• Akbar Shahriari Mehr (RTT)</li> <li>• Ali Rastjou (Medical Engineering)</li> </ul>	
15:00-15:20	<b>Representative of Varan Parto Co. (Varian)</b> <ul style="list-style-type: none"> <li>• Babak Mehrabani (Medical Engineering)</li> <li>• Hossein Homaie (Medical Engineering)</li> </ul>
15:20-15:40	<b>Representative of Fanavari Azmayeshgahi Co. (Elekta)</b> <ul style="list-style-type: none"> <li>• Cyrus Khalil Azar (Medical Engineering)</li> <li>• Farzad Masoumi Zadeh (Medical Engineering)</li> </ul>
15:40-16:00	<b>Representative of Matlab Medical Co. (Ziemens)</b> <ul style="list-style-type: none"> <li>• Amin Bahmani (Medical Engineering)</li> </ul>



## Day 3: Friday, December 21, 2018 - Hegmataneh Hall

Time	Lecture Title
	<b>Uncertainty Workshop in Radiotherapy Focusing on Patients' Set up</b>
<b>08:45-09:00</b>	<b>Welcome And Opening</b>
<b>09:05-09:20</b>	<b>Introduction Session: Radiotherapy: To Heal or to Harm, How Certain We Are about and How Certain We Can Be?</b> <ul style="list-style-type: none"> <li>• Hassan Nosrati (RTT)</li> </ul>
<b>09:25-10:05</b>	<b>Interactive Session: What to Do When Your Target Is not Sitting Still?</b> <ul style="list-style-type: none"> <li>• Hamed Alizadeh (Medical Physicist)</li> </ul>
<b>10:10-10:30</b>	<b>Uncertainty: Clinician's Perspective Session Inter-Observer Variability and Clinical Considerations</b> <ul style="list-style-type: none"> <li>• Dr Nima Mousavi (Radiation Oncologist)</li> </ul>
<b>10:30-11:00</b>	<b>Coffee Break</b>
<b>11:05-11:30</b>	<b>Uncertainty: Physicist's Perspective Session: Accuracy and Uncertainty in Radiotherapy: Physics Point of View</b> <ul style="list-style-type: none"> <li>• Dr Mohammad Hadi Gholami (Medical Physicist)</li> </ul>
<b>11:35-12:05</b>	<b>Conclusion: Uncertainty Management Session How to Survive in a World of Uncertainty?</b> <ul style="list-style-type: none"> <li>• Hamed Alizadeh (Medical Physicist)</li> </ul>
<b>12:10-12:55</b>	<b>Panel Discussion and Workshop Closing</b>
<b>13:00</b>	<b>Congress Closing Ceremony</b>

The Third  
International  
Clinical  
Oncology  
Congress

Hegmataneh  
Hall

**Day 3**

Friday  
Dec 21  
2018



Young  
Oncologists'  
Session

The Third  
International  
Clinical  
Oncology  
Congress

Room  
#1

Day 1

Wednesday  
Dec 19  
2018

**Day 1: Wednesday, December 19, 2018 - Room #1**

Time	Lecture Title
<b>First Session:</b>	
14:00-14:15	<b>Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer</b> <ul style="list-style-type: none"><li>• Dr Hamide Mahmoudi Alemi</li></ul>
14:15-14:30	<b>Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma</b> <ul style="list-style-type: none"><li>• Dr Alireza Keramati</li></ul>
14:30-14:45	<b>Efficacy and Cardiac Safety of the Concurrent Use of Trastuzumab and Anthracycline-based Neoadjuvant Chemotherapy for HER2-positive Breast Cancer: A Systematic Review and Meta-analysis</b> <ul style="list-style-type: none"><li>• Dr Masoumeh Shafiei</li></ul>
14:45-15:00	<b>Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality</b> <ul style="list-style-type: none"><li>• Dr Nasibe Tabatabayi</li></ul>
15:00-17:00	<b>Contouring Workshop: CNS Tumor (GLIOMA)</b> <ul style="list-style-type: none"><li>• Dr Amir Anvari</li></ul>



**Day 2: Thursday, December 20, 2018 - Parseh Hall**

Time	Lecture Title
<b>First Session:</b>	
14:00-14:15	<p><b>9 weeks' vs 1-year Adjuvant Trastuzumab in Combination with Chemotherapy: Final Results of the Phase III Randomized Short-HER Study</b></p> <ul style="list-style-type: none"> <li>• Dr Sara Rastin</li> </ul>
14:15-14:30	<p><b>Towards Omitting Breast Cancer Surgery in Select Patient Groups: Assessment of Pathologic Complete Response after Neoadjuvant Systemic Therapy Using Biopsies—The MICRA Trial</b></p> <ul style="list-style-type: none"> <li>• Dr Mansoureh Dehghani</li> </ul>
14:30-14:45	<p><b>Radiotherapy Plus Cetuximab or Cisplatin in Human Papillomavirus-positive Oropharyngeal Cancer (NRG Oncology RTOG 1016): A Randomised, MultiCenter, Non-inferiority Trial</b></p> <ul style="list-style-type: none"> <li>• Dr Zeynab Abyar</li> </ul>
14:45-15:00	<p><b>11 years' Follow-up of Trastuzumab after Adjuvant Chemotherapy in HER2-positive Early Breast Cancer: Final Analysis of the Herceptin Adjuvant (HERA) Trial</b></p> <ul style="list-style-type: none"> <li>• Dr Alireza javadynia</li> </ul>
15:00-17:00	<p><b>Contouring Workshop: BREAST Cancer</b></p> <ul style="list-style-type: none"> <li>• Dr Amir Anvari</li> </ul>

Index  
Alphabetical

The Third  
International  
Clinical  
Oncology  
Congress

Index

Name	Hall	Day	Time
Abbasi Simin	Hegmataneh	Day 2	09:50
Abdel Azim Hamdy	Main	Day 2	08:50
	Main	Day 2	09:10
	Main	Day 2	09:10
Abdollahi Sara	Hegmataneh	Day 2	12:20
	Hegmataneh	Day 2	12:20
Abyar Zeynab	Room #1	Day 2	14:30
	Room #1	Day 2	14:30
Aghili Mahdi	Main	Day 3	11:15
	Hegmataneh	Day 1	14:00
	Hegmataneh	Day 1	15:00
Ahmadzadeh Amin	Hegmataneh	Day 2	11:00
	Hegmataneh	Day 2	11:00
Akbari Mohamad Esmail	Main	Day 1	08:30
	Main	Day 1	08:30
Akrami Majid	Main	Day 3	09:10
	Main	Day 3	09:10
Alagheband Hossein	Main	Day 1	10:15
	Main	Day 1	10:15
Ali Nedaie Hassan	Hegmataneh	Day 1	11:00
	Hegmataneh	Day 1	11:00
Alizadeh Asal Azin	Main	Day 2	08:30
	Main	Day 2	08:30
Alizadeh Hamed	Hegmataneh	Day 3	09:25
	Hegmataneh	Day 3	11:35
	Hegmataneh	Day 3	11:35
Almasroo Hamzeh	Hegmataneh	Day 2	10:10
	Hegmataneh	Day 2	10:10
Amouheidari Alireza	Main	Day 1	12:00
	Main	Day 1	12:00
Ansari Mansour	Main	Day 3	08:30
	Main	Day 3	08:30
Anvari Amir	Main	Day 1	14:10
	Room #1	Day 1	15:00
	Room #1	Day 2	15:00
	Room #1	Day 2	15:00
Anvari Kazem	Main	Day 3	08:30
	Main	Day 3	08:30
Arbabi Farshid	Hegmataneh	Day 2	12:00
	Hegmataneh	Day 2	12:00
Arefpour Amir Mohammad	Main	Day 1	13:10
	Main	Day 1	13:10
Arnold Drik	Main	Day 2	13:00
	Main	Day 3	08:50
	Main	Day 3	11:30
Aslani Hanieh	Hegmataneh	Day 2	12:40
	Hegmataneh	Day 2	12:40
Atashzadeh Forozan	Tooska	Day 1	09:00
	Tooska	Day 1	09:00
Atri Morteza	Main	Day 1	10:15
	Main	Day 1	10:15
Azimi Nejadan Parisa	Main	Day 2	11:00
	Main	Day 2	11:00
Bagherian Samaneh	Tooska	Day 3	11:45
	Tooska	Day 3	11:45

Name	Hall	Day	Time
Bagherinejad Mohammadreza	Main	Day 1	10:15
	Main	Day 1	10:15
Bahmani Amin	Hegmataneh	Day 2	15:40
	Hegmataneh	Day 2	15:40
Bahrami Masoud	Tooska	Day 2	09:00
	Tooska	Day 2	09:30
	Tooska	Day 3	09:00
	Tooska	Day 3	11:00
Bakhshandeh Mohsen	Hegmataneh	Day 1	15:00
	Hegmataneh	Day 2	12:00
	Hegmataneh	Day 2	12:00
Baloochi Beydokhti Tahereh	Tooska	Day 2	10:00
	Tooska	Day 2	10:00
Baratpour Zahra	Hegmataneh	Day 2	13:20
	Hegmataneh	Day 2	13:20
Basiri Abbas	Main	Day 1	12:00
	Main	Day 1	12:00
Bayati Maryam	Tooska	Day 2	11:15
	Tooska	Day 2	11:15
Binti Alip Adlinda	Main	Day 2	10:10
	Main	Day 2	12:40
	Main	Day 3	14:00
	Main	Day 3	14:00
Bohloli Mehrdad	Main	Day 3	09:10
	Main	Day 3	09:10
Borzoueisileh Sajad	Hegmataneh	Day 1	12:10
	Hegmataneh	Day 1	12:10
Davaei Manouchehr	Main	Day 3	10:30
	Main	Day 3	10:30
Dehghani Mansoureh	Room #1	Day 2	14:15
	Room #1	Day 2	14:15
Derakhshani Saeid	Main	Day 3	11:30
	Main	Day 3	11:30
Divan Beigi Iman	Main	Day 2	11:00
	Main	Day 2	11:00
Erfanian Teyeb	Hegmataneh	Day 2	13:00
	Hegmataneh	Day 2	13:00
Eskandari Yousef	Hegmataneh	Day 2	11:00
	Hegmataneh	Day 2	11:00
Farmani Mohammad Kazem	Hegmataneh	Day 2	11:15
	Hegmataneh	Day 2	11:15
Farzad Far Farshad	Main	Day 1	09:10
	Main	Day 1	09:10
Farzin Mostafa	Hegmataneh	Day 1	15:00
	Hegmataneh	Day 1	15:00
Fazlalizadeh Abdollah	Main	Day 2	08:30
	Main	Day 2	08:30
Foudazi Hossein	Hegmataneh	Day 1	11:00
	Hegmataneh	Day 1	11:00
Foroghizadeh Moghadam Mohsen	Hegmataneh	Day 1	08:50
	Hegmataneh	Day 1	09:50
	Hegmataneh	Day 1	09:50
Ghavam-Nassiri Mohammad Reza	Main	Day 1	10:15
	Hegmataneh	Day 2	09:30
	Hegmataneh	Day 2	09:30
Gholami Mohammad Hadi	Hegmataneh	Day 3	11:05
	Hegmataneh	Day 3	11:05
Gholamzadeh Hesam	Tooska	Day 3	09:45
	Tooska	Day 3	09:45



Name	Hall	Day	Time	Name	Hall	Day	Time
Habibi Mohsen	Hegmataneh	Day 2	11:30	Khosravi Hossein	Hegmataneh	Day 1	12:30
Hadadian Fateme	Tooska	Day 2	09:45	Mafi Ahmad	Main	Day 1	10:30
Haddad Peiman	Main	Day 1	12:00	Mahdavi Maziar	Hegmataneh	Day 1	16:30
Hadi F.	Hegmataneh	Day 1	14:50	Mahdavi S. Rabie	Hegmataneh	Day 1	09:20
Haeri Abolghasem	Hegmataneh	Day 1	14:00		Hegmataneh	Day 1	15:00
Hafezi Davoud	Hegmataneh	Day 2	09:30		Hegmataneh	Day 2	12:00
Hajian Mohammad Esmael	Hegmataneh	Day 2	09:30	Mahmodzadeh Habibolah	Main	Day 1	12:00
	Hegmataneh	Day 2	12:00	Mahmoudi Alemi Hamideh	Room #1	Day 1	14:00
Hasan Shiri Fatemeh	Tooska	Day 3	09:30	Malekzadeh Mona	Main	Day 2	09:50
Heidari Heshmatollah	Tooska	Day 2	12:00	Malekzadeh Reza	Main	Day 1	08:30
Heshmati Fatemeh	Tooska	Day 1	09:00	Masjedi Mohamadreza	Main	Day 2	11:40
	Tooska	Day 1	12:00	Masoumi Zadeh Farzad	Hegmataneh	Day 2	15:20
Heshmati Nabavi Fatemeh	Tooska	Day 1	10:30	Mehrabani Babak	Hegmataneh	Day 2	15:00
	Tooska	Day 1	10:45	Mir Mohammad Reza	Main	Day 2	08:30
Homaie Hossein	Hegmataneh	Day 2	15:00	Mirzaei Hamidreza	Main	Day 2	10:10
Hosseini Farideh	Hegmataneh	Day 1	12:40	Mirzaei Sahar	Tooska	Day 2	09:15
Hosseini Jalil	Main	Day 1	10:15	Mofid Bahram	Hegmataneh	Day 1	08:50
Ilkhani Mahnaz	Tooska	Day 1	12:00	Moghaddasi Jaefar	Tooska	Day 1	09:00
	Tooska	Day 1	14:30		Tooska	Day 1	09:30
	Tooska	Day 3	11:00		Tooska	Day 2	10:15
	Tooska	Day 3	12:00		Tooska	Day 2	11:30
Irvani Masoud	Main	Day 3	11:30	Mohammadi Mohammad	Hegmataneh	Day 2	09:30
J.Bichay Tewfik	Main	Day 3	08:30		Hegmataneh	Day 2	09:50
Jaberi Ramin	Hegmataneh	Day 1	11:40		Hegmataneh	Day 2	11:45
	Hegmataneh	Day 1	14:00	Mojir Sheibani Khosro	Main	Day 3	10:30
	Hegmataneh	Day 1	15:00	Mokhtari Majid	Main	Day 2	11:40
	Hegmataneh	Day 2	11:00	Moosavi Soolmaz	Tooska	Day 3	11:30
Jafarian Ali	Main	Day 3	11:00	Mortazavi Mohammad Javad	Hegmataneh	Day 1	08:50
Jamati Hamidreza	Main	Day 2	11:40		Hegmataneh	Day 1	11:00
Jamshidi Hamidreza	Main	Day 1	08:50		Hegmataneh	Day 1	16:30
Janatolmakan Maryam	Tooska	Day 1	09:15	Mosalaei Ahmad	Main	Day 3	11:30
	Tooska	Day 1	09:45	Mosleh Shirazi Amin	Hegmataneh	Day 1	08:50
	Tooska	Day 3	09:15		Hegmataneh	Day 1	11:00
Javadynia Alireza	Room #1	Day 2	14:45	Mottagh Ali	Main	Day 1	09:50
Keramati Alireza	Room #1	Day 1	14:15	Mousavi Nima	Hegmataneh	Day 3	10:10
Keshavarz Naeimeh	Tooska	Day 2	12:00	Mozdarani Hossein	Hegmataneh	Day 1	08:30
Khalil Azar Cyrus	Hegmataneh	Day 2	15:20		Hegmataneh	Day 1	11:20
Khoei Samideh	Hegmataneh	Day 1	11:00		Hegmataneh	Day 1	15:00
	Hegmataneh	Day 1	14:00		Hegmataneh	Day 1	16:30





Name	Hall	Day	Time
Murik Omar			
	Hegmataneh	Day 2	11:00
	Hegmataneh	Day 2	12:00
Nabikhani Marzieh			
	Hegmataneh	Day 2	13:00
Naderi Mansour			
	Hegmataneh	Day 2	12:00
Nafisi Nahid			
	Main	Day 2	11:00
Neshastezhiz Ali			
	Hegmataneh	Day 1	08:50
	Hegmataneh	Day 1	15:00
Nikeghbalian Saman			
	Main	Day 3	09:10
Nikoofar Alireza			
	Hegmataneh	Day 1	11:00
	Hegmataneh	Day 1	15:00
Nikopour Hamed			
	Main	Day 3	09:10
NikShoar Mohamad Reza			
	Main	Day 3	10:30
Noferesti Gholamhossein			
	Main	Day 2	11:40
Nosrati Hassan			
	Hegmataneh	Day 1	16:30
	Hegmataneh	Day 2	09:30
	Hegmataneh	Day 3	09:05
Olfat Bakhsh Asieh			
	Main	Day 2	08:30
Oliaeimansh Alireza			
	Main	Day 1	09:30
Omrani Poor Ramesh			
	Main	Day 2	10:10
Oujian Parastoo			
	Tooska	Day 1	10:15
Pakniyat Fatemeh			
	Hegmataneh	Day 1	16:30
	Hegmataneh	Day 1	12:00
Pirjani Pooneh			
	Tooska	Day 2	12:00
Rasekhi Alireza			
	Main	Day 3	09:10
Rastin Sara			
	Room #1	Day 2	14:00
Rastjou Ali			
	Hegmataneh	Day 2	15:00
Rauh Stephan			
	Main	Day 1	10:45
Raulh Stephan			
	Main	Day 2	12:20
Razi Ali			
	Main	Day 1	12:00
Razzaghdoust Abolfazl			
	Hegmataneh	Day 1	15:00
Rezaeyan Abolhasan			
	Hegmataneh	Day 1	12:50
Rezvani Alireza			
	Main	Day 3	09:10
Rohani Camelia			
	Tooska	Day 3	09:00
	Tooska	Day 3	10:15
Rostami Aram			
	Hegmataneh	Day 2	12:00
Saadatmand Pegah			
	Hegmataneh	Day 1	12:20
Salarvand Shahin			
	Tooska	Day 3	10:00

Name	Hall	Day	Time
	Tooska	Day 3	11:00
Salmani Nayere			
	Tooska	Day 1	10:00
Samiee Farhad			
	Main	Day 3	11:30
Sanei Mastaneh			
	Main	Day 3	08:30
Sardari Kermani Manochehr			
	Main	Day 2	08:30
Sedigh Amirhoushang			
	Hegmataneh	Day 2	11:00
Senkus-Konefka Elzbieta			
	Main	Day 2	09:30
	Main	Day 2	11:00
Sepanlou Nader			
	Hegmataneh	Day 2	12:00
Shabestani Monfared Ali			
	Hegmataneh	Day 1	14:00
	Hegmataneh	Day 1	14:20
	Hegmataneh	Day 1	16:30
Shafiei Masoumeh			
	Room #1	Day 1	14:30
Shahbazian Hojat			
	Main	Day 3	11:30
Shahriari Mehr Akbar			
	Hegmataneh	Day 2	15:00
Shahriari Mohsen			
	Tooska	Day 2	11:00
	Tooska	Day 2	11:45
Shahriyarian Shahriyar			
	Main	Day 3	11:30
Shakeri Jafar			
	Main	Day 3	09:10
Shalchi Keivan			
	Hegmataneh	Day 2	15:00
Shirazi Alireza			
	Hegmataneh	Day 1	14:00
	Hegmataneh	Day 1	16:30
Soltani Fariba			
	Hegmataneh	Day 2	10:10
Sotodeh Masoud			
	Main	Day 3	11:30
Tabatabaee Amir			
	Tooska	Day 3	11:15
Tabatabayi Nasibe			
	Room #1	Day 1	14:45
Tahmatan Mehdi			
	Main	Day 3	09:10
Taleghani Fariba			
	Tooska	Day 2	09:00
	Tooska	Day 2	11:00
Tofighi Rad Navid			
	Main	Day 2	11:00
Varaei			
	Tooska	Day 2	11:00
	Tooska	Day 3	09:00
Wrona Anna			
	Main	Day 2	12:00
Yaghobi Joybari Ali			
	Main	Day 1	12:30
Yahyazadeh Hossein			
	Main	Day 1	12:50
Yazdani Mehdi			
	Hegmataneh	Day 2	15:00
Zanganeh Masoumeh			
	Hegmataneh	Day 1	14:40

Once you choose **hope**  
every thing's possible

نوآوران دارویی **کیمیا**



**XITENT**<sup>®</sup>  
Sunitinib  
12.5 / 25 / 50 mg

**KIMOTAR**<sup>®</sup>  
Erlotinib  
150 mg

**SORANEX**<sup>®</sup>  
Sorafenib  
200 mg

**IMATINIB**  
400 mg / 100 mg



+98 21 88 01 29 46

[www.kimia-pharma.co](http://www.kimia-pharma.co)

[info@kimia-pharma.co](mailto:info@kimia-pharma.co)

گروه شرکت‌های  
آزاد طب درمان



AZADTEB DARMAN  
GROUP OF COMPANIES

SHINVA

XHA1400  
Dual-Energy  
LINEAR ACCELERATOR



SHINVA

XHA600E DIGITAL  
LINEAR ACCELERATOR



تهران، خیابان شهید مطهری، خیابان فجر (جم)، پلاک ۳۴، طبقه سوم

تلفن: ۵-۸۸۸۶۱۳۵۴ | فکس: ۸۸۱۴۱۳۹۱

[www.azadteb.com](http://www.azadteb.com) [support@std-co.com](mailto:support@std-co.com)





LESS TALK.  
MORE ACTION.

**28%**  
risk reduction in DFS events  
with Diphereline<sup>™</sup>+Exemestane  
vs. Diphereline<sup>™</sup>+Tamoxifen\*

\*HR 0.72; (95% CI, 0.602-0.855, p=0.0002)

**PRESCRIBING INFORMATION:** (Before prescribing please consult the full Summary of Product Characteristics (SPiC)) Presentation: Chewable tablets containing 250 mg, 500 mg, 750 mg or 1000 mg of letrozole (as letrozole carbonate hydrate). Oral powder containing 750 mg or 1000 mg of letrozole (as letrozole carbonate hydrate). Both the chewable tablets and oral powder contain dextrose, containing glucose. Use: Femara is indicated in adult patients as a preoperative adjuvant for use in the control of hyperproliferative in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Femara is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > 1.75 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels. **Dosage and Administration:** For oral use. Adults, including older people (>65 years): Femara should be taken with or immediately after food, with the daily dose divided into two equal divided whole tablets. To aid with chewing the tablets may be crushed. Femara oral powder is intended to be mixed with a small quantity of soft food (e.g. applesauce or other similar food product) and consumed immediately (within 15 minutes). The dose of Femara should be titrated every 2-3 weeks until an acceptable serum phosphate level is reached. Control of serum phosphate level has been demonstrated at doses starting from 750mg per day. The maximum daily dose studied, in a limited number of patients, is 3750mg. Patients who respond to letrozole therapy usually achieve acceptable serum phosphate levels at doses of 1500-3000mg letrozole per day. Paediatric population (<18 years): The safety and efficacy of Femara in children and adolescents has not been established. Use in children and adolescents is not recommended. **Heuristic impairment:** The effect of hepatic impairment on Femara pharmacokinetics has not been assessed. Due to its mechanism of action and the lack of liver metabolism, doses in hepatic impairment should not be modified, but patients should be monitored carefully. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Hyperproliferative Agents:** Special Warnings and Precautions: Tissue deposition of letrozole has been shown with Femara in animal studies and in bone biopsies from patients treated with Femara, some for up to 4.5 years, using levels of letrozole well above those used in clinical studies beyond 2 years of currently limited. However, treatment of subjects with Femara for up to 4 years has not demonstrated a change in the breast risk profile. Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease or bowel obstruction were not included in clinical studies with Femara. Femara should be used in these patients following careful assessment of benefit and risk. Femara is known to cause constipation and therefore caution should be exercised in patients predisposed to bowel obstruction (e.g. previous abdominal surgery, peritonitis). Patients with renal insufficiency may develop hypocalcaemia. Serum calcium levels should be monitored at regular intervals for this patient population and appropriate supplements given. As the liver is the principal organ of elimination of absorbed letrozole monitoring of liver function tests is recommended. Letrozole is not metabolised by liver enzymes but it is most likely excreted in the bile. Conditions resulting in a marked reduction of bile flow may be associated with increasingly slower elimination of letrozole, which may result in higher plasma levels and increased tissue deposition of letrozole. Femara should be discontinued if hyperproliferative agents are used. Abdominal cramps of patients taking letrozole carbonate may have a radio-opaque appearance typical of an imaging agent. Patients with rare glucose-galactose malabsorption should not take this medicine. **Interactions:** Femara may increase gastric pH. It is recommended that compounds, which are known to interact with antacids, should not be taken within 2 hours of dosing with Femara (e.g. cholinergic, anticholinergic and antacid). Interactions with drugs such as terfenadine, doxycycline and doxypine are theoretically possible. Therefore it is recommended that they are not taken within 2 hours of dosing with Femara. The bioavailability of oral contraceptives was decreased by approximately 50% when taken with Femara in a single dose study in healthy volunteers. It is recommended that oral contraceptives are taken at least 2 hours before or 4 hours after Femara. **Precautions:** Studies (including Femara) have been shown to reduce the absorption of levothyroxine. Consequently, thyroid hormone replacement therapy should not be taken within 2 hours of dosing with Femara and close monitoring of TSH levels is recommended in patients receiving both medicinal products. **Fertility, Pregnancy and Lactation:** Femara is not recommended in pregnancy. The risk/benefit for continuing/discontinuing either Femara or breast feeding should be carefully considered. There are no fertility data available on letrozole carbonate in humans. **Driving:** Femara may induce dizziness and vertigo, which may impair the ability to drive and use machinery. **Adverse Effects:** Very common (>10%): headache, abdominal pain, diarrhoea, nausea, vomiting, allergic skin reactions. Common (1% to <10%): patients: constipation, dyspepsia, flatulence, hypocalcaemia. Common SMC in relation to less common side effects. Date of Revision: January 2015. Name and Address of MA Holder: Shire Pharmaceutical Contracts Limited, Hampshire International Business Park, Chiswick, Uxbridge, Middlesex, UK. Further information is available on request. **FOSENLK** is a registered trade name. Adverse events should be reported to Shire at: [globalpharmacovigilance@shire.com](mailto:globalpharmacovigilance@shire.com)



LESS TALK.  
MORE ACTION.

**30%**  
risk reduction in DFS events  
with Diphereline<sup>™</sup>+Exemestane  
vs. Tamoxifen alone\*

\* In patients who received adjuvant chemotherapy. HR 0.70; (95% CI, 0.53-0.92)

**PRESCRIBING INFORMATION:** (Before prescribing please consult the full Summary of Product Characteristics (SPiC)) Presentation: Chewable tablets containing 250 mg, 500 mg, 750 mg or 1000 mg of letrozole (as letrozole carbonate hydrate). Oral powder containing 750 mg or 1000 mg of letrozole (as letrozole carbonate hydrate). Both the chewable tablets and oral powder contain dextrose, containing glucose. Use: Femara is indicated in adult patients as a preoperative adjuvant for use in the control of hyperproliferative in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Femara is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > 1.75 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels. **Dosage and Administration:** For oral use. Adults, including older people (>65 years): Femara should be taken with or immediately after food, with the daily dose divided between meals. The tablets must be chewed completely and not swallowed whole. To aid with chewing the tablets may be crushed. Femara oral powder is intended to be mixed with a small quantity of soft food (e.g. applesauce or other similar food product) and consumed immediately (within 15 minutes). The dose of Femara should be titrated every 2-3 weeks until an acceptable serum phosphate level is reached. Control of serum phosphate level has been demonstrated at doses starting from 750mg per day. The maximum daily dose studied, in a limited number of patients, is 3750mg. Patients who respond to letrozole therapy usually achieve acceptable serum phosphate levels at doses of 1500-3000mg letrozole per day. Paediatric population (<18 years): The safety and efficacy of Femara in children and adolescents has not been established. Use in children and adolescents is not recommended. **Heuristic impairment:** The effect of hepatic impairment on Femara pharmacokinetics has not been assessed. Due to its mechanism of action and the lack of liver metabolism, doses in hepatic impairment should not be modified, but patients should be monitored carefully. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Hyperproliferative Agents:** Special Warnings and Precautions: Tissue deposition of letrozole has been shown with Femara in animal studies and in bone biopsies from patients treated with Femara, some for up to 4.5 years, using levels of letrozole well above those used in clinical studies beyond 2 years of currently limited. However, treatment of subjects with Femara for up to 4 years has not demonstrated a change in the breast risk profile. Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease or bowel obstruction were not included in clinical studies with Femara. Femara should be used in these patients following careful assessment of benefit and risk. Femara is known to cause constipation and therefore caution should be exercised in patients predisposed to bowel obstruction (e.g. previous abdominal surgery, peritonitis). Patients with renal insufficiency may develop hypocalcaemia. Serum calcium levels should be monitored at regular intervals for this patient population and appropriate supplements given. As the liver is the principal organ of elimination of absorbed letrozole monitoring of liver function tests is recommended. Letrozole is not metabolised by liver enzymes but it is most likely excreted in the bile. Conditions resulting in a marked reduction of bile flow may be associated with increasingly slower elimination of letrozole, which may result in higher plasma levels and increased tissue deposition of letrozole. Femara should be discontinued if hyperproliferative agents are used. Abdominal cramps of patients taking letrozole carbonate may have a radio-opaque appearance typical of an imaging agent. Patients with rare glucose-galactose malabsorption should not take this medicine. **Interactions:** Femara may increase gastric pH. It is recommended that compounds, which are known to interact with antacids, should not be taken within 2 hours of dosing with Femara (e.g. cholinergic, anticholinergic and antacid). Interactions with drugs such as terfenadine, doxycycline and doxypine are theoretically possible. Therefore it is recommended that they are not taken within 2 hours of dosing with Femara. The bioavailability of oral contraceptives was decreased by approximately 50% when taken with Femara in a single dose study in healthy volunteers. It is recommended that oral contraceptives are taken at least 2 hours before or 4 hours after Femara. **Precautions:** Studies (including Femara) have been shown to reduce the absorption of levothyroxine. Consequently, thyroid hormone replacement therapy should not be taken within 2 hours of dosing with Femara and close monitoring of TSH levels is recommended in patients receiving both medicinal products. **Fertility, Pregnancy and Lactation:** Femara is not recommended in pregnancy. The risk/benefit for continuing/discontinuing either Femara or breast feeding should be carefully considered. There are no fertility data available on letrozole carbonate in humans. **Driving:** Femara may induce dizziness and vertigo, which may impair the ability to drive and use machinery. **Adverse Effects:** Very common (>10%): headache, abdominal pain, diarrhoea, nausea, vomiting, allergic skin reactions. Common (1% to <10%): patients: constipation, dyspepsia, flatulence, hypocalcaemia. Common SMC in relation to less common side effects. Date of Revision: January 2015. Name and Address of MA Holder: Shire Pharmaceutical Contracts Limited, Hampshire International Business Park, Chiswick, Uxbridge, Middlesex, UK. Further information is available on request. **FOSENLK** is a registered trade name. Adverse events should be reported to Shire at: [globalpharmacovigilance@shire.com](mailto:globalpharmacovigilance@shire.com)



LESS TALK.  
MORE ACTION.

**26%**  
risk reduction in DFS events  
with Diphereline<sup>™</sup>+Tamoxifen  
vs. Tamoxifen alone\*

\* In patients less than 40 years old. HR 0.74 (95% CI, 0.53-1.03)

**PRESCRIBING INFORMATION:** (Before prescribing please consult the full Summary of Product Characteristics (SPiC)) Presentation: Chewable tablets containing 250 mg, 500 mg, 750 mg or 1000 mg of letrozole (as letrozole carbonate hydrate). Oral powder containing 750 mg or 1000 mg of letrozole (as letrozole carbonate hydrate). Both the chewable tablets and oral powder contain dextrose, containing glucose. Use: Femara is indicated in adult patients as a preoperative adjuvant for use in the control of hyperproliferative in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Femara is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > 1.75 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels. **Dosage and Administration:** For oral use. Adults, including older people (>65 years): Femara should be taken with or immediately after food, with the daily dose divided between meals. The tablets must be chewed completely and not swallowed whole. To aid with chewing the tablets may be crushed. Femara oral powder is intended to be mixed with a small quantity of soft food (e.g. applesauce or other similar food product) and consumed immediately (within 15 minutes). The dose of Femara should be titrated every 2-3 weeks until an acceptable serum phosphate level is reached. Control of serum phosphate level has been demonstrated at doses starting from 750mg per day. The maximum daily dose studied, in a limited number of patients, is 3750mg. Patients who respond to letrozole therapy usually achieve acceptable serum phosphate levels at doses of 1500-3000mg letrozole per day. Paediatric population (<18 years): The safety and efficacy of Femara in children and adolescents has not been established. Use in children and adolescents is not recommended. **Heuristic impairment:** The effect of hepatic impairment on Femara pharmacokinetics has not been assessed. Due to its mechanism of action and the lack of liver metabolism, doses in hepatic impairment should not be modified, but patients should be monitored carefully. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Hyperproliferative Agents:** Special Warnings and Precautions: Tissue deposition of letrozole has been shown with Femara in animal studies and in bone biopsies from patients treated with Femara, some for up to 4.5 years, using levels of letrozole well above those used in clinical studies beyond 2 years of currently limited. However, treatment of subjects with Femara for up to 4 years has not demonstrated a change in the breast risk profile. Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease or bowel obstruction were not included in clinical studies with Femara. Femara should be used in these patients following careful assessment of benefit and risk. Femara is known to cause constipation and therefore caution should be exercised in patients predisposed to bowel obstruction (e.g. previous abdominal surgery, peritonitis). Patients with renal insufficiency may develop hypocalcaemia. Serum calcium levels should be monitored at regular intervals for this patient population and appropriate supplements given. As the liver is the principal organ of elimination of absorbed letrozole monitoring of liver function tests is recommended. Letrozole is not metabolised by liver enzymes but it is most likely excreted in the bile. Conditions resulting in a marked reduction of bile flow may be associated with increasingly slower elimination of letrozole, which may result in higher plasma levels and increased tissue deposition of letrozole. Femara should be discontinued if hyperproliferative agents are used. Abdominal cramps of patients taking letrozole carbonate may have a radio-opaque appearance typical of an imaging agent. Patients with rare glucose-galactose malabsorption should not take this medicine. **Interactions:** Femara may increase gastric pH. It is recommended that compounds, which are known to interact with antacids, should not be taken within 2 hours of dosing with Femara (e.g. cholinergic, anticholinergic and antacid). Interactions with drugs such as terfenadine, doxycycline and doxypine are theoretically possible. Therefore it is recommended that they are not taken within 2 hours of dosing with Femara. The bioavailability of oral contraceptives was decreased by approximately 50% when taken with Femara in a single dose study in healthy volunteers. It is recommended that oral contraceptives are taken at least 2 hours before or 4 hours after Femara. **Precautions:** Studies (including Femara) have been shown to reduce the absorption of levothyroxine. Consequently, thyroid hormone replacement therapy should not be taken within 2 hours of dosing with Femara and close monitoring of TSH levels is recommended in patients receiving both medicinal products. **Fertility, Pregnancy and Lactation:** Femara is not recommended in pregnancy. The risk/benefit for continuing/discontinuing either Femara or breast feeding should be carefully considered. There are no fertility data available on letrozole carbonate in humans. **Driving:** Femara may induce dizziness and vertigo, which may impair the ability to drive and use machinery. **Adverse Effects:** Very common (>10%): headache, abdominal pain, diarrhoea, nausea, vomiting, allergic skin reactions. Common (1% to <10%): patients: constipation, dyspepsia, flatulence, hypocalcaemia. Common SMC in relation to less common side effects. Date of Revision: January 2015. Name and Address of MA Holder: Shire Pharmaceutical Contracts Limited, Hampshire International Business Park, Chiswick, Uxbridge, Middlesex, UK. Further information is available on request. **FOSENLK** is a registered trade name. Adverse events should be reported to Shire at: [globalpharmacovigilance@shire.com](mailto:globalpharmacovigilance@shire.com)



LESS TALK.  
MORE ACTION.

**SOFT & TEXT**  
studies led guidelines\* to recommend  
OFS use with Tamoxifen or Exemestane  
as a new therapeutic option\*\*

\*\* In high-risk patients

**PRESCRIBING INFORMATION:** (Before prescribing please consult the full Summary of Product Characteristics (SPiC)) Presentation: Chewable tablets containing 250 mg, 500 mg, 750 mg or 1000 mg of letrozole (as letrozole carbonate hydrate). Oral powder containing 750 mg or 1000 mg of letrozole (as letrozole carbonate hydrate). Both the chewable tablets and oral powder contain dextrose, containing glucose. Use: Femara is indicated in adult patients as a preoperative adjuvant for use in the control of hyperproliferative in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Femara is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > 1.75 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels. **Dosage and Administration:** For oral use. Adults, including older people (>65 years): Femara should be taken with or immediately after food, with the daily dose divided between meals. The tablets must be chewed completely and not swallowed whole. To aid with chewing the tablets may be crushed. Femara oral powder is intended to be mixed with a small quantity of soft food (e.g. applesauce or other similar food product) and consumed immediately (within 15 minutes). The dose of Femara should be titrated every 2-3 weeks until an acceptable serum phosphate level is reached. Control of serum phosphate level has been demonstrated at doses starting from 750mg per day. The maximum daily dose studied, in a limited number of patients, is 3750mg. Patients who respond to letrozole therapy usually achieve acceptable serum phosphate levels at doses of 1500-3000mg letrozole per day. Paediatric population (<18 years): The safety and efficacy of Femara in children and adolescents has not been established. Use in children and adolescents is not recommended. **Heuristic impairment:** The effect of hepatic impairment on Femara pharmacokinetics has not been assessed. Due to its mechanism of action and the lack of liver metabolism, doses in hepatic impairment should not be modified, but patients should be monitored carefully. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Hyperproliferative Agents:** Special Warnings and Precautions: Tissue deposition of letrozole has been shown with Femara in animal studies and in bone biopsies from patients treated with Femara, some for up to 4.5 years, using levels of letrozole well above those used in clinical studies beyond 2 years of currently limited. However, treatment of subjects with Femara for up to 4 years has not demonstrated a change in the breast risk profile. Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease or bowel obstruction were not included in clinical studies with Femara. Femara should be used in these patients following careful assessment of benefit and risk. Femara is known to cause constipation and therefore caution should be exercised in patients predisposed to bowel obstruction (e.g. previous abdominal surgery, peritonitis). Patients with renal insufficiency may develop hypocalcaemia. Serum calcium levels should be monitored at regular intervals for this patient population and appropriate supplements given. As the liver is the principal organ of elimination of absorbed letrozole monitoring of liver function tests is recommended. Letrozole is not metabolised by liver enzymes but it is most likely excreted in the bile. Conditions resulting in a marked reduction of bile flow may be associated with increasingly slower elimination of letrozole, which may result in higher plasma levels and increased tissue deposition of letrozole. Femara should be discontinued if hyperproliferative agents are used. Abdominal cramps of patients taking letrozole carbonate may have a radio-opaque appearance typical of an imaging agent. Patients with rare glucose-galactose malabsorption should not take this medicine. **Interactions:** Femara may increase gastric pH. It is recommended that compounds, which are known to interact with antacids, should not be taken within 2 hours of dosing with Femara (e.g. cholinergic, anticholinergic and antacid). Interactions with drugs such as terfenadine, doxycycline and doxypine are theoretically possible. Therefore it is recommended that they are not taken within 2 hours of dosing with Femara. The bioavailability of oral contraceptives was decreased by approximately 50% when taken with Femara in a single dose study in healthy volunteers. It is recommended that oral contraceptives are taken at least 2 hours before or 4 hours after Femara. **Precautions:** Studies (including Femara) have been shown to reduce the absorption of levothyroxine. Consequently, thyroid hormone replacement therapy should not be taken within 2 hours of dosing with Femara and close monitoring of TSH levels is recommended in patients receiving both medicinal products. **Fertility, Pregnancy and Lactation:** Femara is not recommended in pregnancy. The risk/benefit for continuing/discontinuing either Femara or breast feeding should be carefully considered. There are no fertility data available on letrozole carbonate in humans. **Driving:** Femara may induce dizziness and vertigo, which may impair the ability to drive and use machinery. **Adverse Effects:** Very common (>10%): headache, abdominal pain, diarrhoea, nausea, vomiting, allergic skin reactions. Common (1% to <10%): patients: constipation, dyspepsia, flatulence, hypocalcaemia. Common SMC in relation to less common side effects. Date of Revision: January 2015. Name and Address of MA Holder: Shire Pharmaceutical Contracts Limited, Hampshire International Business Park, Chiswick, Uxbridge, Middlesex, UK. Further information is available on request. **FOSENLK** is a registered trade name. Adverse events should be reported to Shire at: [globalpharmacovigilance@shire.com](mailto:globalpharmacovigilance@shire.com)



# PhaRes

Pharma Resources  
[www.pha-res.com](http://www.pha-res.com)



PhaRes  
Pharma Resources

Pharma Resources - that is the profitable combination of the company's 20-year history and 25 years of the partner's market experience in the areas of service and contract manufacturing for pharmaceuticals, medical products and biotechnology.

## FLUOROURACIL PhaRes

500 & 250 mg



## CARBOPLATIN PhaRes

150 & 50 mg



## TOPOTECAN PhaRes

4 mg



## IRINOTECAN PhaRes

100 mg/5ml



**We are there for you, when you need us - always!**

**SANDOZ** A Novartis  
Division

## PET-CT کار دیولوژی

- پرفیوژن میوکارد
- نارسائی قلبی
- گردش خون قلبی
- گردش خون کلیوی

با رادیو داروی  $^{13}\text{NH}_3\text{-}82\text{Rb}^+$



## PET-CT آنکولوژی

- سرطان هوچکین و لنفوم ها
- سرطان پستان، کولون، ریه و پروستات
- سرطان ملانوم، رحم، تخمدان و مثانه
- سایر ضایعات نئوپلاستیک

با رادیو داروی  $^{18}\text{F-FDG}$

- تشخیص سریع‌تر تومورها
- بررسی تمام بدن از نظر پخش شدن سرطان (متاستاز) Staging
- بررسی رشد ضایعات خوش خیم و بدخیم
- بررسی میزان تهاجم کانسرها
- ارزیابی پاسخ به درمان
- تشخیص زودرس عود تومورها

## اولین مرکز اسکن PET-CT

تشخیص دقیق ضایعات بدخیم و التهابی



## PET-CT نورولوژی

- تشخیص زود رس :
- بیماری آلزایمر
- بیماری پارکینسون
- صرع های فوکال
- متاستازهای مغزی

با رادیو داروی  $^{150}\text{-H}_2\text{O}$

## PET-CT بیماری های عفونی و التهابی

- سارکوئیدوز
- سل و ایدز
- بیماریهای التهابی ریه

با رادیو داروی  $^{18}\text{F-FDG}$

آدرس: دارآباد، انتهای خیابان شهید پورابتهاج، بیمارستان دکتر مسیح  
دانشوری، ساختمان اورژانس، طبقه زیر زمین، مرکز پزشکی هسته‌ای فردوس  
تلفن: ۲۷۱۲۲۷۱۱-۲  
نمابر: ۲۶۱۰۹۵۰۴  
تارنما: <http://pet-ct.nritld.sbmu.ac.ir>  
Email: [pet-ct.nritld@sbmu.ac.ir](mailto:pet-ct.nritld@sbmu.ac.ir)

# NAVELBINE<sup>®</sup> Oral

vinorelbine

RIGHT FROM THE FIRST LINE

## Metastatic Breast Cancer Non Small Cell Lung Cancer

Recommended by  
International Guidelines

NCCN

ASCO

ESMO



THE EFFECTIVE  
ORAL CHEMOTHERAPY  
TO START WITH



Pierre Fabre  
Oncology

\*NAVELBINE<sup>®</sup> Oral is indicated as a single agent or in combination for the first-line treatment of stage 3 or 4 non-small cell lung cancer and the treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline-containing regimen.

Summary of product characteristics available at the booth.

► Behyaar Sanaat Sepahan Co.  
[www.behyaar.com](http://www.behyaar.com)  
[info@behyaar.com](mailto:info@behyaar.com)



دستگاه برش شیلد های درمانی



دستگاه شتاب دهنده خطی پزشکی  
سیستم های دوزیمتری  
آلیاژ سروبند

behyaar

شرکت دانش بنیان  
بهیار صنعت سپاهان

ما می توانیم با دانش و تخصص  
بومی از رنج بیماری بکاهیم

◀ دفتر مرکزی: اصفهان، شهرک علمی تحقیقاتی، شرکت دانش بنیان  
بهیار صنعت سپاهان. تلفن: ۰۸۰-۳۱۳۳۹۳۲۲۷۶. فکس: ۰۳۱۳۳۹۳۲۲۷۵.  
◀ دفتر تهران: خیابان سهروردی شمالی، خیابان خرمشهر، خیابان  
عربعلی، کوچه هفت، پلاک هفت. تلفن: ۰۲۱۸۸۵۳۰۸۶۶. فکس: ۰۲۱۸۶۰۳۱۳۵۴





**KHATAM**  
PET / CT CENTER  
[www.petctkhatam.ir](http://www.petctkhatam.ir)

## مرکز پت سی تی بیمارستان خاتم الانبیاء (ص)

تشخیص دقیق زمینه ساز درمان موفق


مجهزترین دستگاه PET/CT کشور با CT ۱۲۸ اسلایس



$^{68}\text{Ga}$ -PSMA PET/CT



$^{18}\text{F}$ -FDG PET/CT




$^{68}\text{Ga}$ -DOTATATE PET/CT

خیابان ولیعصر، بالاتر از میرداماد، خیابان رشید یاسمی، بیمارستان  
فوق تخصصی خاتم الانبیاء (ص)      تلفن: ۸۳۵۵۷۰۸۰ - ۸۳۵۵۷۰۷۰

Exhibition Plan



The Third International Clinical Oncology Congress







# Abstracts and Posters of The Third International Clinical Oncology Congress

The 13<sup>th</sup> Iranian Annual Clinical Oncology Congress  
Clinical Radiobiology Seminar  
The Third International Clinical Oncology Nursing Congress  
Annual Radiotherapy Technologists' Program

All the accepted abstracts of The Third International Clinical Oncology Congress are accessible online at the website of the official journal of Iranian Society of Clinical Oncology:

Reports of Radiotherapy & Oncology  
<http://radioncology.com/en/index.html>



## CLINICAL ABSTARCTS

### 1. ROLE OF AUTOPHAGY SIGNALING AND MECHANISM OF TREATMENT IN GLIOBLASTOMA

Mohammad Amin Dehghani<sup>1\*</sup>, Saleh Rasras<sup>2</sup>, Fatemeh Dehghani<sup>3</sup>, Seyyed Hossein Hassanpour<sup>4</sup>, Maryam Shirani<sup>1,5</sup>

1. Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2. Department of Neurosurgery, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3. Department of Geneticss, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
4. Young Researchers and Elite Club, Yasooj Branch, Islamic Azad University, Yasooj, Iran
5. Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

\* Correspondance: Mohammad Amin Dehghani  
Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran  
E-mail: mohammaddeh83@yahoo.com

### 2. RELATIONSHIP BETWEEN NEOADJUVANT CHEMORADIOTHERAPY TO SURGERY INTERVAL AND RESPONSE TO TREATMENT IN RECTAL CANCER

Ali Taghizadeh<sup>1\*</sup>, Mohsen Aliakbarian<sup>2</sup>, Kambiz Akhavan Rezayat<sup>3</sup>, Human Mozafari Mosanan<sup>3</sup>, Mona Joudi<sup>1</sup>, Arezou Mohtasham<sup>2</sup>

1. Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2. Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3. Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

\* Correspondance: taghizadeha@mums.ac.ir

### 3. A GENETICS POLYMORPHISM IN THE CYTOCHROME-P450-FAMILY-1-SUBFAMILY-B-POLYPEPTIDE-1 GENE IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS: AN IRANIAN MASHHAD COHORT STUDY RECRUITED OVER 10 YEARS

Seyed Amir Aledavood<sup>1</sup>, Soodabeh Shahid Sales<sup>1\*</sup>, Azam Rastgar Moghadam<sup>1</sup>, Mehrane Mehramiz<sup>2</sup>, Kazem Anvari<sup>1</sup>, Saeideh Ahmadi Simab<sup>1</sup>, Amir Avan<sup>2</sup>

1. Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

\* Corresponding author: Soodabeh Shahidsales  
shahidsaless@mums.ac.ir

#### 4. THE EFFECT OF BMI ON SURVIVAL OF PATIENTS WITH COLORECTAL CANCER

Azar Fanipakdel<sup>1</sup>, Sare Hosseini<sup>1</sup>, Roham Salek<sup>1</sup>, Farzin Afkhami Jedi<sup>2</sup>, Mostafa Vasei<sup>3</sup>

1. Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  2. Mashhad University of Medical Sciences, Mashhad, Iran
  3. Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
- 

#### 5. COMPARISON OF SECONDARY CANCER RISK INCIDENCE AFTER RADIOTHERAPY OF SEMINOMA IN CONVENTIONAL AND CONFORMAL RADIOTHERAPY

Hamid Ghaznavi<sup>1</sup>, Zeinab Salehi<sup>2</sup>, Hamid Emami<sup>3</sup>, Farzaneh Allahwaisi<sup>4</sup>, Parvaneh Shokrani<sup>5</sup>

1. MSc Graduated of Medical Physics, Engineering and Medical Physics Department, Isfahan University of Medical Sciences, Isfahan, Iran
  2. Assistant Professor of Radiation Oncology, Radiotherapy Department, Kurdistan University of Medical Sciences, Kurdistan, Iran
  3. Associated Professor of Radiation Oncology, Radiation Oncology Department, Isfahan University of Medical Sciences, Isfahan, Iran
  4. Assistant Professor of Medical Physics, Medical Physics Department, Kurdistan University of Medical Sciences, Kurdistan, Iran
  5. Professor of Medical Physics, Engineering and Medical Physics Department, Isfahan University of Medical Sciences, Isfahan, Iran
- 

#### 6. MICRONUCLEUS CHANGES IN PERIPHERAL BLOOD LYMPHOCYTES BEFORE AND AFTER CHEMOTHERAPY AND ITS ROLE IN PREDICTING SURVIVAL OF PATIENTS WITH GASTRIC CANCER

Kamrani G<sup>1</sup>, Abbasi B<sup>1</sup>, Mahmoudzadeh A<sup>1</sup>

1. Department of Biosciences and Biotechnology, Malek-Ashtar University of Technology, Tehran, Iran
- 

#### 7. PROTECTION OF RESVERATROL AGAINST GENOTOXICITY DAMAGE AND TISSUE ANTIOXIDANT STATUS INDUCED BY X- RADIATION EXPOSURE IN MICE

Farideh Koochian<sup>1</sup>, Mahbobeh Koochian<sup>2</sup>, Ahmad Shanei<sup>1</sup>

1. Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
-

## 8. SNHG7 HAS AN ONCOGENIC ROLE IN CRC VIA POTENTIAL MIRNA SPONGING

Farinaz Ziaee, Mohammadreza Hajjari, Seyed Reza Kazeminezhad

Department of Geneticss, Faculty of Science, Shahid Chamran University of Ahwaz, Ahwaz, Iran

---

## 9. THE ROLES OF THIOREDOXIN SYSTEM IN CANCER PATHOGENESIS AND ITS TARGETING FOR CANCER THERAPY

Fariba Mohammadi<sup>1</sup>

dr.f.mohammadi1@gmail.com

Cell Phone Number: 09155306409

1. Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

---

## 10. EVALUATION OF PATIENT SET-UP ERRORS AND ORGAN MOTION IN PROSTATE INTENSITY MODULATED RADIATION THERAPY USING EPID'S IMAGING TECHNIQUE

Meisam Ebrahimi Bardar<sup>1</sup>, Mehdi Momennezhad<sup>1</sup>, Mohsen Bakhshandeh<sup>2,\*</sup>, Shahrokh Nasser<sup>1</sup>, Bahram Mofid<sup>3</sup>

1. Department of Medical Physics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2. Department of Radiology Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Department of Radiation Oncology, Shohada Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

\* Corresponding Author: Mohsen Bakhshandeh

Associate Professor, Radiology Technology Department, Allied Medical Faculty, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Zip postal Code: 1989934148

Phone: +98 21 22711131 Fax: +98 21 22717503

mbakhshandeh@sbmu.ac.ir

---

## 11. ROL OF HYPOXIA SIGNALING AND MECHANISM OF TREATMENT IN GLIOBLASTOMA

Mohammad Amin Dehghani<sup>1\*</sup>, Saleh Rasras<sup>2</sup>, Jeiran Haghighi<sup>3</sup>, Fatemeh Dehghani<sup>4</sup>, Maryam Shirania<sup>5</sup>

1. Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  2. Department of Neurosurgery, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  3. School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  4. Department of Geneticss, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  5. Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
-

## 12. EVALUATION THE EFFECTS OF SILIBININ ON METASTASIS OF LUNG CANCER CARCINOMA CELL LINE A549.

Seyed Mohamadsaleh Zahraei<sup>1</sup>, Hamid Ghalehdari

1. zahraei.saleh@gmail.com

---

## 13. DESIGN AND PREPARATION OF TUMOR TARGETED BISMUTH- GOLD -ALBUMIN NANOHYBRIDS FOR ENHANCED X-RAY RADIATION THERAPY OF BREAST CANCER

Fatemeh Abhari<sup>1</sup>, Hamed Nosrati<sup>2\*</sup>, Alireza Farajollahi<sup>3</sup>, Hamed RezaeeJam<sup>4</sup>, Hosein Danafar<sup>5</sup>

1. Department of Medical Physics School of Medical , Tabriz University of Medical Sciences
  2. Department of Medicinal Chemistry, School of Pharmacy, Zanjan University of Medical Sciences
  3. Department of Medical Physics School of Medical , Tabriz University of Medical Sciences
  4. Department of Radiology School of ParaMedical, Zanjan University of Medical Sciences
  5. Department of Medicinal Chemistry, School of Pharmacy, Zanjan University of Medical Sciences
- 

## 15. TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA: A NOVEL THERAPEUTIC APPROACH

Mohammad Amin Dehghani<sup>1\*</sup>, Fatemeh Dehghani<sup>2</sup>, Jeiran Haghighi<sup>3</sup>

1. Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  2. Department of Geneticss, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  3. School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
- \* Correspondence: Mohammad Amin Dehghani  
Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran  
mohammaddeh83@yahoo.com  
Mobile:09337584981
- 

## 16. MODELING OF TEMPERATURE DISTRIBUTION IN BRAIN TUMOR IN ELECTROMAGNETIC HYPERTHERMIA WITH FE3O4 NANOPARTICLES

P.Ghahramani<sup>1</sup>, M.Sohrabi<sup>2</sup>, L.Khalafi<sup>3</sup>, S.R.Mahdavi<sup>3</sup>

1. Radiation Medicine Engineering Department, Sharif University of Technology, Tehran, IRAN.
  2. Radiation Medicine Engineering Department, Islamic Azad University, Science and Research Branch, Tehran, IRAN.
  3. Department of Medical Physics, Faculty of Medical Science, Iran University of Medical Sciences, Tehran, IRAN.
-

## 17. EVALUATION OF TWIST1 PROMOTER METHYLATION IN BREAST CANCER

Abbas Ardalan<sup>1</sup>, Ahmad Hamta<sup>2,\*</sup>, Sedigheh Khazaei<sup>3</sup>

1. MSc Department of Biology, Faculty of Sciences, Arak University, Arak, Iran
  2. Associate Professor of Molecular Geneticss and CytoGenetics Department of Biology, Faculty of Sciences, University of Arak, Zip Code: 8349-8-38156
  3. Molecular Pathology Research Center of Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
- \* Corresponding Author: Dr. Ahmad Hamtah, E-mail: a-hamta@araku.ac.ir
- 

## 18. IN SILICO EVALUATION OF MIR-124 AND ITS TARGETS IN METASTATIC TUMOR SAMPLES OF LUNG CANCER.

Seyed Mohammadsaleh Zahraei<sup>1</sup>, Hamid Galehdari

1. zahraei.saleh@gmail.com
- 

## 19. INCREASING RADIO SENSITIVITY OF BREAST CANCER CELLS BY CONCOMITANT OF CHEMOTHERAPY, ANTI-HER ONCOGENE, ANTIBODIES AND RADIO THERAPY

Edris Farhadi<sup>1</sup>

1. Technology Radiology Student, Faculty of Para-Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Edris\_farhadi@yahoo.com
- 

## 20. EVALUATING THE SENSITIVITY OF DIFFERENT COLON CANCER SCREENING METHODS: BARIUM ENEMA, COLONOSCOPY AND HIDDEN BLOOD IN THE STOOL TEST

Marziyeh Tahmasbi<sup>1</sup>, Seyde Simin Mosavi Aveny<sup>2,\*</sup>

1. Assistant Professor of Medical Physics, Department of Radiologic Technology, Faculty of ParaMedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  2. MSc Student of Medical Physics, Department of Medical Physics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- \* Correspond Author: Seyde Simin Mosavi Aveni  
Tel: 09357410299  
siminmosavii@gmail.com
-

## 21. DIFFERENT BREAST CANCER SUBTYPES IN WOMEN YOUNGER THAN 35 YEARS OLD

Mona Joudi, Ali Taghizadeh, Leila Pourali, Zahra Zajabpour

Mashhad University of Medical Sciences

---

## 22. INVESTIGATING THE SENSITIVITY OF DIFFERENT IMAGING MODALITY (CT, MRI, US, PET) FOR HEPATIC METASTASES DETECTION

Sara Zahmatkesh<sup>1</sup>, Marziyeh Tahmasbi<sup>2</sup>

1. Technology Radiology Student, Department of Radiologic Technology, Faculty of ParaMedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  2. Assistant Professor of Medical Physics, Department of Radiologic Technology, Faculty of ParaMedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- 

## 23. THE EFFECTS OF NANO-CURCUMIN ON RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH BLADDER CANCER: A PILOT PHASE II STUDY

Saleh Sandoughdaran<sup>1,2,\*</sup> Abolfazl Razzaghdoust<sup>3,\*</sup> and Bahram Mofid<sup>1,2</sup>

1. Shohada-e-Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Urology and Nephrology Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Urology and Nephrology Research Center, Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran

\* The First Two Authors contributed Equally to This Work

Correspondence to: Prof. Bahram Mofid, MD, Urology and Nephrology Research Center, No 103, 9th Boustan., Pasdaran Ave., Tehran, Iran, Postal Code: 1666697751  
Email: mofid429@sbmu.ac.ir, Tel: +98 2122567222, Fax: +98 2122567282

---

## 24. RELATIONSHIP BETWEEN BREAST CANCER AND THYROID DISORDERS

Fadavi Pedram<sup>1</sup>, Khoshbakht Ahmadi Helaleh<sup>1,\*</sup>, Mafi Ahmad R<sup>2</sup>, Arefpour Nariman<sup>3</sup>, Tabatabaeeifar Morteza<sup>2</sup>

1. Department of Radiation Oncology, Iran University of Medical Sciences, Shohadaye 7 Tir hospital, Tehran, Iran
2. Department of Radiation Oncology, Shahid Beheshti University of Medical Science Tehran Iran
3. Department of Radiation Oncology, Iran University of Medical Sciences, Tehran, Iran

\* For Correspondence: Khoshbakht.h@iums.ac.ir

---

## 25. HEAT SHOCK PROTEINS 27, 70 AND 90 PROTEIN EXPRESSION IN GASTRIC ADENOCARCINOMA: PROGNOSTIC, PREDICTIVE AND CELLULAR DIFFERENTIATION SIGNIFICANCES

Ali Taghizadeh<sup>1</sup>, Mona Joudi<sup>1,\*</sup>, Mehdi Zardadi<sup>2</sup>, Hamidreza Sima<sup>3</sup>, Kamran Ghafarzadegan<sup>4</sup>, Sara Lari<sup>5</sup>

1. Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  2. Reza Radiotherapy Oncology Center, Mashhad, Iran
  3. Division of Gastroenterology, Department of Medicine, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  4. Razavi Cancer Research Center, Razavi Hospital, Imam reza international University, Mashhad, Iran
  5. Mashhad Pathobiology Lab, Mashhad, Iran
- Corresponder: Mona Joudi
- 

## 26. ADULT T CELL LEUKEMIA / LYMPHOMA IN 23-YEAR-OLD MALE, A CASE REPORT

Ali Eishi Oskouie<sup>1</sup>, Rahim Nasrollahi<sup>2</sup>, Bita Solahae Kahnamouii<sup>2</sup>

1. Professor of Hematology / Medical Oncology, Urmia University of Medical Sciences.
  2. Medical Student, Urmia University of Medical Sciences
- 

## 27. IDENTIFICATION AND ANALYSIS OF ADVERSE DRUG REACTIONS ASSOCIATED WITH COLORECTAL AND GASTRIC CANCER CHEMOTHERAPY IN HOSPITALIZED PATIENTS

Ghazal Askarpoor<sup>1</sup>, Sepideh Elyasi<sup>1</sup>, Azar Fani Pakdel<sup>2</sup>, Mohammad Mahdi Kooshyar<sup>3</sup>

1. Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad
  2. Cancer Research Center, Mashhad University of Medical Sciences, Mashhad
  3. Department of Hematology and Oncology, Mashhad University of Medical Sciences, Mashhad
- 

## 28. THE IMPORTANCE OF COLONOSCOPY IN COLORECTAL CANCER SCREENING

Mohammad Hossein Jamshidi<sup>1,\*</sup>, Maedeh Zangoeei Motlagh<sup>1</sup>

1. Department of Radiologic Technology, Faculty of ParaMedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
-



## 29. PERFORMANCE EVALUATION OF MRI TUMOR SEGMENTATION USING CLUSTERING ALGORITHMS

Soheila Refahi<sup>1\*</sup>, Meysam Siyah Mansoor<sup>2</sup>

1. Ardabil University of Medical Sciences, Ardabil, Iran.
  2. Kermanshah University of Medical Sciences, Kermanshah, Iran  
s.refahi@arums.ac.ir
- 

## 30. PATIENT PREPARATION FOR STOMA SURGERY: WHAT WE DID AND WHAT WE NEED TO DO MORE?

Zohre Pouresmail<sup>1</sup>, Fatemeh Heshmati Nabavi<sup>2</sup>

1. Student Research Committee, Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
  2. Evidence Based Care Research Centre, Department of Public Health Nursing and Psychiatric Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
- 

## 31. ENDOMETRIAL CANCER AND SERUM LIPIDS

Zahra Mohebbi Dehnavi<sup>1</sup>

1. zahra.midwife@yahoo.com
- 

## 32. SARCOMA OF EXTREMITIES, A SINGLE CENTER REPORT.

Hamid Nasrollahi, Elahe Aghel, Mohammad Zare BandAmiri, Seyyed Hassan Hamed, Mahdi Shariat, Mansour Ansari, Niloofar Ahmadloo, Mohammad MohammadianPanah, Shapour Omidvari, Ahmad Mosalaei

---

## 33. HEAD AND NECK SARCOMAS, AN UNCOMMON CANCER AND REPORT OF SINGLE CENTER.

Hamid Nasrollahi, Elahe Aghel, Mohammad Zare BandAmiri, Seyed Hassan Hamed, Mahdi Shariat, Mansour Ansari, Niloofar Ahmadloo, Mohammad MohammadianPanah, Shapour Omidvari, Ahmad Mosalaei

---

## 34. EFFECTIVENESS OF HIGH INTENSITY FOCUSED ULTRASOUND IN CANCER TREATMENT

Zahra Farzanegan<sup>1</sup>

1. fn.spring2014@gmail.com
-

### 35. THE ROLE OF EXTERNAL BEAM RADIATION THERAPY (EBRT) IN THE MANAGEMENT OF THYROID CARCINOMAS; AN OUTCOME SURVEY IN IRAN CANCER INSTITUTE: ROLE OF EXTERNAL RADIOTHERAPY IN THYROID CANCERS

Reza Ghalehtaki, Saeed Alizadeh, Bahare Salekani, Alireza Aleyasin, Bitakalaghchi, Mohammad Babaei, Marzieh Lashkari, Ebrahim Esmati\*

\* Corresponding Author: Ebrahim Esmati, MD, Assistant Professor  
Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran  
E-mail: eb\_esmati@yahoo.com

### 36. PREVENTIVE EFFECTS OF TOMATO PULP ON ORAL PRE-NEOPLASTIC CHANGES INDUCED BY 4-NITROQUINOLINE-1-OXIDE IN THE RAT

Seyed Davood Haji Seyedi<sup>1</sup>, Mohammad Mashayekhi, Sara Haji Seyedi, Shabnam Rezaee

1. Email: seyeddavoodhajiseyedi@yahoo.com

### 37. IMPROVING KNOWLEDGE AND ATTITUDE OF PHYSICIANS WORKING IN CANCER CENTERS THROUGH A SHORT EDUCATIONAL PALLIATIVE AND SUPPORTIVE CARE COURSE: THE FIRST SUCCESSFUL COURSE IN IRAN

Ali Taghizadeh, Mona Joudi, Mehrdad Mokarram

1. Mashhad University of Medical Sciences

### 38. PREFERENTIAL RADIOENHANCEMENT AND GENOTOXIC EFFECTS OF ZNO AND GADOLINIUM-DOPED ZNO NPS IN COMBINATION WITH MEGAVOLTAGE RADIATION IN LUNG CANCER CELLS MEASURED BY MICRONUCLEUS ASSAY AND QRT-PCR IN VITRO

Masoumeh Zanganeh<sup>1</sup>, Hassan Ali Nedaie<sup>1,2\*</sup>, Hossein Mozdarani<sup>3</sup>, Aziz Mahmoudzadeh<sup>4</sup>

1. Department of Medical Physics and BioMedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2. Radiotherapy Oncology Department, Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
4. Department of BioSciences and Biotechnology, Malek-Ashtar University of Technology, Tehran, Iran

\* Corresponding Author: Dr. Hassan Ali Nedaie, Telephone number: +9866192569  
Fax number: +98 2166948673, Email address: Nedaieha@sina.tums.ac.ir

### 39. EVALUATION OF BOLUS EFFECT ON BREAST SKIN DOSE IN RADIOTHERAPY TECHNIQUES: A GAFCHROMIC FILM DOSIMETRY STUDY

Mohsen Saeb, Mahshad Neshasteriz, Faranak Felfeliyan, Shahram Monadi, Nadia Najafzadeh

1. Email: Mohsen.saeb93@gmail.com

---

### 40. DISCORDANCE OF HORMONE RECEPTORS AND HER2/NEU STATUS AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER

Saleh Sandoughdaran, Pegah Sasanpour, Hojjat rastegari ,Mona Malekzadeh\*

\* Correspondence to: Mona Malekzadeh, Department of Radiation Oncology, Shohada-e-Tajrish Hospital, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.  
Email: M.malekzadeh20@gmail.com

---

### 41. RADIOBIOLOGIC COMPARISON OF FORWARD INTENSITY MODULATED RADIATION THERAPY AND CONVENTIONAL TANGENTIAL BEAM TECHNIQUES IN RADIOTHERAPY OF CONSERVATIVE BREAST CANCER

Farzaneh Allaveisi<sup>1,\*</sup>, Zeinab Salehi<sup>2</sup>, Farid Jalilian<sup>2</sup>

1. Department of Medical Physics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
  2. Department of Radiation Therapy, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
- 

### 42. TREATING CANCER WITH HEAT: HYPERTHERMIA IN COMBINATION WITH EXTERNAL BEAM RADIATION THERAPY AS PROMISING STRATEGY TO IMPROVE TREATMENT OF CANCER

Fahimeh Faghihi Moghadam<sup>1</sup>, Mohsen Bakhshandeh<sup>2,\*</sup>, Bahram Mofid, Hamidreza mirzaei<sup>3</sup>

1. Department of Medical Physics, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran ,Iran.
  2. Associate Professor, Department of Radiation Technology, Faculty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  3. Professor, Department of Radiation Oncology, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.  
mbakhshandeh@sbmu.ac.ir
-

#### 43. RADIOFREQUENCY ABLATION OF MALIGNANT LIVER TUMORS

Niloofer Mirzaei\*, Mohammad Hossein Jamshidi

Department of Radiologic Technology, Faculty of ParaMedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

---

#### 44. IMAGING STUDIES OF PRIMARY HEPATIC CANCER

Niloofer Mirzaei\*, Mohammad Hossein Jamshidi

Department of Radiologic Technology, Faculty of Para Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

---

#### 45. THE SELENIUM STATUS AND ITS ASSOCIATION WITH MALNUTRITION IN PATIENTS WITH RENAL CELL CARCINOMA ASSOCIATED WITH CHRONIC RENAL FAILURE IN NORTHERN IRAN

Ali Akbar Hafezi<sup>1,\*</sup>, Shadi Zohourinia<sup>2</sup>, Saeid Amir Khanlou<sup>3</sup>, Anna Rashedi<sup>4</sup>, Sajjad Ghaffari<sup>5</sup>

1. MD, Resident of Radiation Oncology  
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (dr.hafezi\_a2016@yahoo.com)
2. MD, Radiation Oncologist  
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (shadizohorinia@yahoo.com)
3. MD, Nephrologist, Assistant Professor  
Department of Internal Medicine, Golestan University of Medical Sciences, Gorgan, Golestan, Iran (dr.ali.h1987@gmail.com)
4. MD, Radiologist, Assistant Professor  
Department of Radiology, Golestan University of Medical Sciences, Gorgan, Golestan, Iran (young\_dr2010@yahoo.com)
5. MD, Resident of Urology  
Department of Urology, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Fars, Iran (a.fa41@yahoo.com)

\* Corresponding Author: Ali Akbar Hafezi, MD, Resident of Radiation Oncology  
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Fars, Iran  
E-mail: dr.hafezi\_a2016@yahoo.com Tel: +987136474320 Mobile: +989395911106

---

#### 46. CAR-T CELL THERAPY IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL)

Muhammad Sadeqi Nezhad<sup>1,\*</sup>

1. Department of Laboratory Science, Young Researchers and Elites Club, Gorgan Branch, Islamic Azad University, Gorgan, Iran  
Email: Labmsn9@gmail.com phone number: 09101554766
-

#### 47. RISK OF BREAST CANCER IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A SYSTEMATIC REVIEW

Simin Haghdoost, Farzaneh Pazandeh\*

M.sc. Midwifery Student of Shahid Beheshti School of Nursing and Midwifery Tehran, Iran

\* Assistant Professor in Reproductive Health Midwifery and Reproductive Health Department Shahid Beheshti School of Nursing and Midwifery Tehran, Iran\* pazandehz@gmail.com (Author Responsible)

---

#### 48. THE EFFECT OF L-CARNITINE ON COLORECTAL CANCER: A REVIEW ON CURRENT EVIDENCE

Fatemeh Radkhoy<sup>1</sup>, Behnood Abbasi<sup>2,\*</sup>

1. B.Sc. Student of Nutrition, Department of Nutrition, Science and Research Branch, School of Medical Sciences, Islamic Azad University, Tehran, Iran.

2. Assistant Professor of Nutrition, Department of Nutrition, School of Medical Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran.

\* Corresponding Author: All correspondence should be addressed to Dr.Behnood Abbasi.  
E-mail: abbasi.b@srbiau.ac.ir

---

#### 49. EVALUATION OF CORRELATION BETWEEN SERUM LEVEL OF DIHYDROPYRIMIDINE DEHYDROGENASE ENZYME AND CAPECITABINE INDUCED ADVERSE REACTION

Maryam Sheikhvanloo<sup>1,\*</sup>, Abolghasem Allahyari<sup>2</sup>, Mahdi Jannati Yazdan Abad<sup>1</sup>, Sepideh Elyasi<sup>1</sup>, Fatemeh Kalalinia<sup>3</sup>, Amir Hooshang Mohamadpoor<sup>1,4</sup>

1. Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2. Hematology-Oncology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3. Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran

4. Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

\* Corresponding Author: Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Email: sheikhanloum2@mums.ac.ir

---

#### 50. ROLE OF CYTOSPONGE TEST IN DETECTION ESOPHAGEAL ADENOCARCINOMA (EAC)

Zeynab Yaberi Mohammad\*, Mohammad Hossein Jamshidi, Amir Hasanvand

Department of Radiologic Technology, Faculty of ParaMedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Zeynabyaberi@yahoo.com

---

## 51. RECENT REPORTS ON THE MECHANISMS OF ACTION OF SORAFENIB RESISTANCE IN THE PATIENTS WITH HEPATOCELLULAR CARCINOMA

Mohammad Amin Dehghani\*, Maryam Shirani, Pezhman Alavinejad, Seyyed Hossein Hassanpour, Fatemeh Dehghani

\* Correspondance: Mohammad Amin Dehghani  
Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran  
E-mail:mohammaddeh83@yahoo.com

## 52. EPIDEMIOLOGY AND RISK FACTORS OF LEUKEMIA AND LYMPHOMA IN IRAN: A SYSTEMATIC REVIEW

Neamatshahi M<sup>2</sup>, Keykhosravi A<sup>1</sup>, Navipour E<sup>3</sup>, Barabadi Z<sup>4</sup>, Mohammad Neamatshahi<sup>5</sup>

1. Department of Pediatrics, Faculty of Medicine, Sabzevar University of Medical Sciences, Iran. drakeykhosravi@yahoo.com
2. Department of Community Medicine, Faculty of Medicine, Research Center Social Determinants Health, Sabzevar University of Medical Sciences, Iran. mahneamatshahi@yahoo.com
3. Department of Biostatistics, Faculty of Allied Medical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran. Elham.navipour@gmail.com
4. Department of Physiology and Pharmacology, School of Medicine, Sabzevar University of Medical Sciences, Iran. zbarabadi@yahoo.com
5. Department of anesthesiology, Faculty of Medicine, Sabzevar University of Medical Sciences, Iran. 9151737407mn@gmail.com

## 53. THE EFFECT OF RELAXATION ON THE SELF-ESTEEM AMONG CANCER PATIENTS: A RANDOMIZED CLINICAL TRIAL

Maryam Abbasi<sup>1</sup>

1. Masoud.rezaei68@yahoo.com

## 54. THE PROGNOSTIC VALUE OF EPIDERMAL GROWTH FACTOR RECEPTOR (HER1) R497K IN PATIENTS WITH BREAST CANCER

Soodabeh ShahidSales<sup>1\*</sup>, Masoumeh Baderi<sup>2</sup>, Amir Avan<sup>2</sup>

1. Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2. Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

## 55. MAMMALIAN TARGET OF RAPAMYCIN SIGNALING PATHWAY AND ITS INHIBITORS TO MANAGE HEPATOCELLULAR CARCINOMA: AN OVERVIEW ARTICLE

Mohammad Amin Dehghani<sup>1,\*</sup>, Maryam Shirani<sup>2</sup>, Pezhman Alavinejad<sup>3</sup>, Fatemeh Dehghani<sup>4</sup>, Afarin Aghajari<sup>5</sup>

1. Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2. Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3. Research Institute for Infectious Diseases of the Digestive System, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4. Department of Geneticss, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
5. School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

\* Correspondance: Mohammad Amin Dehghani

Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

E-mail:mohammaddeh83@yahoo.com

---

## 56. EXPRESSION OF ANDROGEN RECEPTOR IN RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Hossein Abdi, Mehrdad Payandeh, Nasrin Amirifard, Malihe Daiani, Edris Sadeghi

Corresponding Author: Edris Sadeghi, Department of Nursing, Kermanshah University of Medical Sciences, Kermanshah, Iran

Email: Sadeghi\_mkn@yahoo.com

---

## 57. SARCOMA OF CHEST WALL, REPORT OF 33 CASES

Hamid Nasrollahi, Elahe Aghel, Mohammad Zare\_BandAmiri, Seyed Hassan Hamed, Mehdi Shariat, Mansour Ansari, Niloofar Ahmadloo, Mohammad Mohammadian Panah, Shapour Omidvari, Ahmad Mosalaei

Shiraz University of Medical Sciences

---

## 58. TREATMENT COMPLICATION, PATHOLOGIC COMPLETE RESPONSE AND SURVIVAL AFTER NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER

Sare Hosseini<sup>1</sup>, Malihe Hasanzadeh<sup>2</sup>, Elahe Aghel<sup>3</sup>, Fatemeh Homaei Shandiz<sup>4</sup>, Azar Fani Pakdel<sup>4</sup>, Zohre Yousofi<sup>2</sup>, Soodabeh Shahid Sales<sup>4</sup>, Marjaneh Farazestanian<sup>5</sup>, Mona Joudi Mashhad<sup>1</sup>

1. Assistant Professor, Department of Radiation Therapy, Faculty of Medicine, Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
2. Professor, Department of Obstetrics and Gynecology, Women's Health Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3. Resident, Department of Radiation Oncology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
4. Associate Professor, Department of Oncology, Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
5. Assistant Professor, Department of Obstetrics and Gynecology, Women's Health Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

## 59.A CASE OF GBM WITH LONG TERM SURVIVAL (10 YEARS)

Nilofar Ahmadloo MD, Mansour Ansari MD, Mohammad Mohammadianpanah MD, Ahmad Mosalaei MD, Shapour Omidvari MD, Seyed Hassan Hamedei MD, Hamid Nasrollahi MD, Nezhat Khanjani MD.

Department of Radiation Oncology, Shiraz University of Medical Science, Shiraz, Iran

## 60. HEAD AND NECK SARCOMAS, AN UNCOMMON CANCER AND REPORT OF SINGLE CENTER.

Hamid Nasrollahi, Elahe Aghel, Mohammad Zare BandAmiri, Seyed Hassan Hamedei, Mahdi Shariat, Mansour Ansari, Nilofar Ahmadloo, Mohammad Mohammadian Panah, Shapour Omidvari, Ahmad Mosalaei

Shiraz University of Medical Sciences

## 61. SECOND CANCER RISK AFTER 3D-CRT FOR BREAST CANCER BY BEIRVII RADIOBIOLOGICAL MODEL

Nasibeh Kavousi<sup>1,\*</sup>, Hassan Ali Nedaie<sup>2</sup>, Shima Mahmoudi<sup>1</sup>, Mohsen Hasani<sup>3</sup>

1. Department of Medical Physics and Medical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
2. Radiotherapy Oncology Research Centre, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran; Department of Medical Physics and BioMedical Engineering, Tehran University of Medical Sciences, Tehran, Iran.
3. Department of Medical Radiation, Engineering Faculty, Central Tehran Branch, Islamic Azad University, Tehran, Iran.

\* Corresponding Author: Nasibeh kavousi  
Email: nasibeh.kavoosi@gmail.com

## 62. THE RELATIONSHIP BETWEEN ANTI-THYROID PEROXIDASE SERUM LEVELS WITH PROGNOSTIC FACTORS IN BREAST CANCER AND TWO-YEAR SURVIVAL OF PATIENTS

Hossein javid<sup>1</sup>, Fatemeh Homaei Shandiz<sup>2</sup>, Bahman Khalili<sup>3</sup>, Amir Zangouei<sup>3</sup>, Mohammad Soukhtanloo<sup>4,\*</sup>



1. Ph.D Student of Clinical Biochemistry, Mashhad University of Medical Sciences, Mashhad, Iran
  2. Associate Professor in Radiation oncology, Mashhad University of Medical Sciences, Ghaem Hospital of Mashhad, Iran.
  3. Medical Student of Mashhad University of Medical Sciences, Mashhad, Iran
  4. Associate Professor of Clinical Biochemistry, Department of Clinical Biochemistry, Mashhad University of Medical Sciences, Mashhad, Iran
- \* Corresponding Author: Mohammad Soukhtanloo  
Address: Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IRAN. Post Code: 917794-8564  
Tel: +98 51 38002365, Fax: +98 51 38828574, E.mail: labratorylabratory@yahoo.com
- 

### 63. COMPARATIVE EVALUATION OF INHIBITORY EFFECT OF PHYCOCYANIN (ANABAENA SP. ISC 55) AND PACLITAXEL ON 4T1 BREAST CANCER CELLS

Farnaz Dabbagh Moghaddam<sup>1</sup>, Somayeh Hamed<sup>2,\*</sup>

1. Department of Biology, Karaj Branch, Islamic Azad University, Alborz, Iran  
Phone number: 09128593701
  2. Department of Basic Sciences, Faculty of Veterinary Medicine, Islamic Azad University, Karaj Branch, Alborz, Iran
- \* Corresponding Author: Somayeh Hamed, Department of Basic Sciences, Faculty of Veterinary Medicine, Islamic Azad University, Karaj Branch, Alborz, Iran. P.O. Box: 31485-313 Tel: +982634182550 Fax: +982634418156, E-mail:sahar\_hamed@yahoo.com
- 

### 64. COLORECTAL CANCER SCREENING IN PATIENTS WITH CANCER TREATED WITH PELVIC RADIATION, CASE SERIES AND LITERATURE REVIEW

Neda Nozari

Gastroenterologist, Yas Hospital, Tehran University of Medical Sciences, Tel: +982142046,  
Fax: +98 2188948217, E-mail: nozari\_neda@yahoo.com.

---

### 65. EVALUATION OF ASSOCIATION OF CD18 + POLYMORPHISM WITH THE INCIDENCE OF THYROID CANCER

Ramin Nouri<sup>1</sup>, Morteza Hakimian<sup>2</sup>, Sasan Talaneh<sup>3</sup>

1. Young Researchers and Elite Club, Ahar Branch, Islamic Azad University, Ahar, Iran
  2. Young Researchers and Elite Club, Arbab Branch, Islamic Azad University, Ardabil, Iran
  3. Young Researchers and Elite Club, Ahar Branch, Islamic Azad University, Ahar, Iran
-

## 66. CROCIN SYNERGISTICALLY ENHANCES THE ANTI-PROLIFERATIVE ACTIVITY OF 5-FU THROUGH WNT/PI3K PATHWAY IN A MOUSE MODEL OF COLITIS-ASSOCIATED COLORECTAL CANCER

Amir Avan<sup>1,4,\*</sup>, Forouzan Amerizadeh<sup>4</sup>, Soodabeh Shahidsales<sup>6</sup>, Seyed Mahdi Hassanian<sup>1,2,3</sup>, Nastaran Rezaei<sup>5</sup>, Farzad Rahmani<sup>2</sup>, Reyhaneh Moradi Marjaneh<sup>5</sup>, Nadia Boroumand<sup>2</sup>, Abolfazl Nosrati Tirhani<sup>2</sup>, Majid Khazaei<sup>5</sup>

1. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2. Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3. Microanatomy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
4. Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
5. Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
6. Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

## 67. PERCEPTIONS OF FEMALE CANCER PATIENTS REGARDING HEALTH-RELATED BEHAVIORS: A QUALITATIVE APPROACH

Dr Marjan Mardani Hamooleh<sup>1</sup>, Dr Taraneh Taghavi Larijani<sup>2</sup>, Dr Haydeh Heidari<sup>3</sup>

1. Department of Nursing, Iran University of Medical Sciences, Tehran, Iran (Telephone: 09132864077, E-mail:marjjanmardani@ymail.com)
2. Department of Nursing, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Nursing, Shahrekord University of Medical Sciences, Shahrekord, Iran

## 68. RETROPERITONEAL SARCOMA, AN UNCOMMON AND CHALLENGING TUMOR.

Hamid Nasrolahi, Elahe Aghel, Mohammad Zare-BandAmiri, Seyyed Hassan Hamed, Mehdi Shariat, Mansour Ansari, Nilofar Ahmadloo, Mohammad MohammadianPanah, Shapour Omidvari, Ahmad Mosalaei

## 69. REFRACTORY FOLLICULITIS KELOIDALIS NUCHEA TREATED WITH EXTERNAL IRRADIATION

Nilofar Ahmadloo, Mohammad Mohammadianpanah, Ahmad Mosalaei, Shapour Omidvari, Mansour Ansari, Hamid Nasrollahi, Nezhat Khanjani, Seyed Hassan Hamed

Department of Radiation Oncology, Shiraz University of Medical Science, Shiraz, Iran

## 70. EFFECT OF CARDAMOM AROMAS ON THE CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN CANCER PATIENTS: A BLOCK-RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED TRIAL

Zahra Khalili<sup>1</sup>, Mahnaz Khatiban<sup>2\*</sup>, Arash Khalili<sup>3</sup>

1. Faculty Member, Chronic Disease (Home Care) Research Center, Department of Medical Surgical Nursing, School of Nursing and Midwifery, Hamadan University of Medical Sciences, Hamadan, Iran  
E-mail: zkhalili90@yahoo.com
2. Associate Professor, Mother & Child Care Research Center, Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Hamadan University of Medical Sciences, Hamadan, Iran.  
Corresponding Author: Mahnaz Khatiban  
Email: mahnaz.khatiban@gmail.com
3. Faculty Member, Mother and Child Care Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

## ۷۱. اثربخشی آموزش گروهی مبتنی بر روان‌درمانی مثبت‌گرا بر خرده‌مقیاس‌های بهزیستی روانشناختی در بیماران دارای سرطان‌های غیرخونی بیمارستان ولیعصر (عج) شهرستان قم

دکتر محمد مهدی مجاهد<sup>۱</sup>، سید محمد مهدی آل یاسین<sup>۲</sup>

۱. آنکولوژیست بیمارستان ولیعصر (عج)، mm\_mojahed@yahoo.com

۲. کارشناسی ارشد روانشناسی بالینی- اولین عضو (ایرانی) جامعه بین‌المللی روان‌سرطان‌شناسی در ایران  
psychologist9295@yahoo.com

## ۷۲. بررسی تأثیر آموزش هوش معنوی بر شأن انسانی در بیماران مبتلا به کانسر: کارآزمایی بالینی

بی بی مریم هاشمی<sup>۱\*</sup>، مسعود کاشانی لطف‌آبادی<sup>۲</sup>، سعید سراییان<sup>۳</sup>، ساره حسینی<sup>۴</sup>

۱- دانشجوی کارشناسی ارشد روانشناسی اسلامی، دانشگاه پیام نور گناباد، گناباد، ایران.

۲- دانشجوی دکترای روانشناسی بالینی، مرکز تحقیقات روانپزشکی و علوم رفتاری، بیمارستان روانپزشکی ابن‌سینا، دانشگاه علوم پزشکی مشهد، مشهد، ایران.

۳- استادیار گروه روانشناسی بالینی کودک و نوجوان، دانشگاه پیام نور مرکز مشهد، مشهد، ایران

۴- استادیار گروه رادیوتراپی و آنکولوژی، مرکز تحقیقات سرطان، دانشکده پزشکی، دانشگاه علوم پزشکی مشهد، مشهد، ایران  
hashemem96@gmail.com

### ۷۳. ارزیابی فراوانی درگیری غدد لنفاوی در بیماران مبتلا به سرطان معده مراجعه‌کننده به بیمارستان امام سجاد (ع) شهرستان رامسر طی سال‌های ۱۳۸۹ الی ۱۳۹۴

دکتر شهریانو کیهانیان<sup>۱</sup>، دکتر مریم ذاکری حمیدی<sup>۲\*</sup>

۱. دانشیار هماتولوژی و انکولوژی، گروه پزشکی، دانشکده پزشکی، دانشگاه آزاد اسلامی واحد تنکابن، تنکابن، ایران
  ۲. استادیار بهداشت باروری، گروه مامایی، دانشکده پزشکی، دانشگاه آزاد اسلامی واحد تنکابن، تنکابن، ایران
- ۰۹۱۱۳۹۳۴۳۸۶

\* نویسنده مسئول: مریم ذاکری حمیدی maryamzakerihamidi@yahoo.com

### ۷۴. بررسی سطح دی دایمر سرم در بیماران مبتلا به سرطان پستان مراجعه‌کننده به بیمارستان امام سجاد (ع) رامسر در سال ۱۳۹۴-۹۵

دکتر مریم ذاکری حمیدی<sup>۱\*</sup>، دکتر شهریانو کیهانیان<sup>۲</sup>

۱. استادیار بهداشت باروری، گروه مامایی، دانشکده پزشکی، دانشگاه آزاد اسلامی واحد تنکابن، تنکابن، ایران
  ۲. دانشیار هماتولوژی و انکولوژی، گروه پزشکی، دانشکده پزشکی، دانشگاه آزاد اسلامی واحد تنکابن، تنکابن، ایران
- \* نویسنده مسئول: مریم ذاکری حمیدی maryamzakerihamidi@yahoo.com

### ۷۵. اثربخشی آموزش گروهی مبتنی بر روان‌درمانی مثبت‌گرا بر عملکرد خانواده در بیماران دارای سرطان‌های غیر خونی بیمارستان ولیعصر (عج) شهرستان قم

دکتر محمد مهدی مجاهد<sup>۱</sup>، سید محمد مهدی آل یاسین<sup>۲</sup>

۱. آنکولوژیست بیمارستان ولیعصر (عج) mm\_mojahed@yahoo.com
۲. کارشناسی ارشد روانشناسی بالینی - اولین عضو (ایرانی) جامعه بین‌المللی روان‌سرطان شناسی در ایران psychologist9295@yahoo.com

### ۷۶. فراوانی درگیری غدد لنفاوی زیر بغل در بیماران زن مبتلا به سرطان پستان در بیمارستان‌های منتخب شمال ایران از سال ۱۳۹۱ تا ۱۳۹۴

دکتر شهریانو کیهانیان<sup>۱</sup>، دکتر مریم ذاکری حمیدی<sup>۲</sup>

۱. دانشیار هماتولوژی و انکولوژی، گروه پزشکی، دانشکده پزشکی، دانشگاه آزاد اسلامی واحد تنکابن، تنکابن، ایران
  ۲. استادیار بهداشت باروری، گروه مامایی، دانشکده پزشکی، دانشگاه آزاد اسلامی واحد تنکابن، تنکابن، ایران
- ۰۹۱۱۳۹۳۴۳۸۶

## ۷۷. آلوئه ورا و پیشگیری از درماتیت ناشی از پرتودرمانی

مهتاب طیبی<sup>۱</sup>، محبوبه سجادی<sup>۲</sup>، احمدرضا عابدی<sup>۳</sup>، فتح‌الله... محقق<sup>۴</sup>

۱. کارشناسی ارشد پرستاری (گرایش داخلی جراحی)
  ۲. دکترای پرستاری کودکان، استادیار و عضو هیئت علمی دانشگاه علوم پزشکی اراک
  ۳. دکترای آموزش پرستاری و عضو هیئت علمی دانشگاه علوم پزشکی اراک
- متخصص انکولوژی و رادیوتراپی، عضو هیئت علمی دانشگاه علوم پزشکی اراک

## ۷۸. بررسی فراوانی افسردگی در بیماران مبتلا به سرطان پستان ماستکتومی شده در

مراکز انکولوژی رامسر و تنکابن در سال ۱۳۹۵

دکتر مریم ذاکری حمیدی<sup>۱\*</sup>، دکتر شهریانو کیهانیان<sup>۲</sup>

۱. استادیار بهداشت باروری، گروه مامایی، دانشکده پزشکی، دانشگاه آزاد اسلامی واحد تنکابن، تنکابن، ایران
  ۲. دانشیار هماتولوژی و انکولوژی، گروه پزشکی، دانشکده پزشکی، دانشگاه آزاد اسلامی واحد تنکابن، تنکابن، ایران
- \* نویسنده مسئول: مریم ذاکری حمیدی ۰۹۱۱۳۹۳۴۳۸۶

## ۷۹. بررسی ارتباط بین پلی مورفیسم گلوکوتائین اس ترانسفراز با بروز سرطان پستان در

زنان استان آذربایجان غربی

Sasan Talaneh<sup>1</sup>, Zahra Azad Kasb<sup>2</sup>, Noshin Ensafi<sup>3</sup>

۱. دانشگاه آزاد اسلامی، واحد اهر، باشگاه پژوهشگران جوان و نخبگان، اهر، ایران
۲. دانشگاه علوم پزشکی ارومیه، دانشکده مامایی، ارومیه ایران
۳. دانشگاه علوم پزشکی ارومیه، دانشکده مامایی، ارومیه ایران

## NURSING ABSTARCTS

### 1. LEVEL OF STIGMA IN INDIVIDUAL WITH CANCER IN IRANIAN SOCIETY

Fatemeh Hasan Shiri<sup>1</sup>, Jamileh Mohtashami<sup>2</sup>, Hومان Manoochehri<sup>3</sup>, Camelia Rohani<sup>4</sup>, Malihe Nasiri<sup>5</sup>

1. PhD in Nursing, Faculty of Paramedicine, Kashan University of Medical Sciences, Kashan-Iran
  2. Associate Professor, Department of Basic Sciences, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  3. Assistant Professor, Department of Community Health Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  4. Assistant Professor, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  5. Assistant Professor, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran-Iran.
- 

### 2. THE EFFECT OF A SELECTED CARE PLAN ON QUALITY OF LIFE OF ADOLESCENTS WITH CANCER

Parastoo Oujian

1. Assistant Professor, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran-Iran.
- 

### 3. THE RELATIONSHIP BETWEEN RESILIENCE AND SPIRITUAL INTELLIGENCE AMONG MOTHERS OF CHILDREN WITH CANCER

Naiire Salmani

---

### 4. THE EFFECT OF EDUCATION ON SELF-CARE BEHAVIORS OF GASTROINTESTINAL SIDE EFFECTS ON PATIENTS UNDERGOING CHEMOTHERAPY

Shokoh Varaei<sup>1</sup>, Ehsan Abadi Pische<sup>2</sup>

1. Associate Professor of Tehran University of Medical Sciences, Tehran-Iran
  2. Master of Nursing
-

## 5. FATIGUE AND ITS RELATED FACTORS IN PATIENTS ADMITTED TO ONCOLOGY

Maryam Janatolmakan<sup>1,\*</sup>, Alireza Khatony<sup>2</sup>, Fatemeh Janatolmakan<sup>3</sup>, Fatemeh Kahrizi<sup>4</sup>

1. MSc, Of Medical Surgical, Clinical Research Development Center, Imam Reza Hospital, Kermanshah
2. Associate Professor, Clinical Research Development Center, Imam Reza Hospital, Kermanshah
3. BSc, of Mathematics, Razi University of Kermanshah
4. Ph.D. Student of Razi University of Kermanshah

\* Corresponding Author; Clinical Research Development Center, Imam Reza Hospital, Kermanshah  
Email:mjanat135@yahoo.com

---

## 6. THE ATTITUDE OF THE FAMILIES OF CHILDREN WITH CANCER FROM THE DIAGNOSIS OF THEIR CHILD'S ILLNESS

Maryam Janatolmakan<sup>1,\*</sup>, Alireza Khatony<sup>2</sup>, Fatemeh Janatolmakan<sup>3</sup>, Fatemeh Kahrizi<sup>4</sup>

1. MSc, Of Medical Surgical, Clinical Research Development Center, Imam Reza Hospital, Kermanshah
2. Associate Professor, Clinical Research Development Center, Imam Reza Hospital, Kermanshah
3. BSc, of Mathematics, Razi University of Kermanshah
4. Ph.D. Student of Razi University of Kermanshah

\* Corresponding Author; Clinical Research Development Center, Imam Reza Hospital, Kermanshah  
Email:mjanat135@yahoo.com

---

## 7. EVALUATION OF QUALITY OF LIFE AND ITS EFFECTIVE FACTORS IN THE FAMILIES OF CHILDREN WITH CANCER

Maryam Janatolmakan<sup>1,\*</sup>, Alireza Khatony<sup>2</sup>, Fatemeh Janatolmakan<sup>3</sup>, Fatemeh Kahrizi<sup>4</sup>

1. MSc, Of Medical Surgical, Clinical Research Development Center, Imam Reza Hospital, Kermanshah
2. Associate Professor, Clinical Research Development Center, Imam Reza Hospital, Kermanshah
3. BSc, of Mathematics, Razi University of Kermanshah
4. Ph.D. Student of Razi University of Kermanshah

\* Corresponding Author; Clinical Research Development Center, Imam Reza Hospital, Kermanshah  
Email:mjanat135@yahoo.com

---

## 8. EFFECT OF BLEND EDUCATION PROGRAMS ON SOME PERFORMANCE INDICATORS IN CANCER PATIENTS OF AHWAZ IN 2014

Maryam Bayati

---

## 9. THE VIEWS OF NURSES ON PARENTAL INVOLVEMENT IN CARING FOR CHILDREN IN ONCOLOGY

Maryam Janatolmakan<sup>1,\*</sup>, Alireza Khatony<sup>2</sup>, Fatemeh Janatolmakan<sup>3</sup>, Fatemeh Kahrizi<sup>4</sup>

1. MSc, Of Medical Surgical, Clinical Research Development Center, Imam Reza Hospital, Kermanshah
2. Associate Professor, Clinical Research Development Center, Imam Reza Hospital, Kermanshah
3. BSc, of Mathematics, Razi University of Kermanshah
4. Ph.D. Student of Razi University of Kermanshah

\* Corresponding Author; Clinical Research Development Center, Imam Reza Hospital, Kermanshah  
Email:mjanat135@yahoo.com

## 10. STUDY THE PROBLEMS OF FAMILIES OF CHILDREN WITH CANCER

Maryam Janatolmakan<sup>1,\*</sup>, Alireza Khatony<sup>2</sup>, Fatemeh Janatolmakan<sup>3</sup>, Fatemeh Kahrizi<sup>4</sup>

1. MSc,Of Medical Surgical, Clinical Research Development Center, Imam Reza Hospital, Kermanshah
2. Associate Professor, Clinical Research Development Center, Imam Reza Hospital, Kermanshah
3. BSc, of Mathematics, Razi University of Kermanshah
4. Ph.D. Student of Razi University of Kermanshah

## 11. EXPLANNING NURSES EXPERIENCES IN CARING FOR CHILDREN WITH CANCER

Maryam Janatolmakan<sup>1,\*</sup>, Alireza Khatony<sup>2</sup>, Fatemeh Janatolmakan<sup>3</sup>, Fatemeh Kahrizi<sup>4</sup>

1. MSc,Of Medical Surgical, Clinical Research Development Center, Imam Reza Hospital, Kermanshah
2. Associate Professor, Clinical Research Development Center, Imam Reza Hospital, Kermanshah
3. BSc, of Mathematics, Razi University of Kermanshah
4. Ph.D. Student of Razi University of Kermanshah

## 12. THE EFFECT OF A FAMILY-CENTERED EMPOWERMENT PROGRAM ON ANXIETY, STRESS AND DEPRESSION IN THE FAMILY OF CHILDREN WITH LEUKEMIA

Jaefar Moghaddasi<sup>1</sup>, Fariba Taleghani<sup>2</sup>, Alireza Moafi<sup>3</sup>, Azadeh Malekian<sup>4</sup>, Mahrokh Keshvari<sup>5</sup>, Sherin F, Tahmasbi.

1. Student Research Committee, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran. Department of Medical Surgery Nursing, School of Nursing and Midwifery, Shahrekord University of Medical Sciences, Shahrekord, Iran.
2. Professor Nursing, Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran.
3. Associate Professor, Pediatric Hematology and Oncology, Isfahan University of Medical Sciences, Isfahan, Iran.
4. Assistant Professor, Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
5. Assistant Professor, Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: keshvari@med.mui.ac.ir.



### 13. PATIENT PREPARATION FOR STOMA SURGERY: WHAT WE DID AND WHAT WE NEED TO DO MORE?

Fatemeh Heshmati Nabavi<sup>2</sup>, Zohre Pouresmail<sup>1</sup>

1. Student Research Committee, Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
  2. Evidence Based Care Research Centre, Department of Public Health Nursing and Psychiatric Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
- 

### 14. EMPOWERING NURSES IN PROVIDING PALLIATIVE CARE TO CANCER PATIENTS: ACTION RESEARCH STUDY

Mohsen Shahriari<sup>1</sup>, Fariba Taleghani<sup>1</sup>, Nasrollah Alimohammadi<sup>1</sup>

1. Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
- 

### 15. IMPACT OF FAMILY-CENTERED EMPOWERMENT PROGRAM ON THE QUALITY OF LIFE AND SELF-ESTEEM OF FAMILIES WITH CHILDREN WITH LEUKEMIA.

Jaefar Moghaddasi<sup>1</sup>, Fariba Taleghani<sup>2</sup>, Alireza Moafi<sup>3</sup>, Azadeh Malekian<sup>4</sup>, Mahrokh Keshvari<sup>5</sup>, Sherin F, Tahmasbi.

1. Student Research Committee, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran. Department of Medical Surgery Nursing, School of Nursing and Midwifery, Shahrekord University of Medical Sciences, Shahrekord, Iran. E-mail: jaefar\_moghadda@nm.mui.ac.ir.
  2. Professor Nursing, Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: Taleghani@nm.mui.ac.ir.
  3. Associate Professor, Pediatric Hematology and Oncology, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: moafi@med.mui.ac.ir.
  4. Assistant Professor, Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: azadeh.malekian@gmail.com.
  5. Assistant Professor, Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: keshvari@med.mui.ac.ir
- 

### 16. REVIEW OF MEASURING CANCER PATIENTS INFORMATION NEEDS: DISEASE OR ACTION-ORIENTED QUESTIONNAIRE

Baloochi Beydokhti Tahereh<sup>1</sup>, Heshmati Nabavi Fatemeh<sup>2</sup>

1. PhD Student, Mashhad University of Medical Sciences
  2. Assistant Professor, Mashhad University of Medical Sciences
-

## 17. THE EFFECT OF A HEALTH LITERACY PROMOTION PROGRAM ON THE LEVEL OF HEALTH LITERACY AND DEATH ANXIETY IN WOMEN WITH BREAST CANCER

Masoud Bahrami<sup>1</sup>, Marjan Aboudzadeh<sup>2</sup>

1. Associate Professor, Department of Adult Health Nursing, Nursing & Midwifery Care Research Center, School of Nursing & Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
  2. MsN Student, Department of Adult Health Nursing, School of Nursing & Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
- 

## 18. HOW IS HEALTH-RELATED QUALITY OF LIFE IN BREAST CANCER SURVIVORS AFTER TREATMENTS?

Sahar Mirzaei<sup>1</sup>, Camelia Rohani<sup>2</sup>, Fateme Moradipour<sup>3</sup>, Robab Anbiaei<sup>4</sup>

1. PhD. Candidate. Student Research Committee, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
  2. PhD., Assistant Professor, Department of Community Health Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  3. RN, Mahdiah Hospital, Shahid Beheshti University of Medical Sciences Tehran, Iran
  4. Oncologist, Assistant Professor, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 

## 19. SIGNIFICANT COMPONENTS OF CANCER PATIENTS' COMPREHENSIVE SUPPORTIVE CARE NEEDS UNDERGOING CHEMOTHERAPY; IRANIAN ONCOLOGISTS' PERCEPTIONS

Shahin Salarvand<sup>1</sup>, Simin Hemati<sup>2</sup>, Payman Adibi<sup>3</sup>, Fariba Taleghani<sup>4</sup>

1. Community Health Nursing Department,, Faculty of Nursing and Midwifery, Lorestan University of Medical Sciences, Khorramabad, Iran
  2. Radiotherapy and Oncology Department, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
- 

## 20. DEVELOP A CURRICULUM SHORT-TERM NURSING EDUCATION PROGRAM FOR BREAST CANCER NURSE SPECIALIST

Fateme Hadadian<sup>1</sup>, Fariba Taleghani<sup>2</sup>, Mahnaz Ilkhani<sup>3</sup>

1. Faculty Member of Department of Medical surgical Nursing, Kermanshah University of Medical Sciences. Ph.D. Nursing Student, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences.

2. Faculty Member of Department of Medical surgical Nursing, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences.
  3. Assistant Professor, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences
- 

## 21. THERAPEUTIC TOUCH IN PATIENTS WITH CANCER: A CONTENT ANALYSIS STUDY

Amir Tabatabaee<sup>1</sup>, Mansoureh Zagheri Tafreshi<sup>2</sup>, Maryam Rassouli<sup>3</sup>

1. Department of Nursing, Quchan Branch, Islamic Azad University, Quchan, Iran
  2. Department of Management, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. Department of Pediatric & Neonatal Intensive Care Nursing, Nursing & Midwifery School, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 

## 22. IRANIAN CANCER PATIENT'S PERCEPTION OF DIGNITY: A QUALITATIVE CONTENT ANALYSIS

Samaneh Bagherian, Camellia Torabizadeh, Farkhondeh Sharif, Ladan Zarshenas, Payam Izadpanahi

1. Student Research Committee, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan-Iran.
- 

## 23. IS THE PRESENCE OF A PSYCHIATRIC NURSE IN THE SPECIALIZED DEPARTMENT OF CANCER OF CHILDREN

Jafar Moghaddasi<sup>1</sup>, Fariba Taleghani<sup>2</sup>, Mohammad Akbari<sup>4</sup>, Maryam Moghimiyan<sup>5</sup>, Musa Alavi<sup>3</sup>, Reyhaneh Niknejad<sup>6</sup>

1. Student Research Committee, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran. Department of Medical Surgery Nursing, School of Nursing and Midwifery, Shahrekord University of Medical Sciences, Shahrekord, Iran. E-mail: jaefar\_moghadda@nm.mui.ac.ir.
  2. Professor Nursing, Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: Taleghani@nm.mui.ac.ir.
  3. Associate Professor, Research Center of Isfahan Nursing and Midwifery Faculty, Isfahan, Iran
  4. Ph.D. Nursing Students, Student Research Committee of Isfahan Nursing and Midwifery Faculty, Isfahan, Iran
  5. Nursing and Midwifery Research Center, Najaf Abad Unit, Islamic Azad University, Najaf Abad, Iran
  6. Master's Degree Student Operating Room, Student Research Committee of Isfahan Nursing and Midwifery Faculty, Isfahan, Iran
-

## 24. CORRELATION BETWEEN ADJUSTMENT AND SELF-EFFICACY IN PATIENTS WITH INTESTINAL OSTOMY

Fatemeh Heshmati-Nabavi<sup>1</sup>, Zohre Pouresmail<sup>2</sup>, Tahereh Sadeghi<sup>3</sup>, Mohammad Naser Shafiee Jafarabadi<sup>4</sup>, Hamid Reza Behnam Voshani<sup>5</sup>

1. Evidence Based Care Research Centre, Department of Nursing Management, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran
2. Student Research Committee, Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
3. Department of Pediatrics, Mashhad Faculty of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
4. Head of English Department, Mashhad University of Medical Sciences, Iran.
5. Department of Pediatrics, Mashhad Faculty of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.

## 25. SENSE OF COHERENCE AS A RESILIENCE-RECOVERY FACTOR IN CANCER PATIENTS' HEALTH-RELATED QUALITY OF LIFE: INVESTIGATING THE MEDIATING OR MODERATING MECHANISMS AND ITS APPLICATION IN CLINIC

Camelia Rohani<sup>1</sup>

1. PhD., Assistant Professor, Community Health Nursing Department, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran-Iran

## 26. THE REWARDS AND CHALLENGES OF IRANIAN ONCOLOGY NURSES

Mahnaz Ilkhani<sup>1</sup>

1. Doctorate in Clinical Practice, Assistant Professor, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran

## 27. STUDYING THE SPIRITUAL NEEDS OF PATIENTS WITH CANCER

Soolmaz Moosavi<sup>1</sup>, Camelia Rohani<sup>2\*</sup>, Fariba Borhani<sup>3</sup>, Mohamad Esmaeil Akbari<sup>4</sup>

1. Doctoral Student in Nursing, School of Nursing & Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ORCID: 0000-0002-2095-283X. Email: moosavi.soolmaz@yahoo.com. Tel: 00989127907783. Fax: 00982188202521.
2. Assistant Professor, Community Health Nursing Department, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ORCID: 0000-0002-6456-6586
3. Associate Professor, Medical Surgical Department, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ORCID: 0000-0002-8937-2649. Email: faribaborhani@msn.com. Tel: 00989133439254. Fax: 00982188202521.
- \* Professor, Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ORCID: 0000-0002-9938-3587. Email: proposalcrc@yahoo.com. Tel: 009821-22748001-2.

## 28. RANDOMIZED TRIAL TO EVALUATE FOOT REFLEXOLOGY EFFECTS ON QUALITY OF LIFE OF PATIENTS SUFFERING CHEMOTHERAPY-INDUCED NEUROPATHY IN COLORECTAL CANCER PATIENTS

Hesam Gholamzadeh<sup>1</sup>, Dr Mahnaz Ilkhani<sup>2</sup>

1. Master Student, School of Nursing and Midwifery, Shahid Behashati University of Medical Sciences
  2. Assistant Professor, School of Nursing and Midwifery, Shahid Behashati University of Medical Sciences
- 

## 29. THE EFFECT OF AURICULAR ACUPRESSURE ON NAUSEA AND VOMITING INDUCED BY CHEMOTHERAPY AMONG BREAST CANCER PATIENTS

Dr Shokoh Varaei<sup>1</sup>

1. Associate Professor of Tehran University of Medical Sciences
-

## NURSING POSTERS

### 1. STRUCTURAL CHALLENGES OF PROVIDING PALLIATIVE CARE FOR PATIENTS WITH BREAST CANCER

Somaye Pouy<sup>1</sup>, Latif Panahi<sup>2</sup>

1. Master of Pediatric Nursing, School of Nursing and Midwifery, Student Research Committee, Guilan Beheshti University of Medical Sciences, Rasht, Iran, somayepouy@gmail.com
2. Bachelor of Pediatric Nursing, School of Nursing and Midwifery, Guilan Beheshti University of Medical Sciences, Rasht, Iran, Panahi\_p2020@yahoo.com

### 2. RISK BREAST CANCER IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A SYSTEMATIC REVIEW

Simin Haghdoost<sup>1</sup>, Farzaneh pazandeh<sup>1,\*</sup>

1. M.sc .Midwifery Student of Shahid Beheshti School of Nursing and Midwifery Tehran,Iran
- \* Author Responsible: Assistant Professor in Reproductive Health Midwifery and Reproductive Health Department, Shahid Beheshti School of Nursing and Midwifery Tehran,Iran\* pazandehz@gmail.com

### 3. THE ROLE OF PHYTOESTROGENS IN PREVENTION OF BREAST CANCER

Somaye Pouy<sup>1</sup>, Latif Panahi<sup>2</sup>

1. Master of Pediatric Nursing, School of Nursing and Midwifery, Student Research Committee, Guilan Beheshti University of Medical Sciences, Rasht, Iran, somayepouy@gmail.com
2. Bachelor of Pediatric Nursing, School of Nursing and Midwifery, Guilan Beheshti University of Medical Sciences, Rasht, Iran, Panahi\_p2020@yahoo.com

### 4. EVALUATION OF THE EFFECT OF HERBAL MEDICINE ON THE COMPLICATIONS OF CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER: SYSTEMATIC REVIEW

Shahin Pashaie<sup>1</sup>, Hesam Gholamzadeh<sup>2</sup>, Meimanat Hosseini<sup>3</sup>

1. Graduate Student of Nursing, Student Research Committee, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Graduate Student of Nursing, Student Research Committee, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Assistant Professor, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran

## 5. EFFECT OF PRE-TREATMENT EDUCATION PROGRAMS ON THE ANXIETY OF PATIENTS RECEIVING RADIOTHERAPY: AN INTEGRATIVE LITERATURE REVIEW

Atefeh Behboudifar<sup>1,\*</sup>, Fatemeh Heshmati Nabavi<sup>2</sup>, Zohre Pouresmail<sup>3</sup>, Mohammad Naser Shafiee<sup>4</sup>

1. School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran
  2. Evidence Based Care Research Centre, Department of Public Health Nursing and Psychiatric Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
  3. Student Research Committee, Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
  4. Head of English Department, Faculty of Medicine, Mashhad University of Medical Sciences, Iran
- 

## 6. A REVIEW OF STUDIES ON THE ROLE OF SPIRITUAL THERAPY GROUP ON DEATH ANXIETY OF PATIENTS WITH BREAST CANCER

Zahra Gholipour<sup>1</sup>, Seyedeh Maryamn Mousavi<sup>2</sup>

1. Student of Nursing, Rasht Branch, Islamic Azad University, Rasht, Iran.
  2. PhD of Health Psychology, Department of psychology, Rasht Branch, Islamic Azad University, Rasht, Iran.
- 

## 7. THE EFFECT OF SELF-CARE EDUCATION ON QUALITY OF LIFE FOR PEOPLE WITH GASTROINTESTINAL OSTOMY

Shadiyeh Kanani<sup>1,\*</sup>, Yaghoob Madmoli<sup>2</sup>

1. Student Research Committee, Iran University of Medical Sciences, Tehran, Iran, Shadikanani@rocketmail.com
  2. Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran\*
- 

## 8. THE EFFECT OF REFLEXOLOGY ON REDUCING THE PAIN OF CANCER WITH PATIENTS: REVIEW ARTICLE

Sahar Haghighat<sup>1</sup>, Dr Mahnaz Ilkhani<sup>2</sup>

1. Student Research Committee, School of Nursing & Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Haghighat\_sahar85@yahoo.com
  2. Director of Continuing Education Cente, DCLinP, AONC, BCCN, Assistant Professor Shahid Beheshti University of Medical Sciences, Tehran, Iran. m\_ilkhani@sbmu.ac.ir
-

## 9. ADAPTATION OF CLINICAL GUIDELINE FOR PREPARATION AND SAFE ADMINISTRATION OF INTRAVENOUS CHEMOTHERAPY IN ADULT CANCER PATIENTS FOR NURSES IN ONCOLOGY CENTERS IN IRAN.

Tayebeh Karimi<sup>1</sup>, Masoud Bahrami<sup>2</sup>

1. PhD Candidate in Nursing, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran.
2. Cancer Prevention Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran

## 10. PREPARATION STEPS FOR PATIENTS WITH COLORECTAL CANCER FOR INTESTINAL OSTOMY

Zohre Pouresmail<sup>2</sup>, Fatemeh Heshmati Nabavi<sup>1</sup>

1. Evidence Based Care Research Centre, Department of Public Health Nursing and Psychiatric Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
2. Student Research Committee, Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.

## 11. ASSESSMENT THE QUALITY OF NURSES SUPPORTIVE CARES AS PERSONS WHO HAVE COLON CANCER : REVIEW ARTICLE

Masoud Saeidi<sup>1,\*</sup>, Zahra Mohammadghasemi<sup>2</sup>

1. Nursing Expert, Imam Khomeini hospital, Mahabad ,Iran
2. Nursing Student, Islamic Azad University, Najafabad ,Iran

## 12. QUALITY OF LIFE IN WOMEN WITH BREAST CANCER AFTER MASTECTOMY: A SYSTEMATIC REVIEW

Aram Halimi<sup>1</sup>, Mahnaz Ilkhani<sup>2,\*</sup>, Mahmood Hosseini<sup>3</sup>, Mohsen Safar Abadi<sup>4</sup>, Mahdie Ghale Noee<sup>5</sup>, Milad Amiri<sup>6</sup>

1. Student Research Committee, (Department and Faculty of Nursing Midwifery), Shahid Beheshti University of Medical Science, Tehran, Iran
2. Assistant Professor at Department and Faculty of Nursing Midwifery Shahid Beheshti University of Medical Science, Tehran, Iran
3. Student Research Committee, (Department and Faculty of Nursing Midwifery), Shahid Beheshti University of Medical Science, Tehran, Iran
4. Student Research Committee, (Department and Faculty of Nursing Midwifery), Shahid Beheshti University of Medical Science, Tehran, Iran
5. Psychiatric Nursing Department, School of Nursing & Midwifery, Shahid Beheshti University of Medical Science, Tehran, Iran.



6. Student Research Committee, (Department and Faculty of Nursing Midwifery), Shahid Beheshti University of Medical Science, Tehran, Iran
- \* Corresponding Author: Assistant Professor at Department and Faculty of Nursing Midwifery Shahid Beheshti University of Medical Science, Tehran, Iran. E-mail: M\_ilkhani@yahoo.com, Contact: +982188202508
- 

### 13. THE EFFECT OF YOGA ON QUALITY OF LIFE IN WOMEN WITH BREAST CANCER: A SYSTEMATIC REVIEW

Aram Halimi<sup>1</sup>, Mahnaz Ilkhani<sup>2,\*</sup>, Arta Garmsiri<sup>3</sup>, Faezeh Payan<sup>4</sup>, Mohammad Reza Davari<sup>5</sup>, Rashid Aslani<sup>6</sup>

1. Student Research Committee, (Department and Faculty of Nursing Midwifery), Shahid Beheshti University of Medical Science, Tehran, Iran
  2. Assistant Professor at Department and Faculty of Nursing Midwifery Shahid Beheshti University of Medical Science, Tehran, Iran
  3. Student Research Committee, (Department and Faculty of School of Medicine), Shahid Beheshti University of Medical Science, Tehran, Iran
  4. Student Research Committee, (Department and Faculty of Nursing Midwifery), Shahid Beheshti University of Medical Science, Tehran, Iran
  5. Student Research Committee, (Department and Faculty of Nursing Midwifery), Shahid Beheshti University of Medical Science, Tehran, Iran
  6. Student Research Committee, (Department and Faculty of Nursing Midwifery), Shahid Beheshti University of Medical Science, Tehran, Iran
- 

### 14. OCCUPATIONAL HEALTH AND ITS RELATED FACTORS OF IN ONCOLOGY NURSING: A REVIEW ARTICLE

Mozhgan Soheili<sup>1</sup>, Fariba Taleghani<sup>2</sup>, Fariba Jokar<sup>3</sup>

1. PhD Student of Nursing, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran. Email: mozhgan.sohei@yahoo.com
  2. Professor of Nursing School of Nursing and Midwifery, Nursing and Midwifery Care Research Center, Isfahan University of Medical Sciences
  3. Assistant Professor, Department of Medical Education ,EDC, Isfahan University of Medical Sciences, Isfahan, Iran
- 

### 15. THE ROLE OF NURSES IN THE DECREASE OF ORAL AND MAXILLOFACIAL PROBLEMS, IN PATIENTS WHO GET CHEMOTHERAPY AND RADIOTHERAPY

Somayeh Rahmani<sup>1</sup>, Mobina Sanaie Pour <sup>2,\*</sup>

1. Assistant Professor of Oral Medicine Department, Dental School, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail: Somayehrahmani2016@gmail.com National Code: 5749954791 – Phone: 09122977464
  2. Bachelor of Nursing.
- \* E-mail: mobinasanaie76@gmail.com National Code: 0521062217 – Phone: 09129376954
-

## ۱۶. بررسی عوارض گوارشی حین شیمی درمانی در مراجعین به بخش شیمی درمانی بیمارستان واسعی سبزوار در سال ۱۳۹۷

بتول کیخسروی<sup>۱</sup>، زهرا رضوانی راد<sup>۲</sup>، زهرا شیرخانی<sup>۲</sup>، راحله عرب اسدی<sup>۲</sup>، شهربانو طالبی<sup>۳</sup>

۱. کارشناس پرستاری، مسئول بخش شیمی درمانی، مرکز آموزشی، پژوهشی و درمانی واسعی، دانشگاه علوم پزشکی سبزوار.
۲. کارشناس پرستاری، پرستار بخش شیمی درمانی، مرکز آموزشی، پژوهشی و درمانی واسعی، دانشگاه علوم پزشکی سبزوار.
۳. کارشناس ارشد پرستاری، سوپروایزر آموزشی، مرکز آموزشی، پژوهشی و درمانی واسعی، دانشگاه علوم پزشکی سبزوار.

---

## 17. THE QUALITY OF LIFE OF PEOPLE WITH GASTROINTESTINAL OSTOMY IN IRAN

---

## RADIOBIOLOGY & RADIOTHERAPY ARTICLES

### 1. THE EFFECT OF GOLD NANOPARTICLES DISPERSED ON TISSUE-EQUIVALENT BOLUS ON THE ABSORBED DOSE DISTRIBUTION TO THE SKIN SURFACE IN RADIATION THERAPY FOR BREAST CANCER PATIENTS USING MONTE CARLO SIMULATION

Elham Saeedzadeh<sup>1</sup>, Hossein Khosravi<sup>2</sup>, Maryam Yaftian<sup>3</sup>

1. Faculty of Medical Engineering and Technology, Tehran, Iran.
  2. Medical Physics Department, Malek Ashtar University, Tehran, Iran.
  3. Department of Medical Engineering, Science and Research Branch University, Tehran, Iran
- 

### 2. POTENTIATING EFFECT OF SAFFRON ON RADIATION INDUCED CHROMATID BREAKS IN G2 FETAL AMNIOCYTES

Sahar Mozdarani<sup>1</sup>, Saeed Zaker Bostan abad<sup>1</sup>, Hossein Mozdarani<sup>2</sup>, Hassan Nosrati<sup>3</sup>

1. Department of Developmental Cell Biology, Islamic Azad University, Parand Branch, Parand, Iran.
  2. Department of Medical Geneticss, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. mozdarah@modares.ac.ir
  3. Radiation Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran
- 

### 3. THE SYNERGISTIC EFFECT OF MAGNETO-PLASMONIC NANOPARTICLES-MEDIATED RADIO FREQUENCY HYPERTHERMIA AND RADIOTHERAPY ON MCF-7 BREAST CANCER CELLS

Fahimeh Hadi<sup>1,2</sup>, Ali Neshastehriz<sup>1, 2</sup>, Shima Tavakkol<sup>3</sup>, Vahid Pirhajati<sup>3,4</sup>, Seied Rabi Mahdavi<sup>1,5</sup>, Ali Shakeri Zadeh<sup>1,5,\*</sup>

1. Radiation Biology Research Center, Iran University of Medical Science (IUMS), Tehran, Iran
  2. Radiation Science Department, Iran University of Medical Science (IUMS), Tehran, Iran
  3. Cellular and Molecular Research Center, Iran University of Medical Science (IUMS), Tehran, Iran
  4. Neuroscience Research Center, Iran University of Medical Science (IUMS), Tehran, Iran
  5. Medical Physics Department, School of Medicine, Iran University of Medical Science (IUMS), Tehran, Iran
- 

### 4. GAMMA-H2AX IN RESPONSE TO DNA DSB DURING HIGH DOSE BYSTANDER SIGNALING

F Pakniyat<sup>1</sup>, H.A Nedaie<sup>2</sup>, H Mozdarani<sup>3</sup>, A Mahmoodzadeh<sup>4</sup>

1. Department of Medical Physics and BioMedical Engineering, Tehran University of Medical Sciences, Tehran, Iran
2. Radiation Oncology Department, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran

3. Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  4. Department of Bioscience and Biotechnology, Malek-Ashtar University of Technology, Tehran, Iran
- 

## 5. PROTECTIVE EFFECT OF OLEUROPEIN ON RADIATION-INDUCED GENOTOXICITY IN HUMAN LYMPHOCYTES

Fatemeh Amani<sup>1</sup>, Mehdi Allahbakhshian Farsani<sup>2</sup>, Mehرداد Gholami<sup>3</sup>, Seyed Mahmoud Reza Aghamiri<sup>4</sup>, Mohsen Bakhshandeh<sup>1</sup>

1. Radiation Technology Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. Department of Hematology and Blood Banking, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. Department of Medical Physics, Lorestan University of Medical Sciences, Khorramabad, Iran
  4. Radiation Medicine Department, Shahid Beheshti University, Tehran, Iran
- 

## 6. RADIOBIOLOGICAL APPROACH OF HYPO-FRACTION TECHNIQUE OF GRID RADIATION THERAPY IN BYSTANDER CELLS

F Pakniyat<sup>1</sup>, H.A Nedaie<sup>2</sup>, H Mozdarani<sup>3</sup>, A Mahmoodzadeh<sup>4</sup>, S Gholami<sup>5</sup>, M Salimi<sup>6</sup>

1. Department of Medical Physics and BioMedical Engineering, Tehran University of Medical Sciences, Tehran, Iran
  2. Radiation Oncology Department, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  4. Department of Bioscience and Biotechnology, Malek-Ashtar University of Technology, Tehran, Iran
  5. Radiation Oncology Department, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
  6. Department of Medical Genetics, Medical Biotechnology Institute, National Institute of Genetics Engineering and Biotechnology, Tehran, Iran
- 

## 7. ALGINATE HYDROGEL CO-LOADED WITH CISPLATIN AND GOLD NANOPARTICLES AS NANOTHERASTONIC AGENT IN COLON CANCER

Marzieh Keshavarz<sup>1</sup>, Kave Moloudi<sup>2</sup>, Reza Paydar<sup>2,3</sup>, Ziaeddin Abed<sup>1</sup>, Jaber Beik<sup>1</sup>, Habib Ghaznavi<sup>4</sup>, Ali Shakeri-Zadeh<sup>1,3</sup>

1. Department of Medical Physics, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran
  2. Radiation Sciences Department, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
  3. Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran
  4. Cellular and Molecular Research Center, Zahedan University of Medical Sciences (ZaUMS), Zahedan, Iran
-

## 8. EVALUATION AND MODELLING OF LATERAL SCATTERING OF PROTON PENCIL BEAMS IN TISSUE ELEMENTS WITH USING MONTE CARLO SIMULATION

Shiva Zarifi<sup>1</sup>, Hadi Taleshi Ahangari<sup>2,\*</sup>, Sayyed Bijan Jia<sup>3</sup>, Mohammad Ali Tajik Mansoury<sup>2</sup>

1. MSc. Student of Medical Physics, Department of Medical Physics, Semnan University of Medical Sciences, Semnan, Iran.
  2. Professor of Medical Physics, Department of Medical Physics, Semnan University of Medical Sciences, Semnan, Iran.
  3. Professor of Physics, Department of Physics, Bojnord University, Bojnord, Iran.
- 

## 9. EVALUATING THE EFFECTS OF RADIATION AND CISPLATIN-BASED CHEMOTHERAPY ON SENSORINEURAL HEARING LOSS IN PATIENTS WITH HEAD AND NECK CANCER

Abolhasan Rezaeyan<sup>1,2</sup>, Seied Rabi Mahdavi<sup>2,3</sup>, Alireza Nikoofar<sup>4</sup>, Masoud Najafi<sup>5</sup>, Azade Amrae<sup>2</sup>, Fereshte Koosha<sup>6</sup>, Susan Cheraghi<sup>3,7,\*</sup>

1. Department of Medical Physics, School of Medicine, Fasa University of Medical Science, Fasa, Iran
  2. Department of Medical Physics, School of Medicine, Iran University of Medical Science, Tehran, Iran
  3. Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran
  4. Department of Radiation Oncology, School of Medicine, Iran University of Medical Science, Tehran, Iran
  5. Radiology and Nuclear Medicine Department, School of ParaMedical Sciences, Kermanshah University of Medical Science, Kermanshah, Iran
  6. Department of Medical Physics and BioMedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  7. Department of Radiology, Faculty of ParaMedical Sciences, Iran University of Medical Sciences, Tehran, Iran
- 

## 10. TRADE-OFF BETWEEN THE CONFLICTING PLANNING GOALS IN CORRELATION WITH PATIENT'S ANATOMICAL PARAMETERS FOR INTENSITY MODULATED RADIOTHERAPY OF PROSTATE CANCER PATIENTS

Amin Banaei<sup>1</sup>, Bijan Hashemi<sup>1</sup>, Mohsen Bakhshandeh<sup>2</sup>, Bahram Mofid<sup>3</sup>

1. Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  2. Radiation Technology Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. Department of Radiation Oncology, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
-

## 11. EFFECT OF MICROWAVE WI-FI RADIATION ON THE BEHAVIOR OF THE ADULT MOUSE

Fatemeh Niksirat<sup>1</sup>, Ali Shabestani Monfared<sup>2,\*</sup>, Sajad Borzoueisileh<sup>3</sup>, Fereshteh Pourabdolhossein<sup>4</sup>

1. Department of Medical Physics Radiobiology and Radiation Protection, School of Medicine, Babol University of Medical Sciences, Babol, I.R.Iran
  2. Cancer Research Center, Babol University of Medical Sciences, Babol, Iran
  3. Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
  4. Neuroscience Research Center, Health Research Institute, Babol University of Sciences, Babol, I.R.Iran
- 

## 12. PREFERENTIAL RADIOENHANCEMENT AND GENOTOXIC EFFECTS OF ZNO AND GADOLINIUM-DOPED ZNO NPS IN COMBINATION WITH MEGAVOLTAGE RADIATION IN LUNG CANCER CELLS MEASURED BY MICRONUCLEUS ASSAY AND QRT-PCR IN VITRO

Masoumeh Zanganeh<sup>1</sup>, Hassan Ali Nedaie<sup>1,2,\*</sup>, Hossein Mozdarani<sup>3</sup>, Aziz Mahmoudzadeh<sup>4</sup>

1. Department of Medical Physics and BioMedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. Radiotherapy Oncology Department, Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. Department of Medical Geneticss, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  4. Department of BioSciences and Biotechnology, Malek-Ashtar University of Technology, Tehran, Iran
- 

## 13. EVALUATING THE EFFECTS OF RADIATION AND CISPLATIN-BASED CHEMOTHERAPY ON SENSORINEURAL HEARING LOSS IN PATIENTS WITH HEAD AND NECK CANCER

Abolhasan Rezaeyan<sup>1</sup>, Seied Rabi Mahdavi<sup>1</sup>, Alireza Nikoofar<sup>2</sup>, Masoud Najafi<sup>3</sup>, Azade Amrae<sup>1</sup>, Fereshte Koosha<sup>4</sup>, Susan Cheraghi<sup>5,\*</sup>

1. Department of Medical Physics, School of Medicine, Iran University of Medical Science, Tehran, Iran
  2. Department of Radiation Oncology, School of Medicine, Iran University of Medical Science, Tehran, Iran
  3. Radiology and Nuclear Medicine Department, School of ParaMedical Sciences, Kermanshah University of Medical Science, Kermanshah, Iran
  4. Department of Medical Physics and BioMedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. Department of Radiology, Faculty of ParaMedical Sciences, Iran University of Medical Sciences, Tehran, Iran
-

#### 14. MODULATING SURVIVIN AS A RADIORESISTANT FACTOR BY OMEGA-3 DOCOSAHEXAENOIC ACID SENSITIZES RADIORESISTANT COLORECTAL CANCER CELLS TO $\gamma$ -IRRADIATION

Farideh Hosseini<sup>1,2</sup>, Mohammad Reza Sam<sup>1</sup>, Nasrollah Jabbari<sup>3</sup>, and Hossein Mozdarani<sup>4</sup>

1. Department of Cellular and Molecular Biotechnology, Institute of Biotechnology, Urmia University, Urmia, Iran.
  2. Department of Radiology Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  3. Department of Medical Physics and Imaging, Solid Tumor Research Center, Urmia University of Medical Sciences, Urmia, Iran.
  4. Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
- 

#### 15. THE ACCURACY OF OUT-OF-FIELD DOSE CALCULATIONS USING DIFFERENT MODEL BASED ALGORITHMS IN SLIDING WINDOW IMRT AND 3DCRT IN PATIENTS WITH PROSTATE CANCER

Fahimeh Faghihi Moghadam<sup>1</sup>, Mohsen Bakhshandeh<sup>2,\*</sup>, Bahram Mofid<sup>3</sup>, Mehdi Ghorbani<sup>4</sup>

1. Department of Medical Physics, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  2. Associate Professor, Department of Radiation Technology, Faculty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  3. Professor, Department of Radiation Oncology, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  4. Assistant Professor, Department of Medical Physics, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 

#### 16. INVESTIGATION OF THE EFFECT OF ARBUTIN IN PREVENTING PULMONARY DAMAGE INDUCED BY X-IRRADIATION IN RATS: A HISTOPATHOLOGICAL STUDY

Abolhasan Rezaeyan<sup>1</sup>, Seyyed Shahab Addin Jahanbani<sup>2</sup>, Abdolreza Babae<sup>2</sup>, Gholam Hassan Haddadi<sup>3</sup>, Mohammad Mehdi Moeni<sup>4</sup>, Ali Jomehzadeh<sup>5</sup>, Sina Moatamedi<sup>6</sup>, Seyed Hassan Eftekhari-Vaghefi<sup>2,\*</sup>

1. Department of Medical Physics, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran, ahrezaeyan@gmail.com
  2. Department of Anatomical Sciences, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
  3. Department of Radiology, School of ParaMedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
  4. Pathology and Stem Cell Research Center, Department of Pathology, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
  5. Department of Medical Physics, Kerman University of Medical Sciences, Kerman, Iran
  6. Department of physiology and Pharmacology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
-

## 17. COMPARATIVE STUDY OF RADIOPROTECTIVE POTENTIAL OF DIFFERENT ANTIOXIDANTS ON HUMAN PERIPHERAL BLOOD LYMPHOCYTES USING CYTOCHALASIN-B BLOCKED MICRONUCLEUS ASSAY

Sohail Mozdarani<sup>1</sup>, Hossein Mozdarani<sup>2</sup>, Sara Ghorbanian<sup>3</sup>, Sahar Mozdarani<sup>1</sup>, Hassan Nosrati<sup>4</sup>

1. Department of CytoGeneticss, Cytogenome Medical Geneticss laboratory, Ale-Ahmad High way, Chamran Medical Building, Tehran, Iran.
2. Department of Medical Geneticss, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. mozdarah@modares.ac.ir
3. Department of Geneticss, University of Sistan and Baluchestan, Zahedan, Iran.
4. Radiation Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran

## 18. DOSIMETRIC EVALUATION OF COLLAPSE CONE CONVOLUTION ALGORITHM IN THORAX PHANTOM WITH LUNG EQUIVALENT HETEROGENEITIES: COMPARISON WITH MONTE CARLO CODE AND EXPERIMENTAL MEASUREMENT

Milad Najafzadeh<sup>1</sup>, Mahmoud Bagheri<sup>2</sup>, Mohammad Haghparast<sup>1</sup>, Mahdieh Afkhami Ardekani<sup>1</sup>, Abolfzal Nickfarjam<sup>3,4,\*</sup>, James C L Chow<sup>5</sup>

1. Department of Radiology, faculty of Para-Medicine, Hormozgan University of Medical Sciences, Bandare-Abbas, Iran;
2. Medical Physics Department, faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran;
3. Medical Physics Department, faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran;
4. Radiotherapy Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran;
5. Department of Radiation Oncology, University of Toronto and Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario M5G 2M9, Canada

## 19. BEAM ANGLE OPTIMIZATION IN INTENSITY MODULATED RADIATION THERAPY PLANNING OF NASOPHARYNGEAL CANCER

Ali Ghanbarzadeh<sup>1</sup>, Majid Pouladian<sup>2,\*</sup>, Ali Shabestani Monfared<sup>3</sup>, Seied Rabi Mahdavi<sup>4</sup>

1. PhD Candidate, Department of Medical Radiation Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran.
  2. Department of BioMedical Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran.
  3. Professor, Cancer Research Center, Medical Physics Department, Babol University of Medical Sciences, Babol, Iran.
  4. Associated Professor, Radiobiology Research Center, Department of Medical Physics, Iran University of Medical Sciences, Tehran, Iran.
- \* Department of BioMedical Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran.



## 20. ACCURACY OF PROWESS PANTHER TREATMENT PLANNING SYSTEM IN PRESENCE OF DENTAL FILLING MATERIAL FOR IMRT IN TREATMENT PLANS DESIGNED USING AN ANTHROPOMORPHIC HEAD AND NECK PHANTOM

Pegah saadatmand<sup>1,\*</sup>, Ahmad Shanei<sup>1</sup>, Alireza Amouheidari<sup>2</sup>, Iraj Abedi<sup>1</sup>

1. Medical Physics Department, Isfahan University of Medical Sciences, Isfahan, Iran.
  2. Radiation Oncology Department, Isfahan Milad Hospital, Isfahan, Iran.
- 

## 21. INVESTIGATING THERAPEUTIC EFFECTS OF PHOTOTHERMAL THERAPY COMBINED WITH RADIOTHERAPY IN THE PRESENCE OF GOLD COATED IRON-OXIDE NANOPARTICLES ON KB CELLS

Zahra Alamzade<sup>1</sup>, Alireza Mehdizadeh<sup>1</sup>, Mohammad Mehdi Movahedi<sup>1</sup>, Gholamreza Taheripak<sup>2</sup>, Ali Shakeri-Zadeh<sup>3,\*</sup>

1. Medical Physics Department, Faculty of Medicine, Shiraz University of Medical Sciences (SUMS), Shiraz, Iran
  2. Biochemistry Department, Faculty of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran
  3. Medical Physics Department, Faculty of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran
- 

## 22. DOSIMETRIC AND RADIOBIOLOGICAL COMPARISON OF THREE DIFFERENT BEAM ARRANGEMENTS IN IMRT TREATMENT PLANNING OF NASOPHARYNGEAL CANCER. EFFECT ON CRITICAL STRUCTURES RADIATION DOSES

Pegah saadatmand<sup>1,\*</sup>, Ahmad Shanei<sup>1</sup>, Alireza Amouheidari<sup>2</sup>, Iraj Abedi<sup>1</sup>

1. Medical Physics Department, Isfahan University of Medical Sciences, Isfahan, Iran.
  2. Radiation Oncology Department, Isfahan Milad Hospital, Isfahan, Iran.
- 

## 23. RADIATION TOXICITY ASSESSMENT: FROM CLASSICAL RADIOBIOLOGY TO RADIOGENOMICS

Hossein Mozdarani<sup>1</sup>

1. Ph.D, Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. mozdarah@modares.ac.ir
-

## 24. 5-AMINOLAEVULINIC ACID AND FOLATE-CONJUGATED BISMUTH OXIDE NANOPARTICLES CAN ENHANCE PHOTODYNAMIC THERAPY EFFICACY

Fatemeh Akbarzadeh<sup>1</sup>, Karim Khoshgard<sup>2</sup>

1. Students Research Committee, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  2. Assistant Professor, Department of Medical Physics, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- 

## 25. DOSIMETRIC AND RADIOBIOLOGIC COMPARISON BETWEEN THE FOUR FIELD BOX AND FORWARD IMRT TECHNIQUES FOR CONFORMAL RADIOTHERAPY OF THE ESOPHAGUS

Farzaneh Allaveisi<sup>1\*</sup>, Farid Jalilian<sup>2</sup>

1. Department of Medical Physics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
  2. Department of Radiation Therapy, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
- 

## 24. DOSE FACTOR DUE TO GOLD NANOPARTICLES IN RADIOTHERAPY USING BY GEL DOSIMETRY AND MONTE CARLO METHODS

Hossein Khosravi<sup>1\*</sup>, Salman Jafari<sup>1</sup>, Karim Ghazikhanlousani<sup>1</sup>, Alireza Neikoofar<sup>2</sup>

1. Department of Radiology, Faculty of Paramedical, Hamadan University of Medical Sciences, Hamadan, Iran.
  2. Department of Radiotherapy, Iran University of Medical Sciences, Tehran, Iran.
-

## AUTHOR INDEX

### A

- Abadi Pische Ehsan 74  
Abbasi B 55  
Abbasi Behnood 65  
Abbasi Maryam 66  
Abdi Hossein 67  
Abed Ziaeddin 88  
Abedi Iraj 93  
Abhari Fatemeh 57  
Aboudzadeh Marjan 78  
Adibi Payman 78  
Afkhami Ardekani Mahdieh 92  
Afkhami Jedi Farzin 55  
Aghajari Afarin 67  
Aghamiri Seyed Mahmoud Reza 88  
Aghel Elahe 61, 67, 68, 70  
Ahmadi Helaleh Khoshbakht 59  
Ahmadi Simab Saeideh 54  
Ahmadloo Niloofar 61, 67, 68, 70  
Akbari Mohamad Esmaeil 80  
Akbari Mohammad 79  
Akbarzadeh Fatemeh 94  
Akhavan Rezayat Kambiz 54  
Alamzade Zahra 93  
Alavi Musa 79  
Alavinejad Pezhman 66, 67  
Aledavood Seyed Amir 54  
Aleyasin Alireza 62  
Aliakbarian Mohsen 54
- Alimohammadi Nasrollah 77  
Alizadeh Saeed 62  
Allahbakhshian Farsani Mehdi 88  
Allahwaisi Farzaneh 55  
Allahyari Abolghasem 65  
Allaveisi Farzaneh 63, 94  
Amani Fatemeh 88  
Amerizadeh Forouzan 70  
Amiri Milad 84  
Amirifard Nasrin 67  
Amirkhanlou Saeid 64  
Amouheidari Alireza 93  
Amrae Azade 89, 90  
Anbiaei Robab 78  
Ansari Mansour 68, 61, 67, 68, 70  
Anvari Kazem 54  
Ardalan Abbas 58  
Askarpoor Ghazal 60  
Aslani Rashid 85  
Avan Amir 54, 66, 70  
Azad Kasb Zahra 73
- Bahrami Masoud 78, 84  
Bakhshandeh Mohsen 56, 63, 88, 91, 89  
Banaei Amin 89  
BandAmiri Mohammad Zare 61  
Barabadi Z 66  
Bardar Meisam Ebrahimi 56  
Bayati Maryam 75  
Behboudifar Atefeh 83  
Behnam Voshani Hamid Reza 80  
Beik Jaber 88  
Beydokhti Tahereh Baloochi 77  
Bijan Jia Sayyed 89  
Borhani Fariba 80  
Boroumand Nadia 70  
Borzoueisileh Sajad 90

### C

- Cheraghi Susan 89, 90  
Chow James C L 92

### D

- Dabbagh Moghaddam Farnaz 69  
Daiani Malihe 67  
Danafar Hosein 57  
Davari Mohammad Reza 85  
Dehghani Fatemeh 54, 56, 57,

66,67

Dehghani Mohammad Amin 54,  
56, 57, 66, 67

## E

Eftekhari-Vaghefi Seyed Hassan  
91

Eishi Oskouie Ali 60

Elyasi Sepideh 60, 65

Emami Hamid 55

Ensafi Noshin 73

Esmati Ebrahim 62

## F

Faghihi Moghadam Fahimeh  
63, 91

Fani Pakdel Azar 60, 67

Fanipakdel Azar 55

Farajollahi Alireza 57

Farazestanian Marjaneh 67

Farhadi Edris 58

Farzanegan Zahra 61

Felfeliyan Faranak 63

## G

Galehdari Hamid 58

Garmsiri Arta 85

Ghafarzagdegan Kamran 60

Ghaffari Sajjad 64

Ghahramani P 57

Ghale Noee Mahdie 84

Ghalehdari Hamid 57

Ghalehtaki Reza 62

Ghanbarzadeh Ali 92

Ghazikhanlousani Karim 94

Ghaznavi Habib 88

Ghaznavi Hamid 55

Gholami Mehrdad 88

Gholami S 88

Gholamzadeh Hesam 81, 82

Gholipour Zahra 83

Ghorbani Mehdi 91

Ghorbanian Sara 92

## H

Hadadian Fateme 78

Haddadi Gholam Hassan 91

Hadi Fahimeh 87

Hafezi Ali Akbar 64

Haghdooost Simin 65, 82

Haghighat Sahar 83

Haghighi Jeiran 56, 57

Haghparast Mohammad 92

Haji Seyedi Sara 62

Haji Seyedi Seyed Davood 62

Hajjari Mohammadreza 56

Hakimian Morteza 69

Halimi Aram 84, 85

Hamed Seyed Hassan 61, 67,  
68, 70

Hamed Somayeh 69

Hamta Ahmad 58

Hasan Shiri Fatemeh 74

Hasani Mohsen 68

Hasanvand Amir 65

Hasanzadeh Malihe 67

Hashemi Bijan 89

Hassanian Seyed Mahdi 70

Hassanpour Seyyed Hossein  
54, 66

Heidari Haydeh 70

Hemati Simin 78

Heshmati Nabavi Fatemeh 61

Heshmati Nabavi Fatemeh 77,  
83, 84, 80

Homaei Shandiz Fatemeh 67,  
68

Hosseini Farideh 91

Hosseini Mahmood 84

Hosseini Meimanat 82

Hosseini Sare 55

Hosseini Sare 67

Ilkhani Mahnaz 78, 80, 81, 83,  
84, 85

Izadpanahi Payam 79

## J

Jabbari Nasrollah 91  
 Jafari Salman 94  
 Jahanbani Seyyed Shahab  
 Addin 91  
 Jalilian Farid 63, 94  
 Jamshidi Mohammad Hossein  
 60, 64, 65,  
 Janatolmakan Fatemeh 75, 76  
 Janatolmakan Fatemeh 75, 76  
 Janatolmakan Maryam 75, 76  
 Jannati Yazdan Abad Mahdi 65  
 Javid Hossein 68  
 Jokar Fariba 85  
 Jomehzadeh Ali 91  
 Joudi Mashhad Mona 67  
 Joudi Mona 54, 59, 60, 62

## K

Kahrizi Fatemeh 75, 76  
 Kalaghchi Bita 62  
 Kalalinia Fatemeh 65  
 Kamrani G 55  
 Kanani Shadiyeh 83  
 Karimi Tayebah 84  
 Kavousi Nasibeh 68  
 Kazeminezhad Seyed Reza  
 56  
 Keshavarz Marzieh 88  
 Keshvari Mahrokh 76, 77

Keykhosravi A 66  
 Khalafi L 57  
 Khalili Arash 71  
 Khalili Bahman 68  
 Khalili Zahra 71  
 Khanjani Nezhat 68, 70  
 Khatiban Mahnaz 71  
 Khatony Alireza 75, 76  
 Khazaei Majid 70  
 Khazaei Sedigheh 58  
 Khoshgard Karim 94  
 Khosravi Hossein 87, 94  
 Koochian Farideh 55  
 Koochian Mahbobeh 55  
 Koosha Fereshte 89, 90  
 Kooshyar Mohammad Mahdi 60

## L

Lari Sara 60  
 Lashkari Marzieh 62

## M

M Neamatshahi 66  
 Madmoli Yaghoob 83  
 Mafi Ahmad 59  
 Mahdavi S.R 57  
 Mahmoodzadeh A 87, 88  
 Mahmoodzadeh A 88

Mahmoudi Shima 68  
 Mahmoudzadeh A 55  
 Mahmoudzadeh Aziz 62, 90  
 Malekian Azadeh 76, 77  
 Malekzadeh Mona 63  
 Manoochehri Hومان 74  
 Mardani Hamooleh Dr Marjan  
 70  
 Mashayekhi Mohammad 62  
 Mehdizadeh Alireza 93  
 Mehramiz Mehrane 54  
 Mirzaei Hamidreza 63  
 Mirzaei Niloofar 64  
 Mirzaei Sahar 78  
 Moafi Alireza 76, 77  
 Moatamedi Sina 91  
 Moeni Mohammad Mehdi 91  
 Mofid Bahram 56, 59, 63, 89, 91  
 Moghaddasi Jaefar 76, 77, 79  
 Moghimiyani Maryam 79  
 Mohammadpoor Amir Hooshang  
 65  
 Mohammadghasemi Zahra 84  
 Mohammadi Fariba 56  
 Mohammadian Panah  
 Mohammad 61, 67, 68, 70  
 Mohebbi Dehnavi Zahra 61  
 Mohtasham Arezou 54  
 Mohtashami Jamileh 74  
 Mokarram Mehrdad 62  
 Moloudi Kave 88

Mommenzhad Mehdi 56  
 Monadi Shahram 63  
 Moosavi Soolmaz 80  
 Moradi Marjaneh Reyhaneh 70  
 Moradipour Fateme 78  
 Morteza Tabatabaeefar 59  
 Mosalaei Ahmad 61, 67, 68, 70  
 Mosavi Avendy Seyde Simin 58  
 Mousavi Seyedeh Maryamn 83  
 Movahedi Mohammad Mehdi 93  
 Mozafari Mosanan Human 54  
 Mozdarani H 87, 88  
 Mozdarani Hossein 62, 87, 90,  
 91, 93  
 Mozdarani Hossein 92  
 Mozdarani Sahar 87  
 Mozdarani Sahar 92  
 Mozdarani Sohail 92

## N

Nabavi Fatemeh Heshmati 77  
 Najafi Masoud 89, 90  
 Najafzadeh Nadia 63  
 Najafzadeh Milad 92  
 Nariman Arefpour 59  
 Nasiri Malihe 74  
 Nasrolahi Hamid 61, 67, 68, 70  
 Nasrollahi Rahim 60  
 Nasser Shahrokh 56  
 Navipour E 66  
 Neamatshahi Mohammad 66

Nedaie H.A 87, 88  
 Nedaie Hassan Ali 62, 68, 90  
 Neikoofar Alireza 94  
 Neshastehriz Ali 87  
 Neshasteriz Mahshad 63  
 Nickfarjam Abolfzal 92  
 Niknejad Reyhaneh 79  
 Nikoofar Alireza 89, 90  
 Nikoofar Alireza 90  
 Niksirat Fatemeh 90  
 Nosrati Hamed 57, 87  
 Nosrati Hassan 92  
 Nosrati Tirkani Abolfazl 70  
 Nouri Ramin 69  
 Nozari Neda 69

## O

Omidvari Shapour 61, 67, 68, 70  
 Oujian Parastoo 74

## P

Pakniyat Fatemeh 87, 88  
 Panahi Latif 82  
 Pashaie Shahin 82  
 Payan Faezeh 85  
 Payandeh Mehrdad 67  
 Paydar Reza 88  
 Pazandeh Farzaneh 65, 82  
 Pedram Fadavi 59  
 Pirhajati Vahid 87

Pouladian Majid 92  
 Pourabdolhossein Fereshteh 90  
 Pourali Leila 59  
 Pouresmail Zohre 61, 77, 80,  
 83, 84  
 Pouy Somaye 82

## R

Rabi Mahdavi Seied 87, 89, 90,  
 92  
 Radkhoy Fatemeh 65  
 Rahmani Farzad 70  
 Rahmani Somayeh 85  
 Rashedi Anna 64  
 Rasras Saleh 54, 56  
 Rassouli Maryam 79  
 rastegari Hojjat 63  
 Rastgar Moghadam Azam 54  
 Razzaghdoust Abolfazl 59  
 Refahi Soheila 61  
 Rezaee Shabnam 62  
 RezaeeJam Hamed 57  
 Rezaei Nastaran 70  
 Rezaeyan Abolhasan 89, 90, 91  
 Rohani Camelia 74, 78, 80

## S

Saadatmand Pegah 93  
 Sadeghi Edris 67  
 Sadeghi Tahereh 80

Sadeqi Nezhad Muhammad 64  
 Saeb Mohsen 63  
 Saeedzadeh Elham 87  
 Saeidi Masoud 84  
 Safar Abadi Mohsen 84  
 Salarvand Shahin 78  
 Salehi Zeinab 55, 63  
 Salek Roham 55  
 Salekani Bahare 62  
 Salimi M 88  
 Salmani Naiire 74  
 Sam Mohammad Reza 91  
 Sanaie Pour Mobina 85  
 Sandoughdaran Saleh 59, 63  
 Sasanpour Pegah 63  
 Shabestani Monfared Ali 90, 92  
 Shafiee Jafarabadi Mohammad Naser 80  
 Shafiee Mohammad Naser 83  
 Shahid Sales Soodabeh 54, 66, 67, 70  
 Shahriari Mohsen 77  
 Shakeri Zadeh Ali 87, 88, 93  
 Shanei Ahmad 53, 55  
 Shariat Mahdi 61, 67, 68, 70  
 Sharif Farkhondeh 79  
 Sheikhvanloo Maryam 65  
 Sherin F 76, 77  
 Shirani Maryam 54, 66, 67  
 Shirania Maryam 56  
 Shokrani Parvaneh 55  
 Sima Hamidreza 60

Siyah Mansoori Meysam 61  
 Soheili Mozghan 85  
 Sohrabi M 57  
 Solahae Kahnamouii Bita 60  
 Soukhtanloo Mohammad 68

## T

Tabatabaee Amir 79  
 Taghavi Larijani Taraneh 70  
 Taghizadeh Ali 54, 59, 60, 62  
 Taheripak Gholamreza 93  
 Tahmasbi 76, 77  
 Tahmasbi Marziyeh 58, 59  
 Tajik Mansoury Mohammad Ali 89  
 Talaneh Sasan 69, 73  
 Taleghani Fariba 76, 77, 78, 79, 85  
 Taleshi Ahangari Hadi 89  
 Tavakkol Shima 87  
 Torabizadeh Camellia 79

## V

Varaei Shokoh 74, 81  
 Vasei Mostafa 55

## Y

Yaberi Mohammad Zeynab 65  
 Yaftian Maryam 87  
 Yousofi Zohre 67

## Z

Zagheri Tafreshi Mansoureh 79  
 Zahmatkesh Sara 59  
 Zahraei Seyed Mohamadsaleh 57, 58  
 Zajabpour Zahra 59  
 Zaker Bostan Abad Saeed 87  
 Zanganeh Masoumeh 62, 90  
 Zangooei Motlagh Maedeh 60  
 Zangouei Amir 68  
 Zardadi Mehdi 60  
 Zare BandAmiri Mohammad 61, 67, 68, 70  
 Zarifi Shiva 89  
 Zarshenas Ladan 79  
 Ziaee Farinaz 56  
 Zohourinia Shadi 64

## نمایه

<b>ع</b>	<b>الف</b>
عابدی احمدرضا ۷۳ عرب اسدی راحله ۸۶	آل یاسین سید محمد مهدی ۷۱ ، ۷۲
<b>ک</b>	<b>ح</b>
کیخسروی بتول ۸۶ کیهانیان شهریانو ۷۲ ، ۷۳	حسینی ساره ۷۱
<b>ل</b>	<b>ذ</b>
لطف آبادی مسعود کاشانی ۷۱	ذاکری حمیدی مریم ۷۲ ، ۷۳
<b>م</b>	<b>ر</b>
مجاهد محمد مهدی ۷۱ ، ۷۲ محقق فتح ا... ۷۳	رضوانی راد زهرا ۸۶
<b>هـ</b>	<b>س</b>
هاشمی بی بی مریم ۷۱	سجادی محبوبه ۷۳ سرابیان سعید ۷۱
	<b>ش</b>
	شیرخانی زهرا ۸۶
	<b>ط</b>
	طالبی شهریانو ۸۶ طییبی مهتاب ۷۳